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Summary 
Chapter 1 introduces small host-defence peptides in cancer therapy. The main 
mechanisms proposed in their interactions with membranes and intracellular targets 
are discussed. The biologically relevant peptide mimetics are also reviewed.  
 
Chapter 2 describes the synthesis and characterisation of alkyne derivatives of 
metallohelices. These alkyne metallohelices demonstrated promising anticancer 
activity in vitro. Investigations of click reactions on alkyne flexicates were partially 
successful.  
 
Chapter 3 describes the click reaction of alkyne triplexes. A range of aromatic clicked 
triplexes were synthesized and characterised. These novel complexes showed potential 
anticancer activity and high selectivity, and antimetastatic properties. Preliminary 
mechanism study revealed these metallohelices inhibit Na+/K+ ATPase activity.  
 
Chapter 4 describes two different methodologies to synthesize and characterise 
glycoconjugate metallohelices. A variety of glyco-metallohelices were then 
investigated for activity and selectivity in cancer cell lines and normal cell lines. The 
glyco-metallohelices displayed similar inhibition to the growth of human tumour 
xenografts, but lower side effect than cisplatin. 
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Chapter 5 focuses on the synthesis and characterisation of triplex metallohelices 
containing triazole ligands and their potential biological application.  
 
Chapter 6 details the experimental procedures used to carry out the work in this thesis. 
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List of abbreviations 
Most of the abbreviations and symbols used in this thesis are in common use within 
the scientific community. Non-standard abbreviations and symbols used in this work 
are given below: 
CuAAC Copper(I)-catalysed Huisgen 1,3-dipolar cycloaddation 
HHH Head-to-Head-to-Head 
HHT Head-to-Head-to-Tail 
FACS Fluorescent-activated cell sorting 
HMBC Heteronuclear Multiple-Bond Correlation  
HMQC Heteronuclear Multiple-Quantum Correlation 
IC50 Half-maximal inhibitory concentration 
NMR Nuclear Magnetic Resonance 
ARPE-19 Human retinal pigment epithelial cells (non-cancerous) 
BPY 2,2'-Bipyridine 
MLCT Metal-ligand charge transfer 
MTT 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium salt 
CD Circular dichroism 
MRSA Methicillin-resistant Staphylococcus aureus 
PBS Phosphate buffered saline 
APT Attached proton test 
PAMC Post-assembly modification via click chemistry 
TCRP Time-dependent cellular response profiles 
TRZ Triazole 
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Chapter 1  
Peptides and peptide mimetics in cancer therapy 
1.1 Cancer therapies 
As a result of dramatic improvements in understanding of disease mechanism, new 
therapeutics and treatment programs have been developed to the point where most 
cancers are no longer regarded as incurable.1 At the same time, the battle continues to 
improve survival rates and the quality of life of patients.  
 Anticancer drug regimens used in clinic have been classified as chemotherapy, 
hormonal therapy and immunotherapy,2 of which chemotherapy is the most frequently 
used. The common mechanism of action of classical chemotherapeutic agents involves 
interaction with tumour DNA.3 The rationale for this approach was based on the notion 
that cancer is characterized by uncontrolled cell proliferation, and rapidly proliferating 
and dividing cells are generally more sensitive to chemotherapeutic compounds than 
are normal cells.1b-1c However, this relative rate of cellular division provides for weak 
selectivity, not least because many types of normal cell have fast proliferation rates: 
famously those present in hair follicles, bone marrow and the gastrointestinal tract.4 
Correspondingly, the common chemotherapy-induced side effects such as immune 
suppression, neuropathies, gastrointestinal conditions, hair loss, fatigue and skin 
disorders almost always accompany treatment.5 
Alongside the efforts to synthesise novel DNA-targeting chemotherapy agents 
with minimal side effects, new classes of anticancer drug such as antibodies,6 
oligonucleotides7 and peptides8 are being developed. They have novel modes of action, 
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targeting e.g. tyrosine kinases,9 mRNA and the cancer cell membrane. Since these 
agents are designed to have fairly specific binding targets they may have lower toxicity 
to the host than DNA binding/damaging drugs, resulting in a higher selectivity 
(therapeutic index).10 
In this chapter we will focus on the potential use of one such group of 
compounds – small host-defence peptides – as cancer therapeutics; the central 
hypothesis of the work described in this volume is that triplex metallohelices11 may 
function as structural and functional mimics of these compounds.  
1.2 Peptide therapeutics 
Peptides are naturally occurring biological molecules and may be defined as amino 
acid polymers containing no more than 50 units, and which feature secondary 
structures such as helices, sheets, turns and strands.12 More than 7000 naturally 
occurring peptides having been identified which conduct or control crucial functions 
in human physiology e.g. hormones, neurotransmitters, growth factors, ion channel 
ligands, and anti-infective and cellular signallers.13 Compared with traditional small 
molecule drugs, peptides may bind with exquisite specificity to their in vivo targets, 
resulting in exceptionally high potencies and dramatically reduced off-target side 
effects.12 Medical markets have witnessed an upsurge in the development of peptides 
therapeutics such that more than 50 peptide-based drugs such as leuprorelin (Lupron)14, 
peginesatide (Hematide),15 goserelin (Zoladex),16 octreotide (Sandostatin),17 and 
enfuvirtide (Fuzeon)18 are currently approved for clinical use. A number of other 
peptides are in late-stage clinical trials.19 
 A subset of the above, the Host defence peptides (HDPs), also known as 
antimicrobial peptides, are widespread in nature and are used by animals and plants to 
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fend off a range of microbes. They are known to have a broad spectrum of 
antimicrobial activity.20 These peptides share some common characteristics such as 
low molecular weight (the majority containing < 30 amino acids), cationic or 
amphipathic structure21 and low antigenicity compared to other proteins.22 The 
principal modes of action are focussed on interactions with the cellular membrane 
(vide infra). In addition to antimicrobial activity, some synthetic or natural HDPs 
including cecropin B,23 magainins,24 melittin,25 tachyplesin,26 BMAP-2827 and 
lactoferrin,28 have been explored as a new class of anticancer agents.29 
The cell-penetrating peptides (CPPs) are of similar size range to the HDPs but 
are distinguished by their ability to cross the cellular membrane via different 
mechanisms, providing access, as with small molecule drugs, to intracellular targets 
and for example promising a strategy for drug delivery.30 The transactivator of 
transcription (TAT) protein of HIV, the first discovered CPP, was found to cross cell 
membranes and be efficiently internalized by cells in vitro in 1988.31 A few years later, 
the Drosophila Antennapedia transcription factor proteins were shown to be able to 
translocate cell membranes and enter cells.32 From then on, a series of natural or 
synthetic CPPs has been identified with the same membrane-crossing properties.33 In 
recent years, various studies have revealed the applications of CCPs serving as vectors 
for the delivery of various cargos such as siRNA,34 nucleic acids,35 small molecule 
therapeutic agents,36 proteins,37 quantum dots,38 cellular imaging agent,39 and MRI 
contrast agents.40 Meanwhile, several bioactive CPPs have been developed with 
notably proapoptotic or antitumor activities.41 The main characteristics of the CPPs 
are low cytotoxicity, capacity to be taken up by a variety of cell types, dose-dependent 
efficiency, and capacity to transport a wide range of size and type of cargo.42 
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With these structure types in mind we will review the main mechanisms of 
action proposed in their interactions with membranes and intracellular targets.  
 
1.3 Membrane interaction & transport mechanisms 
Membrane selectivity 
The outermost leaflet of the microbial cells membrane displays negative charge as a 
result of the preponderance of phospholipids. Electrostatic interactions with cationic 
peptides e.g. HDPs is proposed to be a key factor in the modes of action43,20 as 
described herein. In contrast, the outer membrane of normal/healthy human cells is 
comprised of zwitterionic phosphatidylcholine and sphingomyelin components,44 and 
the consequent relatively weak interactions with cationic peptides forms a basis for 
antimicrobial selectivity. 
 Cancer membrane components are in this sense similar to microbial systems.45 
Anionic lipid phosphatidylserine (PS), normally located in the inner leaflet of 
eukaryotic plasma membranes,44 is exposed 3-7 fold more than in normal 
keratinocytes.46 This has been described as a general phenomenon for cancer cells.21 
Another enhancement of negative charge on the surface of cancer cells arises because 
O-glycosylated mucins, which playing a role against oxidative stress-induced cell 
death, facilitating cell adhesion during tumour metastasis and alter the function of 
surface-interacting proteins47 are aberrantly overexpressed in various malignancies.48 
Membrane fluidity and microvilli may also contribute to the preferential killing of 
cancer cells by HDPs. The increased membrane fluidity of cancer cells will enhance 
the lytic activity of peptides by facilitating membrane destabilization.49 The higher 
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numbers of microvilli on the cancer cell increases the surface area of the tumorigenic 
cell membranes and allows cancer cells to bind a larger amount of HDP.50 
Membrane disruption 
Non-specific membrane disruption, also called cell lysis, refers to a mechanism by 
which agents, often at high concentrations, compromise the integrity of the cell 
membrane and thereby cause cell death. Numerous nonspecific membrane-active 
small molecules exist e.g. biocides, chaotropic agents and other synthetic chemicals.51 
Here, however, we are concerned with some of the more subtle membranolytic 
mechanisms characteristic of the action of peptides. Unsurprisingly, such mechanisms 
are common to many small amphipathic peptides, be they described as HDPs, CPPs 
etc. After adsorption onto the cancer cell membrane surface by electrostatic interaction 
as described above, peptides can induce a variety of membrane changes.52 
Some cationic amphipathic peptides adsorb onto the membrane surface and 
orient parallel to the bilayer surface in a carpet-like manner.53 These peptides cover 
the outer leaflet of the membrane tightly and disrupt the integrity of the supramolecular 
structure. Membrane fragmentation may occur when the peptide carpet accumulation 
is sufficiently dense, causing the leakage of the cytoplasmic contents, ions, and 
biomolecules.52 Such a mechanism is clearly related to simple surfactancy, and 
requires a relatively high concentration of peptide in the membrane.54 
A number of peptides cause cell lysis by pore formation. The accumulation of 
the peptides on the cell surface causes a thinning of the bilayer, by which outwardly 
facing hydrophobic residues interact with the lipid membrane, while hydrophilic 
groups with high curvature form a central lumen to create the transient holes which 
are termed toroidal pores.55 Membrane pores result in the loss of the membrane 
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potential and rapid release of intracellular components, triggering cancer cell 
necrosis.56 
 
Figure 1-1 The mechanism of membrane disruption caused by peptides 
Transport through the Membrane  
Many mechanism have been proposed by which small molecules such as drugs enter 
cells, and it is worth noting that while there is a prevailing assumption that passive 
diffusion is the principal route of ingress, there is a highly credible argument for a 
carrier-mediated view of drug uptake i.e. that drugs predominantly enter cells via 
promiscuous proteinaceous carriers.57 Also, it is worth noting that many of the energy 
independent (passive) and energy-dependent (active) mechanisms we describe below 
might be considered to be closely related to one another.  
There are three main models described for direct translocation of peptides into 
the cytosol via energy-independent pathways: inverted micelle formation58, adaptive 
translocation59 and pore-formation (Figure 1-2).20 
In the inverted micelle formation model it is proposed that the positively 
charged peptide residues interact with the negatively charged phospholipids in the 
plasma membrane, and subsequently, interaction of the hydrophobic segments with 
the membrane core induces destabilization of the bilayer forming a negative 
curvature.60 The concomitant reorganization of the neighbouring lipids leads to the 
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formation of the inverted micelle that encapsulates peptide molecules. Membrane 
disruption releases the peptide on the intracellular side.61 
Adaptive translocation describes the interaction between guanidinium-rich 
peptides and the phosphate lipid head-groups, which masks the peptide charge, 
attenuating its polarity and enabling its adaptive diffusion into and across the 
membrane.59 
In the pore formation model the accumulation of the peptides on a small region 
of the cell surface causes a local thinning of the bilayer, eventually creating a central 
lumen composed principally of negatively charged phospholipids and stabilised by the 
cationic peptide. The passive diffusion of peptides across the plasma membrane is thus 
facilitated.55a, 55b 
 
Figure 1-2 Examples of the proposed mechanisms for direct translocation. (A) Inverted micelle 
formation. (B) Pore-formation. (C) Adaptive translocation. 
Endocytosis is an energy-dependent transport mechanism, which is used to 
take up large objects such as other cells, viruses and bacteria (Figure 1-3).62 Major 
classes of endocytosis include clathrin- and caveolin-dependent endocytosis,63,64 as 
well as macropinocytosis65 and phagocytosis.63, 66 The process consists of: (a) the 
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initial electrostatic interactions between the peptides and negatively charged 
components on the cellular plasma membrane, and destabilizing the bilayer to form a 
negative curvature,60 (b) the concomitant reorganization of the neighbouring lipids 
leading to the formation of the inverted endosome that encapsulates peptides,61 (c) 
endosomal escape; and (d) cytoplasmic or nuclear localization.54 If the transported 
objects remain trapped inside the endosomes, they can be subjected to lysosomal 
degradation which negates the biological effect of the cargo. Endocytosis mechanisms 
cannot cause cancer death directly, but could deliver peptides into cytoplasm so as to 
take part in active-site type mechanisms such as those described below. 
 
Figure 1-3 Schematic Illustration of Some of the Various Mechanisms by which a Cell Penetrating 
Peptide and Attached Cargo May be Internalized into a Cell 
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1.4 Receptor-mediated and other intracellular mechanisms 
We described above the simple idea that cationic peptides are attracted to an anionic 
membrane, and as a result of the charge and/or the amphipathic detergent-like structure, 
the membrane is disrupted. Evidently however, many HDP anticancer mechanisms are 
of a more subtle nature. 
Disruption of mitochondrial membrane 
Molecules such as BH3 peptide,67 DPI peptide,68 pro-apoptotic peptide69 and 
mitochondria penetrating peptides70 penetrate into the cytoplasm, disrupt 
mitochondrial membrane and thereby release cytochrome c (Cyt c), inducing Apaf-1 
oligomerization, caspase 9 activation and the subsequent conversion of pro-caspase 3 
to caspase 3. Finally, caspase 3 will lead to apoptosis of cancer cells.68, 71 Peptide 
mediated mitochondrial membrane perturbation is also part of the Alzheimer’s disease 
mechanism; amyloid β-peptide acts locally in mitochondrial membranes to induce 
oxidative injury, leading to increased membrane permeability and subsequent release 
of caspase-activating factors.72 
 
Inhibition of protein-protein interactions 
Protein–protein interactions (PPIs) are essential for almost all cellular processes, 
including signal transduction, membrane transport, cell proliferation, growth, survival, 
and programmed death.73 There are a total of 650,000 PPIs in the human proteome.74 
PPIs also play a critical role in a broad range of diseases, especially for cancer 
growth.75 For instance, p53/HDM2 interaction has been detected in many types of 
cancers.76 HDM2 downregulates the tumour suppressor p53 which induces cell cycle 
arrest and apoptosis in response to DNA damage and cellular stress.77 A set of β3-
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peptides have been revealed to inhibit the p53/HDM2 interaction with nanomolar 
affinity in cell-free system;78 the potencies in vivo are under investigation. PPIs 
between Bcl-2 family members contribute to tumour initiation, progression and 
resistance to therapy.79 Bcl-2 binding peptide CPM-1285 showed anticancer activities 
inducing apoptosis in vitro and in vivo.80 
All these researches demonstrate the significance of controlling and 
modulating PPIs in the development of new molecular therapeutics. Interestingly PPIs 
are considered to be “undruggable” by small molecules;81 the binding surfaces 
between proteins are usually large (1500–3000 Å2) and involve many polar and 
hydrophobic interactions, whereas most small molecules target well-defined cavities 
of enzymes or receptors.82 In addition, binding surfaces are typically flat, with a less 
well-defined shape for binding of a small-molecule drug.81 An alternative approach 
for the discovery of PPI inhibitors is centred on the role of protein secondary structures 
at protein interfaces, especially the α-helix which is the most common protein 
secondary structural element, and contributes to 62% of PPI interfaces.83 
DNA binding 
Anticancer mechanisms caused by DNA binding can be majorly classified into two 
species, DNA duplex binding and G-quadruplex binding. DNA duplex is generally 
considered as the molecular target for the chemotherapeutic agents.3 DNA duplex 
binding, driven by intercalation, groove binding or covalent binding,84 leads to a 
variety of significant biological responses, including the inhibition of DNA synthesis, 
G2 arrest in the cell cycle, and apoptosis.85 DNA G-quadruplex, enriched in cancer-
related genes and regions,86 are formed by guanine-rich nucleic acid sequences 
through strong hydrogen-bonding.87 DNA G-quadruplex binding could result in 
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downregulation of specific gene expression and telomerase inhibition, and stimulate 
DNA damage responses.88 
A four-ring tripeptide has been demonstrated specifically binding six-base pair 
5'-(A,T)GCGC(A,T)-3' sites in the minor groove of DNA.89 Two peptides mimicking 
basic regions of natural leucine zipper proteins were uncovered to bind in the major 
groove of DNA.90 DNase I footprinting experiments show that a disulphide-bonded 
dimer of peptide containing 27 residues of the basic region of the yeast transcriptional 
activator GCN4 can bind specific sequence with DNA.91 Short peptides derived from 
the non-histone chromosomal protein HMG-I/Y bind specifically to the minor groove 
of DNA.92 LL37 peptide can form a complex with DNA and induce DNA packaging 
into aggregated and condensed structures to trigger Toll-like receptor 9.93 
1.5 Peptide mimetics 
Small peptides commonly exist in random conformational states in solution, adopting 
active secondary structures during the binding event.82 Despite this, they have 
favourable pharmacodynamics, but of course in the unfolded state they have low 
resistance to proteases leading to relatively poor pharmacokinetic profiles. 94 These 
issues have prompted studies into various strategies including helix stabilization,81 and 
the design of non-peptide scaffolds.  
Stapled peptide mimetics 
Stabilisation of the active conformations of peptides, i.e. increasing the α-helical 
content, is expected to reduce the rate of degradation by proteases and thus improve 
pharmacokinetic properties, as well as improving pharmacodynamics. A number of 
methods involving intramolecular side chain to side chain cross-links such as 
intramolecular hydrogen bonds,95 salt bridges,96 metal chelates97 and covalent 
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crosslinks have been developed (Figure 1-4).82 Approaches including thiol-, lactam-, 
hydrocarbon and hydrogen-bonding surrogate staples, have been successfully applied 
to the generation of PPI inhibitors. 
Disulfide Bridge Peptides constrained by intramolecular disulfide bridge at i 
and i+4 or i+7 residues, show an increased α-helical content compared to their acyclic 
counterparts [Figure 1-4 (b)].98 However, disulfide cross-links are labile under 
reductive conditions in the cytoplasm. Further, the replacement of disulphide bridges 
with chemically more stable linkers such as m-xylene99 and bisarylmethylene100 (not 
shown) increased peptide cell permeability and the efficiency as PPI inhibitors. 
Lactam bridge Lactam bridges linking (i, i+3), (i, i+4), or (i, i+7) amino acid 
residues have been used to introduce conformational constraints in peptide structures 
[Figure 1-4 (c)].101 Compared with disulphide bridges, amide bonds are much more 
chemically inert under cellular conditions. Biological studies have focused on the 
potential application of lactam-bridged peptides for peptide-protein recognition, 
protein folding as well as interactions with cell surface receptors.102 
Hydrocarbon bridge The building blocks here are non-proteinogenic bearing 
terminal olefin tethers of varying lengths which are ring-closed by metathesis using 
Grubbs type catalysts [Figure 1-4 (d)].103 Dramatic improvements are observed in 
resistance to proteolytic degradation, cell-penetration, and in vivo half-life.104  
Hydrogen-Bond Surrogates (HBS) This is closely related to the above in that 
ring-closing metathesis105 is used at the position shown [Figure 1-4 (e)]. The overall 
outcome is that a short carbon chain replaces the NH···O=C hydrogen bond moiety 
[Figure 1-4 (a)] in a natural structure.106 Compared with other cross-linkers (e.g. 
disulphide, lactam), the HBS approach exert the desired effect of stabilising the helical 
conformation without dramatically altering the surface topography of the target 
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helix.107 HBS peptides have improved conformational stability and cellular uptake, 
increasing PPI affinity.108 
 
Figure 1-4 Different α-helix stabilization strategies 
Non-peptide scaffolds 
Non-peptide scaffolds have in the main been aimed at the production of rod-like 
structures with appropriately placed functional groups so as to mimic the orientation 
of the side-chains in -helix peptides.109 While this may not only accurately reproduce 
the same binding mode as the native protein, it does provide structural diversity, with 
a potentially large library of synthetic building blocks available, and the products are 
very likely to display resistance to proteolytic mechanisms (Figure 1-5).82 A great 
number of researches have been carried out on the identification of scaffolds with more 
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versatile and accessible synthetic chemistry and with arguably more ‘drug-like’ 
properties than peptides i.e. principally better pharmacokinetics.109 
 
Figure 1-5 Concept of structural a-helix mimetics: Left: Stick and schematic representations of a α-
helix. Right: Stick representation and chemical structure of a terphenyl structural mimetic.82 
Based on different mechanisms by which the helix-like structure is promoted, 
non-peptide scaffolds have been classified in three groups: sterically enforced, 
hydrogen-bond guided, and covalently constrained scaffolds (Figure 1-6).82 
Terphenyls and heterocycles are typical sterically enforced scaffolds in which 
the conjugation of the aromatic rings represents the major contribution to spatial 
preorganization.82 
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Figure 1-6 Examples of the non-peptide scaffolds81 
Aromatic oligoamide templates including trispyridylamides,110 3-O-
alkylated-,111 2-O-alkylated112 and N-alkylated oligobenzamides,113 represent 
hydrogen-bond guided scaffolds. The intramolecular hydrogen bonds between the NH 
group of the amides and the ortho alkoxy functionalities on the same face of the 
molecule induce a structural constraint, resulting in a curvature of this scaffold, thus 
enabling -helix mimicry.110 
Oligooxopiperazines114 and spiroligomers115 are covalently constrained 
scaffolds which possess a chiral backbone. The chirality of the structure has been 
evidenced to render a higher binding specificity.82 
Despite improvements in such helix-proteomimetics, they are not readily able 
to target more than one face on the hot-spot of a PPI.109 Furthermore, the 
preponderance of aromatic rings increases the hydrophobicity of these molecules and 
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limits aqueous solubility. Further, there is a question over their synthetic accessibility 
and eventual cost of goods. All these obstacles provide an impetus for the development 
of new scaffolds. 
Helicates and other Metallohelices 
Metal coordination presents great opportunities for the construction of diverse 
molecular architectures.116 In principle ligands can be tailor-made for specific 
interactions, and the strength, reversibility and defined directionality of coordination 
bonds allows precise control over the three-dimensional structure and stability of the 
final assembly. Peptides frequently use metal ions to control structure, and indeed a 
number of researchers are using ligand-modified peptides to create unnatural 
metallated assemblies.117 In this section we will however focus on non-peptide 
systems arising originally from J.-M Lehn’s “helicate” concept118 focusing on systems 
which are aimed at drug discovery. A large number of helicate systems have been 
produced and this area has been reviewed,119 although few systems have properties 
that make them suitable for application as pharmaceuticals.  
 
Figure 1-7 Bis-pyridylimine ligand and the helicate structure 
In 1997, Hannon and co-workers simplified the well-established bipyridine 
helical systems of Lehn with pyridylimine binding sites linked by a central 
diphenylmethylene group. Reaction of methanol solutions of three equivalents of the 
ligand LH with two equivalents of Fe(II) salts induced the formation of the triple-
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helical architecture of Figure 1-7. The rigid ligand system mechanically couples the 
helical coordination environments, requiring them to adopt the same stereochemistry 
(i.e. Δ,Δ, or Λ,Λ). The ensuing triple-helix structure has a well-defined pitch.  
The reported syntheses of this and closely related compounds involve the use 
of weakly-coordinating anions (PF6
-) for ease of isolation, followed by exchange with 
chloride to provide water solubility. A number of biological studies followed using 
this water-soluble chloride salt “[Fe2LH3]Cl4”. In fact, the synthesis and 
characterisation of this specific moiety has only recently been reported, and contrary 
to earlier reports it is a tetrahydrate.11 Related examples of this helicate class arose 
from replacing the bridging -CH2- with –O-, minor modifications to the pyridines
120 
and Ru(II) analogue(s).121 The latter, along with the original bis-Fe(II) helicate, is 
reported to be resolvable into enantiomers on cellulose,120, 122 but although 
enantiomeric enrichment is supported by circular dichroism, the optical purity was not 
quantified. This might be achieved through the use of an NMR shift reagent as has 
been achieved in related systems.123 Helicates with appended arginine124 and short 
peptide fragments125 were subsequently reported via multi-step routes. Helicity was 
seen to be controlled to within the limit of signal:noise for the NMR spectra 
observed.124  
Antibacterial activity of [Fe2LH3]Cl4 was studied.
126 Unfortunately the 
compound was found to be unstable in standard broths127 so a special in-house medium 
was devised. While this makes comparison with other compounds difficult, potencies 
were certainly low, with reported MICs of 32 μg/ml against Gram-positive B. subtilis 
strain 168, and 64 μg/ml against Gram-negative E. coli strain GM2163 respectively. 
In our hands,11 and in those of others,128 no activity was observed.  
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Great attention has been given to the ability of these helicate to bind DNA 
motifs in vitro, especially the B-DNA major groove121b, 129 and three-way junctions 
(3WJ)124, 130 inducing conformational changes.121b Inhibition of the interaction 
between the HIV-1 transactivator protein Tat and TAR (transactivation responsive 
region) RNA was reported.131 
The anticancer activities of this metallohelicate towards human breast cancer 
cell (HBL-100 and T47D) are 2-5 times lower than cisplatin.132 Qu and co-workers 
discovered that the helicate could specifically target the α/β-discordant stretch and 
strongly inhibit Alzheimer’s disease -amyloid aggregation.133 
 
Figure 1-8 Chemical structures of the pyridyl-1,2,3-triazole ligand; the molecular structure 
of [Ru2LC13](PF6)4 
Crowley and co-workers synthesised a ruthenium(II) triply-stranded helicate 
[Ru2LC13]
4+ by using a bis-bidentate ‘‘click’’ pyridyl-1,2,3-triazole ligand LC1 and 
RuCl3 (Figure 1-8).
128 Extremely modest antimicrobial activity in vitro was observed 
against both Gram positive (S. aureus) and Gram negative bacteria (E. coli) (MIC > 
256 µg/mL).  
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Figure 1-9 Chemical structures of the triazole (bntrz) based ligand; the molecular structure of 
[Pd2(bntrz)4](BF4)4 
The same group synthesised a quadruply-stranded dipalladium architecture 
(Figure 1-9)134 by simple reaction of the 1,3-phenyl linked ditriazole ligand LC2 with 
[Pd(CH3CN)4](BF4)2.
135 The helicate exhibits a range of cytotoxic properties towards 
A549 (lung cancer), Cisplatin resistant MDA-MB-231 (breast cancer) and DU-145 
(prostate cancer). Disappointingly, the [Pd2(bntrz)4](BF4)4 helicate displayed no 
selectivity towards cancerous phenotypes. 
 
 
Figure 1-10 Structure of the ligands and the flexicate 
Scott and co-workers designed and synthesised a series of unusually stable, 
optically pure and water soluble triple-stranded Fe(II) assemblies.136 The chiral 
diamine linker LS1 or dialdehyde linkers LS2 assembling with pyridine aldehyde 
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derivative or the chiral amine in the presence of FeCl2 to form two series (Figure 1-
10). The helicity of the metal-complex comes from steric effects and π-stacking 
interactions pre-programmed in the optically pure monometallic units rather than via 
traditional mechanical coupling, and for this reason i.e. they did not use or rely on 
helication as a method of stereoselection, they were termed “flexicates”. Preliminary 
anticancer screening revealed that while some flexicates have comparable activity to 
cisplatin against MCF7 (human breast adenocarcinoma) and A2780 (human ovarian 
carcinoma) they are ca five times more potent than cisplatin against A2780cis with no 
significant DNA damage.137 Moreover, some flexicates possess excellent selectivity 
towards HCT116 colorectal cancer cells and healthy human retinal pigment epithelial 
(ARPE19) cells.138 Qu and co-workers demonstrated the flexicates can act as a novel 
class of chiral amyloid-β inhibitors by enantioselectively inhibiting Aβ aggregation.139 
The same group also revealed flexicates can stabilize human telomeric hybrid G-
quadruplex DNA and strongly inhibit telomerase activity.140 
 
Figure 1-11 Self-assembly from versatile components of a wide range of functionalized helices in 
which the strands are arranged head-to-head-to-tail 
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The 2-phenyliminopyridine stereogenic unit in the above was also exploited to 
create a highly stereoselective asymmetric self-assembly of very stable, functionalized 
metallohelices with an antiparallel head-to-head-to-tail (HHT) “triplex” strand 
arrangement (dr > 98) (Figure 1-11),11 the name being a reference to structure of 
triplex DNA. The compounds were synthesised by using 3 equiv. of directional ditopic 
ligands LS3 or LS4 in the presence of 2 equiv. FeCl2. The absolute configuration of the 
triplex architectures as well as the uniquely selective directionality arose because this 
maximises the number of phenyl-bipyridine π-stacks which, according to calculations, 
are relatively strong. In addition, one of the two classes of ligand design also gave 
inter-strand bifurcated C–H···O/N interactions. The triplex systems display high 
structure-dependent toxicity to the human colon carcinoma cell-line HCT116 p53++ 
and human breast adenocarcinoma cells (MDA-MB-468), causing dramatic changes 
in the cell cycle without DNA damage. Interestingly, they show no significant toxicity 
to Gram-positive and -negative bacteria. 
 
1.6 Proposal 
Peptides such as HDPs and CPPs feature exceptionally high potencies and reduced 
off-target side effects as cancer therapeutics due to the ability to bind with exquisite 
specificity to their in vivo targets.12 They are selectively absorbed onto the cancer cell 
membrane by electrostatic interactions43,20 and translocated into the cytosol via 
energy-independent pathways20,58,59 or endocytosis.62 The main modes of action 
include disruption of mitochondrial membrane;67-70 inhibition protein–protein 
interactions (PPIs)78 and DNA binding.89,90 However, due to the low resistance to 
proteases, natural peptides have relatively poor pharmacokinetic profiles.94 
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Alternatively, stapled peptide mimetics,82 non-peptide scaffolds109 including 
metallohelices136,11 are being developed.  
Despite the achievements thus far in the use of metallohelices as potential 
peptidomimetic drugs, significant barriers remain in the translation of these 
compounds to a clinical situation. Until recently, rather few such compounds have 
possessed the generic properties of drug candidates, such as optical purity, solubility 
in water and stability in media.141 Several synthetic issues have also hampered their 
development. For instance, in order to couple the absolute configurations of adjacent 
metal centres (helication), rigid ligands must be used. However, the excess of aromatic 
rings thereby employed inevitably leads to hydrophobicity and poor aqueous solubility. 
Further, symmetrical ligands need to be employed so as to reduce the number of 
possible isomers from self-assembly, and the subsequent structures fall far short of the 
exquisite asymmetric topographies of natural peptides. Derivatisation of 
metallohelices is also great challenge; the ligands have to be relatively simple and free 
of extra functionality in order to avoid potential incompatibilities and interference in 
the self-assembly process.142,143 All these obstacles impel us to develop new synthetic 
strategies for making novel asymmetrical, functionalized metallohelices. 
Post assembly modification (PAM) of metal-complexes143-145 allows the 
addition of a more diverse range of functional groups, potentially circumventing the 
limitation of self-assembly conditions, allowing facile purification and isolation, and 
maintains the structural identity of the system. This methodology is especially 
prevalent in metal-organic frameworks (MOFs) which tend to be relatively stable, and 
numerous functionalisation reactions such as alkyne bromination,146 aldehyde 
reduction,147 hydroxyl etherification,148 N-acylation144-145, 149 (e.g. Figure 1-12), N-
alkylation,150 and imine reduction151 have been validated. Although the structure of 
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MOFs are quite different from metallohelices, these researches demonstrate that it is 
reasonable to apply this methodology to the derivatisation of stable complexes.152  
 
Figure 1-12 Modification of pre-formed metal-organic lantern cage144 
The conditions of the PAM reactions above are generally rather harsh, using 
high temperatures or long reaction times, and it is unlikely that metallohelices based 
on relatively labile metal-ligand bonds will be sufficiently robust. Nevertheless, the 
high stability of the so-called flexicate136 and triplex11 metallohelices developed in this 
laboratory may allow them to be modified via relatively mild reactions such as 
Copper-catalysed Azide/Alkyne Click (CuAAC). Such reactions have not been 
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Chapter 2   
Alkyne functionalized metallohelices 
2.1 Introduction 
Alkyne groups, especially the terminal alkyne, are versatile units for organic and 
inorganic synthesis. Reactions including reduction,1 hydration,2 hydrohalogenation,3 
halogenation4 and ozonolysis5 can be used readily to introduce a range of functional 
groups. The recently popularised Huisgen copper-catalysed azide/alkyne 
cycloaddition “click” reaction CuAAC6 allows alkynes to function as latent reactive 
groups, even under biologically compatible conditions, providing potential chemical 
tools for a wide range of applications7 such as click modification of DNA8 and 
proteins,9 cell imaging,10 conjugating to small peptides11 and surface-enhanced Raman 
scatting detection.12, 13 To our knowledge, no metallohelix system has previously 
contained terminal alkyne groups for this kind of application, although this laboratory 
recently developed a synthesis of optically pure heterobimetallic Fe-Cu via CuAAC,14 
and other studies have been reported on the use of click chemistry to form 1,2,3-
triazole groups as active ligands15, 16 or to derivatise metal complexes (See Chapter 
3).17 
In this chapter we will explore the synthesis of alkyne derivatives of 
metallohelices; two types of flexicate architecture and one triplex system. Preliminary 
anticancer studies of these compounds are included. The feasibility of CuAAC 
reactions is also addressed. 
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2.2 Synthesis of alkyne-decorated flexicates 
In earlier work it was found that the CuAAC ‘click’ reactions of the monometallic 
complex14 shown in Scheme 2-1(a) were very efficient, proceeding to completion with 
catalytic quantities of CuI. In this architecture, derived from sub-component amine 1 
the structure is preorganised for coordination of the Cu(I) ion by the subsequent 
triazole units. Indeed, when stoichiometric amounts of CuI were added, stable Fe-Cu 
helicates as shown (a) were created directly, and removal of the Cu ions was not 
achieved without decomposition of the Fe complex.  
 
Scheme 2-1 “Click” reactions between monometallic complexes and PhCH2N3 
In contrast, similar reactions in Scheme 2-1(b) of Fe(II) complexes 
incorporating pyridine 2 were much less efficient, requiring stoichiometric amounts 
of catalyst in order to proceed to completion.14 Thus, for flexicate or triplex systems, 
while we might seek to incorporate alkyne groups into the ligand structure via either 
the pyridine carboxaldehyde (2) or chiral amine (1) sub-components, it is by no means 
clear which would be the most successful. 
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2.2.1 Diamine “Flexicate” alkyne derivatives 
The prototype diamine flexicate architecture18 has recently been expanded 
significantly in this laboratory by Dr Daniel H Simpson. The diphenylether diamine 
system 3 gave a flexicate with MIC of 2 μg/ml in Methicillin-resistant Staphylococcus 
aureus (MRSA). Based on this observation and the high chemical stability of the 
system, this bridge architecture was chosen to be exemplified as an alkyne derivative 
(Scheme 2-2).  
 
Scheme 2-2 Self-assembly of diamine alkyne flexicate 
Synthesis of the alkyne pyridine carboxaldehyde 2 
 
Scheme 2-3 Synthesis of the 5-(prop-2-yn-1-yloxy)picolinaldehyde 
The sub-component 5-(prop-2-ynyloxy)picolinaldehyde (2) was synthesised as shown 
in Scheme2-3. Modified literature procedures were used as far as compound 7.19 First, 
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5-hydroxy-2-methylpyridine was treated with m-chloroperoxybenzoic acid to form 5-
hydroxy-2-methylpyridine-1-oxide (4). Refluxing 4 in acetic anhydride yielded 2-
acetoxymethyl-5-acetoxypyridine (5) quantitatively. Subsequently, 5 was hydrolysed 
in hydrochloric acid to form 6-(hydroxymethyl)pyridin-3-ol (6). Oxidation of 6 with 
activated manganese (IV) dioxide gave 5-(hydroxy)picolinaldehyde (7) which was 
converted to 5-(prop-2-ynyloxy)picolinaldehyde (2) in presence of with two 
equivalents of potassium carbonate and an equimolar amount of propargyl bromide in 
acetonitrile. The crude product was recrystallized in DCM:Hexane (1:4; v:v) to yield 
white yellow solid in overall 39% yield. 
Synthesis of phenylglycinol enantiomers 8 
 
Scheme 2-4 Synthesis of phenylglycinol (R)-8 
Reduction of optically optical pure D-phenylglycine was conducted using lithium 
aluminium hydride to form the phenylglycinol (R)-8 (Scheme 2-4).20, 21 The white 
crystalline compound was obtained by recrystallization in hot toluene. (S)-8 was 
synthesised from L-phenylglycine but was not used in this chapter. 
Synthesis of diphenylether diamine (R,R)-3  
 
Scheme 2-5 Synthesis of diphenylether diamine (R,R)-3 
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Bis(4-(bromomethyl)phenyl)methane was supplied by Dr Daniel H Simpson. 
Deprotonation of (R)-phenylglycinol 8 was conducted using an excess of sodium 
hydride in the presence of ca one equivalent of [15]-crown-[5] (Scheme 2-5). The 
diamine product (R,R)-3 was achieved by subsequent addition of the appropriate 4,4'-
oxybis((bromomethyl)benzene) and was purified by silica gel column 
chromatography using DCM/MeOH/TEA (200/1/1; v:v:v). Diamine 7 was isolated as 
yellow solid in 72% yield. 
Assembly of complex (Rc,ΔFe)-[Fe2L13]Cl4 
The synthesis of the new alkyne-decorated iron(II) flexicate followed the same general 
method as previously reported.18 The diamine (R,R)-3 (3 eq.), alkyne aldehyde 2 (6 
eq.) and iron(II) chloride (2 eq.) were dissolved in methanol and heated to reflux for 
48 h (Scheme 2-2). The dark purple solution was filtered through celite and was 
evaporated carefully to dryness. The product was analysed by NMR, mass 
spectrometry, microanalysis, and circular dichroism. 
The 1H NMR spectrum of (Rc,ΔFe)-[Fe2L13]Cl4 in MeOD at 298 K indicates a single 
bimetallic flexicate (Figure 2-1). The imine peak Ha was observed at 9.24 ppm, along 
with the doublet peak Hb for the NCHPh proton adjacent to the imine nitrogen atom 
at 5.78 ppm. The propargyl protons of Hc (-CH2C≡C) and H
d (C≡CH) were centred at 
4.73 ppm and 3.22 ppm respectively. Other 1H NMR and 13C NMR spectra signals 
were fully assigned and are consistent with the presence of single, non-racemising 
diastereomers in solution. Notably, the alkyne C-H signal is out of phase with the rest 
of the CH and CH3 signals due to the large C-H coupling constant (
1JC-H = 250Hz). 
This is observed for all alkyne groups in the thesis. In the MS, an envelope observed 
at m/z 594 is consistent with the presence of [Fe2L
1
3]
4+ ion isotopomers. 
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Figure 2-1 1H NMR (500 M Hz, MeOD, 298K) and 13C NMR (125 M Hz, MeOD, APT, 298K) 
spectrum of diamine alkyne flexicate (Rc,ΔFe)-[Fe2L13]Cl4. 
2.2.2 Dialdehyde “flexicate” alkyne derivatives 
 
Scheme 2-6 Synthetic route to the formation of (Rc,ΔFe)-[Fe2L23]Cl4 
A series of bimetallic flexicates have been made in presence of dialdehyde linker 
derivative, (R/S)-1-phenylethan-1-amine and FeCl2 by Dr Rebecca A. Kaner in this 
laboratory.22 In vitro cytotoxicity screening revealed that the Δ enantiomer flexicate 
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containing dialdehyde linker 9 was extremely active towards human tumour cell lines: 
MDA-MB-468, HCT116 p53+/+ and HCT116 p53-/-, especially for HCT116 p53-/- 
cancer cell line with IC50 value 40+3 nM. This flexicate also exhibited much lower 
toxicity to the human non-cancer retinal pigment epithelial cells (ARPE19). Therefore, 
the dialdehyde unit 9 was chosen to assemble with chiral alkyne amine 1 to form 
dialdehyde alkyne flexicate (Scheme 2-6). 
Synthesis of alkyne chiral amine enantiomers 1 
 
Scheme 2-7 Synthesis of (R)-1-phenyl-2-(prop-2-yn-1-yloxy)ethan-1-amine 
Optically pure 8 was converted to (R)-1-phenyl-2-(prop-2-yn-1-yloxy)ethan-1-amine 
(1) using a modified Williamson ether synthesis in the presence of sodium hydride and 
propargyl bromide (Scheme 2-7).14 This crude product was purified by silica gel 
column chromatography by using DCM/MeOH/TEA (500/5/2; v:v:v) as the eluent to 
isolate 1 as yellow oil in 75% yield. 
Synthesis of alkene dialdehyde unit 9 
 
Scheme 2-8 Synthesis of alkene dialdehyde unit 9 
The alkene (E)-5,5'-(but-2-ene-1,4-diylbis(oxy))dipicolinaldehyde (9) was 
synthesised via Williamson etherification of 7 with 1,4-trans-dibromobut-2-ene in the 
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presence of potassium carbonate.22 The white solid product was obtained by silica gel 
column chromatography with eluent DCM/MeOH/TEA (350/5/2; v:v:v) in 85% yield. 
Assembly of complex (Rc,ΔFe)-[Fe2L23]Cl4 
Similar synthesis with diamine alkyne iron(II) flexicate (Rc,ΔFe)-[Fe2L13]Cl4, 
dialdehyde alkyne iron(II) flexicate was formed by mixing and refluxing the alkene 
dipicolinaldehyde linker 9 (3 eq.) and (R)-1-phenyl-2-(prop-2-yn-1-yloxy)ethan-1-
amine (1) (6 eq.), with iron(II) chloride (2 eq.) in methanol (Scheme 2-6). After 48 h, 
the dark purple solutions were filtered through celite and evaporated carefully to 
dryness. The products were analysed by NMR, mass spectrometry, microanalysis, 
thermogravimetric analysis, infra-red, UV-vis absorption, and circular dichroism. 
The 1H NMR spectrum of (Rc,ΔFe)-[Fe2L23]Cl4 in MeOD at 298 K indicates 
high diastereomeric purity: the presence of single peak Ha in the imine region (9.03 
ppm), ortho pyridine proton Hb at 6.50 ppm, alkene proton Hc at 6.03 ppm, stereogenic 
centre proton Hd at 5.87 ppm and alkyne proton He at 3.17 ppm. The 13C NMR 
spectrum was also consistent with this and was fully assigned. (Figure 2-2). 
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Figure 2-2 1H NMR (500 M Hz, MeOD, 298K) and 13C NMR (125 M Hz, MeOD, 298K) of 
dialdehyde alkyne flexicate (Rc,ΔFe)-[Fe2L23]Cl4 
The complexes gave excellent electrospray high resolution mass spectrometry 
data [Figure 2-3(a)], (Rc,Fe)-[Fe2L23]Cl4 gave a strong peak at m/z 487.1722 Da for 
the tetracationic molecular ion, which was consistent with calculated value (m/z 
487.1724 Da). Circular dichroism spectra of each pair of enantiomers were recorded 
in methanol. Each displayed equal and opposite spectra, indicating that the complexes 
were formed in non-racemic mixtures of opposite configurations [Figure 2-3(b)]. 
 




Figure 2-3 High resolution mass spectrum: top measured, below calculated (a) and CD spectrum (b) 
of dialdehyde alkyne flexicate [Fe2L23]Cl4 
2.2.3 Click reactions of alkyne flexicates 
Both alkyne flexicates classes above were considered to be sufficiently stable to 
undergo click condition. Benzyl azide was employed to attempt the click reaction on 
alkyne flexicates. CuI was utilized as the Cu (I) catalyst with the reason that CuI is 
effective, low soluble in methanol and easy to remove. 
Attempt to click benzyl azide onto diamine flexicate 
 
Scheme 2-9 Attempt to modify diamine alkyne flexicate by using click chemistry 
The reaction of flexicate (Rc,ΔFe)-[Fe2L13]Cl4 was conducted in methanol with 
1.5 equivalents of azidomethyl benzene in the presence of a catalytic amount of 
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copper(I) iodide (Scheme 2-9). The Cu(I) catalyst was removed by filtration and the 
product was recrystallized from methanol/ethyl acetate. 
 
Figure 2-4 1H NMR spectra (400 MHz, 298K, MeOD) of (a) diamine alkyne flexicate, (b) benzyl 
azide clicked complex 
1H NMR spectra showed the presence of new peaks at 8.08 and 5.50 ppm 
assigned to the triazole and Ph-CH2-triazole protons. [Figure 2-4(b)]. While it is clear 
that the reaction is incomplete any estimate of conversion has to be tentative, but on 
the basis that the imine singlet at 9.23 ppm is “unclicked”, the progress of the reaction 
is calculated to be ca 60%. Addition of further azide did not improve conversion 
substantially. A similar observation was made for the monometallic analogue of 
optically pure heterobimetallic helicates.14 
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Attempt to click benzyl azide onto dialdehyde flexicate 
 
Scheme 2-10 Attempt to modify dialdehyde alkyne flexicate by using click chemistry 
The flexicate (Rc,ΔFe)-[Fe2L23]Cl4 was treated with azidomethyl benzene by the same 
procedure as above (Scheme 2-10).  
 
Figure 2-5 The 1H NMR spectra (400 MHz, 298K, MeOD) of (a) dialdehyde alkyne flexicate, (b) 
benzyl azide clicked complex 
The alkyne resonance at 3.17 ppm in the starting material [Figure 2-5(a)] is not 
present in the product [Figure 2-5(b)], suggesting that the click reaction is complete. 
This was also supported by the appearance of peaks assigned for the triazole proton at 
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8.61 ppm. However, the presence of several peaks in the imine and triazole region 
indicates that a number of products are present in the recrystallized sample. Addition 
of excess CuI to the reaction solution led to little significant change. A reasonable 
explanation that is consistent with these observations would be that the triazole rings 
coordinate to Cu(I) as observed in the monometallic clicked species. 
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2.3 Synthesis of alkyne triplex systems 
A library of asymmetric “triplex” metallohelices have been formed in presence of 2-
phenyliminopyridine and pyridine aldehyde derivative by Dr A.D. Faulkner.23 We 
considered that alkyne-decorated triplexes can be accessed as above by replacing 
pyridine aldehyde derivative with propargyl pyridine aldehyde. 
2.3.1 Synthesis of (R)-2-(2,2'-bipyridine-5-ylmethoxy)-1-phenylethanamine 14 
 
Scheme 2-11 The synthesis of (R)-2-(2,2'-bipyridine-5-ylmethoxy)-1-phenylethanamine 14 
The optically pure amine 14 was required for this study (Scheme 2-11). 2-
Acetylpyridine was treated with iodine and pyridine at 130˚C in an inert atmosphere 
to form 1-(2-pyridylacetyl)pyridinium iodide (10).24, 25 10 was then treated with 
ammonium acetate and freshly distilled methacrolein in formamide to afford 5-
methyl-2,2'-bipyridine (11) as a colourless oil after distillation under reduced pressure. 
5-((Trimethylsilyl)methyl)-2,2'-bipyridine (12) was accessed via deprotonation of the 
5-methyl-2,2'-bipyrdine with LDA at -78 ˚C, followed by the addition of 1.05 
equivalents of trimethylsilyl chloride. 5-(Chloromethyl)-2,2'-bipyridine (13) was 
formed by treatment of 12 with hexachloroethane and caesium fluoride in dry 
acetonitrile.26  
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The direct deprotonation of one equivalent of (R)-phenylglycinol (8) with 
sodium hydride, followed by the addition of the same equivalents of 13 in THF gave 
(R)-2-(2,2'-bipyridine-5-ylmethoxy)-1-phenylethanamine (14) as crude yellow 
compound. After purification on silica gel [ethyl acetate/petroleum 
ether/trimethylamine (8/8/1; v:v:v)], pure 14 was isolated as a white solid. 
2.3.2 Synthesis of Zinc alkyne triplex (Rc,ΔZn)-HHT-[Zn2L33][ClO4]4 
 
Scheme 2-12 Synthesis the alkynl Znic (II) triplex metallohelice (Rc,ΔZn)-HHT-[Zn2L33][ClO4]4 
Reaction of (R)-2-([2,2'-bipyridin]-5-ylmethoxy)-1-phenylethan-1-amine 14 (3 eq.) 
with 5-(prop-2-yn-1-yloxy)picolinaldehyde 2 (3 eq.) in the present of Zn(ClO4)2·6H2O 
(2 eq.) at ambient temperature formed terminal alkyne decorated asymmetric triplex 
metallohelix (Scheme 2-12).27  
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Figure 2-6 (a) 1H NMR (500 MHz, CD3CN, 298K) and (b) 13C NMR spectra (125 MHz, CD3CN, 
298K) of (Rc,ΔZn)-HHT-[Zn2L33][ClO4]4; (c) two sets of phenyl ring protons Hd and He experienced 
unequally through-space shielding from the bpy unit. 
1H NMR spectrum confirmed the asymmetric structure with three 
spectroscopically unique ligand environments (Figure 2-6). The three imine singlets 
Ha were observed at 9.26, 9.17 and 8.80 ppm, along with the two of the bpy protons 
Hb at unusually low field (9.22 and 9.17ppm) which was ascribed to the intramolecular 
hydrogen bond with the ether oxygen atom of an adjacent ligand. The third bpy proton 
Hb with no such interaction was found at 8.39 ppm. Similarly, two sets of phenyl ring 
protons Hd and He (6.80–5.90 ppm) experienced through-space shielding from the bpy 
unit of an adjacent ligand. Whereas, the remaining set of phenyl ring protons Hd and 
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He with no such shielding effect were detected at 7.11 and 6.96 ppm, respectively. The 
rotation frequency of these phenyl rings is faster than the 1H NMR timescale at room 
temperature (293K), and therefore the diastereotopic pairs of protons (Hd/d', and He/e') 
are equivalent. In the variable temperature NMR experiment, these signals begin to 
broaden at lower temperatures (233K) as the rotational frequency slows down with 
respect to the NMR timescale, and the diastereotopic pairs begin to resolve (Figure 2-
7). It is interesting to note, therefore, that the π stacking of the phenyl and bipyridyl 
groups must be dynamic; the chemical shift due to through-space shielding is observed 
but the phenyl groups are rotating. The two of the benzylic protons Hf are found at 
5.46 and 4.96 ppm, while the third overlaps with one of the propargyl CH2 
environments. The latter appear as apparent singlets presumably because they lie 
distant from the chiral architecture and are freely rotating. The rather rigid 
arrangement of the helicand leads to six distinct resonances for Hh, clustered at 4.42-
4.10 ppm (apparent triplets) and 3.63-3.47 ppm (approximately doublets of doublets). 
Three singlets Hj at 3.0-2.8 ppm are assigned to alkyne protons. 13C NMR spectrum 
was also consistent with three unique ligand environments. Three imine carbon peaks 
Ca were found at 163.17-162.28 ppm, three bpy carbon peaks Cb were observed at 
150.72-149.37 ppm. The three benzylic carbon peaks Cf were detected at 69.54, 69.32 
and 67.52 ppm. Propargyl Ci peaks were assigned at 57.30-57.14 ppm. Alkyne carbon 
peaks Cj were found at 78.45-78.28 ppm.  
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Figure 2-7 Variable temperature 1H NMR spectra of (Rc,ΔZn)-HHT-[Zn2L33][ClO4]4 (600 MHz, 
CD3CN) 
Returning for a moment to the 1H NMR spectrum of Figure 2-6 we note the 
presence of a small singlet at 8.7 ppm. Such a peak is present in most (but not all) 
triplex systems prepared in this thesis, and particularly those spectra measured in 
acetonitrile rather than higher polarity media. We assign this to the three-fold 
symmetric HHH isomer of this compound and on this assumption estimate the 
selectivity HHT:HHH to be ca 99%. Other small peaks consistent with the presence 
of this minor isomer can be seen in the baseline. At 6.8 ppm a doublet is tentatively 
assigned to protons of type e in the HHH isomer. It is interesting to note the absence 
of a triplet for type d protons in the region 6.4-6.8 ppm in this minor component; no 
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such signal is expected since there is no phenyl-bpy -stack in the HHH isomer. 
Similarly, no minor doublets for type e protons are expected around 6 ppm. As such, 
the appearance of these minor isomer peaks corroborates our assignments for the 
major isomer.
2.3.3 Synthesis of Iron alkyne triplex (Rc,ΔFe)-HHT-[Fe2L33]Cl4 
 
Figure 2-8 1H NMR (500 MHz, D2O, 298K) and 13C NMR (125 MHz, D2O, 298K) spectra of 
(Rc,ΔFe)-HHT-[Fe2L33]Cl4 
Mixing amine 14, aldehyde 2 and FeCl2 in 3:3:2 molar ratio led to the immediate 
formation of an intense purple solution. After heating at 85 ℃ for 48 h, complete 
conversion of a single bimetallic triplex (Rc,ΔFe)-HHT-[Fe2L33]Cl4 was observed by 
1H NMR spectrum. The triplex with opposite helicity (ɅFe) was prepared similarly 
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starting from (S)-2-phenylglycinol. As with the zinc(II) perchlorate counterparts, the 
characteristic peaks of three imine atoms Ha and two bpy atoms Hb were observed at 
low fields (9.7-9.2 ppm) (Figure 2-8). The remaining bpy proton were observed further 
up field at 7.54 ppm. The three alkyne atoms C≡CH are observed at the fields 3.0-2.7 
ppm. 13C NMR spectrum was also similar with zinc (II) perchlorate counterparts, the 
characteristic peaks were well assigned. 
 
Figure 2-9 Variable temperature 1H NMR spectra of (Rc,ΔFe)-HHT-[Fe2L33]Cl4 (600 MHz, D2O) 
In contrast with their zinc(II) perchlorate counterparts in acetonitrile, the 
phenyl protons (Hd/d' and He/e') of the iron(II) triplex metallohelices in water feature 
broad signals in the region 5.5-6.0 ppm at 293 K (Figure 2-9), and these sharpen as 
the temperature is increased. This is consistent with restricted rotation on this chemical 
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shift timescale of the -stacked phenyl groups. We have previously observed that such 
hydrophobic -stack interactions are strengthened in more polar media.28 
 
Figure 2-10 High resolution mass spectrum: top measured, below calculated (a) and CD spectrum (b) 
of (Rc,ΔFe)-HHT-[Fe2L33]Cl4 
The complex (Rc,ΔFe)-HHT-[Fe2L33]Cl4 gave excellent electrospray mass 
spectrometry data, with a strong peak at m/z 364.1103 Da for the [Fe2L33]
4+ species 
which is consistent with the calculated value (m/z 364.1095 Da) [Figure 2-10(a)]. The 
isotope peaks observed for this molecular ion are separated by 0.25 Da, confirming 
the tetracationic charge. CD spectra of the alkyne iron triplex compounds ∆Fe/ΛFe HHT 
-[Fe2L33]Cl4 recorded in methanol contain bands spanning the whole UV-Visible 
region and were observed to be equal and opposite for the two enantiomers of the same 
complex [Figure 2-10(b)]. 
In the next two chapters, we will describe details of how this asymmetric 
configuration of the alkyne-decorated metallohelices offers the potential advantage to 
successfully click with aromatic azides and sugar azides respectively.  
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2.4 Anticancer study 
2.4.1 Cytotoxicity in vitro evaluation. 
A conventional MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium] assay 
was employed to determine cytotoxicity of several drugs at different concentrations.29 
After incubation and 96 h drug exposure, a dose response curve of drug concentration 
vs % cell survival was obtained and the corresponding half maximal inhibitory 
concentration (IC50) of each compound was calculated. 
The activity of the alkyne flexicate [Fe2L13]Cl4, [Fe2L23]Cl4  and alkyne triplex 
(Rc,ΔFe)-HHT-[Fe2L33]Cl4 were investigated against HCT116 p53
++ (human colon 
carcinoma HCT116 with wild type p53) cancer cell line. ARPE-19 (human retinal 
pigment epithelium), a classic noncancerous cell line,30 was chosen for comparison of 
activity. Both [Fe2L13]Cl4 and [Fe2L23]Cl4 were not soluble in media, therefore 10% 
DMSO was added to increase the solubility. Whereas, [Fe2L33]Cl4 was found to be 
sufficiently soluble under assay conditions.  
Table 2-1 Cytotoxicity assay of alkyne metallohelices against HCT116 p53++ and ARPE-19 cell line 
Cell line 
mean IC50 (µM) ± SD 
HCT116 p53++ ARPE-19 
ΛFe,-[Fe2L13]Cl4 
ΔFe,-[Fe2L13][Cl]4 
0.91 ± 0.52 1.71 ± 0.24 
1.74 ± 0.45 2.50 ± 0.48 
ΛFe,-[Fe2L23]Cl4 
ΔFe,-[Fe2L23][Cl]4 
3.96 ± 1.60 32.62 ± 8.49 
2.06 ± 0.15 25.32 ± 2.52 
ΛFe,HHT-[Fe2L33]Cl4 
ΔFe,HHT-[Fe2L33]Cl4 
5.02 ± 0.21 73.81 ± 13.05 
2.87 ± 0.91 100.44 ± 4.67 
As can be seen in Table 2-1, The alkyne flexicate [Fe2L13]Cl4 enantiomers 
demonstrated strong cytotoxicity against both HCT116 p53++ and ARPE-19 cell line 
with with IC50 ca 2 µM. No obvious anticancer selectivty was observed. The flexicate 
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[Fe2L23]Cl4  enantiomers showed quite high potentency against HCT116 p53
++ (IC50 
ca 3 µM) and high selectivty for ARPE-19, i.e. the IC50 value was ca ten times higher 
than that of HCT116 p53++. Triplex [Fe2L33]Cl4 enantiomers had similar activity 
towards HCT116 p53++ (average IC50 ca 4 µM ), and low cytotoxicity for ARPE-19 
(average IC50 ca 85 µM), therefore demonstring excellent anticancer selectivity.  
2.4.2 Autophagy  
(Rc,ΔFe)-[Fe2L33]Cl4 was selected for mechanistic studies due to the excellent 
anticancer selectivity (SI 35) in vitro. This work was conducted by Dr. Samantha 
Shepherd in Huddersfield University. On treating HCT116 p53++ cells with (Rc,ΔFe)-
HHT-[Fe2L33]Cl4 at the IC50 for 24 h, substantial autophagic vacuoles were detected 
by optical microscopy (Figure 2-11). Autophagy is a dynamic process of degradation 
of cellular proteins and cytoplasmic organelles respond to stress or stravation and is 
believed to play an important role in tumour development.31 We suggest that (Rc,ΔFe)-
HHT-[Fe2L33]Cl4 induces autophagy and thereby causes HCT116 p53
++ cancer cell 
death. More importantly, no such autophagic vacuoles were found in ARPE-19 cells; 
this might be the source of anticancer selectivity of (Rc,ΔFe)-[Fe2L33]Cl4. Further 
investigation which assesses the potency of the compounds after addition of 
commercial autophagy inhibitor 3MA is undergoing.  
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Figure 2-11 HCT116 p53++ and ARPE-19 were treated with IC50 dose of (Rc,ΔFe)-HHT-[Fe2L33]Cl4 
for 24 h. Prominent morphological change (autophagic vacuoles ) was observed in HCT116 p53++ 
cell. 
2.4.3 Drug distribution 
Analysis of the drug distribution in cell can provide the clue of the mechanism. The 
terminal alkyne functionality of [Fe2L23]Cl4  enantiomers or [Fe2L33]Cl4 enantiomers 
can be tagged with fluorescent dye AlexaFluor 555 azide via a copper (II) mediated 
alkyne-azide click reaction.32, 33 This method is highly accurate and sensitive that the 
fluorescent dye is only conjugated with alkyne groups to form triazole covalent bond, 
and thus gives no fluorescence signal in an alkyne free environment.34, 35 In addition, 
4’,6-diamidino-2-phenylindole (DAPI) was utilized as second fluorescent dye to probe 
the potential localization of the alkyne metallohelice relative to the cell nuclei which 
is very common mechanism of metal drugs.36  
HCT116 p53+/+ cells or ARPE19 cells were cultured on eight well glass 
chamber slider for 48 h, then incubated with [Fe2L23]Cl4 or [Fe2L33]Cl4 at 10 µM for 
1 h. The old medium was taken out with no phosphate buffered saline (PBS) wash, 
followed by permiabilising cells with Triton-X. The cells were then treated with Click-
iT® reaction buffer cocktail containing copper (II) sulfate (2 mM) and AlexaFluor® 
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555 azide (5 µM) for 30 minutes in the absence of light. After that, the cells were 
restrained by DAPI (1µg/ml) for 5 minutes, washed with PBS for 3 times and imaged 
by confocal laser microscopy.37 The control was treated with the same procedure with 
no drug exposure. 
 
Figure 2-12 Confocal fluorescent imaging of HCT116 p53++ co-stained with DAPI and Alexa555 dye 
with 10 µM of a) Ʌ-[Fe2L23]Cl4; b) Δ-[Fe2L23]Cl4; c) ɅHHT-[Fe2L33]Cl4; d) ΔHHT-[Fe2L33]Cl4; and 
ARPE19 co-stained with DAPI and Alexa555 dye with 10 µM of e) Ʌ-[Fe2L23]Cl4; f) Δ-[Fe2L23]Cl4; 
g) ɅHHT-[Fe2L33]Cl4; h) ΔHHT-[Fe2L33]Cl4; Control imagines of HCT116 p53++ and ARPE19 were 
treated with DAPI and Alexa 555 dye with no drug exposure. The scale bar represents 10 µm. 
As can be seen in Figure 2-12, the control confirmed the accuracy of staining 
method as only DAPI staining (blue fluorescene) was detected. Whereas, the strong 
Alexa555 staining (red fluorescence) was observed in both HCT116 p53++ and 
ARPE19 cells due to the exposure of the alkyne metallohelices. Both [Fe2L23]Cl4 and 
[Fe2L33]Cl4 exhibit high ratio of cellular internalization (1h) (Figure 2-12, a-h). No 
specific cellular localisation was found in these two cell lines; [Fe2L23]Cl4 and 
[Fe2L33]Cl4 were detected throughout the cells including cytoplasm and nuclei (which 
was co-stained to identify). Interestingly, when HCT116 p53++ cells were treated with 
[Fe2L23]Cl4 enantiomers, the cells treated with Ʌ enantiomer exhibited much weaker 
fluorescence signal than that of Δ enantiomers. This is ascribed to differential uptake 
of the enantiomers and may partially explain why the Δ enantiomer is much more toxic 
than Ʌ. 
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2.5 Conclusion 
Three metallohelix systems (the diamine flexicate class [Fe2L1]Cl4, the dialdehyde 
class [Fe2L2]Cl4 and the triplex [Fe2L33]Cl4) incorporating terminally-positioned 
alkyne groups were prepared. Each complex was fully characterised by NMR 
spectroscopy, mass spectrometry, microanalysis and circular dichroism spectroscopy.  
Attempts to functionlise [Fe2L1]Cl4 and [Fe2L2]Cl4 via click chemistry were 
partially successful in that while the products were consumed, mixtured of triazole 
derivatives were produced. We suggest that steric hindrance and/or intramolecular 
binding of Cu(I) to the products via the triazole units is responsible. The triplex system 
we show in subsequent chapters to be far more successful and leads to several new 
ranges of diverse, optically-pure, water-soluble and biologically active metallohelix. 
The alkyne flexicate [Fe2L13]Cl4, [Fe2L23]Cl4 and alkyne triplex [Fe2L33]Cl4 
have exhibited promising cytotoxcity towards the HCT116 p53++ cancer cell line. In 
particular, Δ-[Fe2L33]Cl4 showed 35 fold selectivity between HCT116 p53
++ and 
ARPE-19 normal cell line. Further mechanism study demonstrated the Δ[Fe2L33]Cl4 
can selectivetly induce prominent autophagic vacuoles in HCT116 p53++ cancer cell 
line than ARPE 19 cell line, indicating that autophagy may contribute to the acitvity 
and selectivty of the complex. The cell localization experiment showed that both 
[Fe2L23]Cl4 and [Fe2L33]Cl4 enantiomers can be effectively taken up into the cancer 
cells and normal cells, and localized in cytoplasm and nuclei. This is the first evidence 
for the drug distribution of metallohelices in cellulo.  
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Chapter 3   
Click reactions of triplex metallohelices with benzylic 
azides 
3.1 Introduction 
The formation of 1,2,3-triazoles by 1,3-dipolar cycloaddition of azides and alkynes 
was first discovered by Arthur Michael in 1893.1 This branch of heterocyclic 
chemistry was slow to reach its full potential, because initially these reactions required 
elevated temperatures and suffered from a lack of regioselectivity, with asymmetric 
alkynes yielding a mixture of the 1,4- and the 1,5-regioisomers.2, 3 However, in 2002, 
Sharpless and Meldal both discovered that copper(I) salts could catalyse the reaction 
and afford high yields of regiospecific 1,4-disubstituted 1,2,3-triazole.4, 5.  
This copper-catalysed azide/alkyne click (CuAAC) reaction,6, 7 has become a 
powerful and versatile synthetic tool in a wide variety of chemical8 and biological 
applications.9 CuAAC is most commonly performed under mild conditions i.e. no heat 
is required and the reaction can be performed in the presence of oxygen and moisture.10 
The conversion in CuAAC reactions is near-quantitative, with few or no side products, 
limiting the need for purification. Alkyne and azide components can be functionalised 
with a wide range of substituents, especially in bioconjugation, giving click chemistry 
enormous synthetic potential.  
CuAAC chemistry has also been exploited in coordination chemistry for the 
synthesis of the supramolecular architectures,11 catalysts12 and transition metal 
complex drugs.13 The versatile 1,4-functionalized 1,2,3-triazoles can be employed to 
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enrich ligand synthesis for metal coordination14 or exploited for post-assembly to 
afford new structures that are inaccessible through traditional coordination synthesis.15  
3.1.1 Click chemistry for ligand synthesis 
The 1,2,3-triazoles have received recent interest as new ligands in coordination 
chemistry and have been used to generate exquisite architectures.14,16 In principle, 1,4-
disubstituted-1,2,3-triazoles can display two different N-donor (N2 and N3)11 and one 
C-donor (C5) coordination modes17 as shown in Figure 3-1 a-c. For instance, Schibli 
et al. developed a “click-to-chelate” approach via the N2, amino, and a carboxylate 
chelating system to form the tumour-targeting monometallic labelling precursor d.18 
Gautier et al. synthesised a cisplatin analogue in which N3 and an amine group 
attached at C4 coordinated to Pt(II) (e).13 Gandelman et al. designed and prepared a 
tridentate pincer-type palladium complex in which the mode of coordination was 
generated by two phosphine groups and the C5 carbene donor of the triazole f.19 The 
potential of a triazole moiety to act as a pyridyl surrogate and form analogues of the 
bis-triazole (bta) j, pyridine-triazole (pyta) k and bis-triazole-pyridine (btpy) l ligands 
is also intriguing. These trizole-containing ligands are extensively exploited to 
construct discrete metallomacrocycles,20 cages21 and helicates.22 
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Figure 3-1 Coordination modes of 1,4-disubstituted-1,2,3-triazole ligands through: a) N2 nitrogen 
atom; b) N3 nitrogen atom; c) C5 carbon atom; Examples of “click-to-chelate” approach to form 
monometallic complex via: d) N2 site; e) N3 site; f) C5 site; Classic pyridine-containing chelate 
centre: g) pyridine; h) bipyridine; i) terpyridine; Triazole act as pyridyl surrogate: j) bis-triazole; k) 
pyridine-triazole; l) bis-triazole-pyridine 
Relatively few examples of the establishment via CuAAC of intermolecular 
linking substituents have been reported,23 perhaps since the triazole moiety could 
provide extra N donor sites to interfere with the self-assembly process.24, 25 Crowley 
et al. established a facile approach to attach a variety of functional moieties to the 
tripyridyl ligand scaffolds and demonstrated that the presence of the 1,2,3-triazole 
units does not disrupt the formation of desired M2L4 palladium(II) cage 
architectures.26,24  
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Figure 3-2 tripyridyl ligand functionalised by triazole linker and [Pd2L4]4+ cage structure
26,24
 
3.1.2 Click chemistry for post-assembly modification of complexes 
In addition to broadening the scope of ligand synthesis, CuAAC chemistry has also 
been employed to introduce functionality to pre-assembled metal complexes.27-32 
There are several distinct advantages of this strategy, which can lead to rapid and 
modular diversification of the structures. In particular potential functional group 
incompatibly in the self-assembly can be circumvented, allowing access to new design 
configurations that are difficult to obtain by conventional ligand-plus-metal 
synthesis.27 Indeed, there are several examples of successful post-assembly 
modifications (PAM) via click chemistry (referred to herein as PAMC), such as 
functionalised MOFs,33 rotaxanes,34-37 ferrocenyl complexes38-40 and nanoparticles 
(Figure 3-3).41 The general synthetic strategy used is first to establish a metal template 
with terminal alkyne/azide groups, and second to click the azide/alkyne derivatives on 
the self-assembled structure.  
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Figure 3-3 Example of PAMC for nanoparticles42 
Compared with the widespread use of PAMC in large metal–ligand assemblies 
such as MOFs and nanoparticles, the application of PAMC in discrete metal 
complexes is far less explored.43-45 The lack of research in this area is mainly ascribed 
to the fact that the Cu(I) catalyst can interfere with labile metal-ligand bonds;44 be 
sequestered by multidentate binding sites of substrates;35 and cause cytotoxicity, 
jeopardising biological applicability.46 Recently, a copper-free click reaction has been 
developed to overcome this issue and is particularly prevalent in biochemistry.47-52 
However, only specific substrates, such as cyclooctyne derivatives or norbornenes, 
were able to undergoing cycloaddition in the absence of Cu(I) catalyst, and the ligand 
synthesis was cumbersome.51 Therefore, structures that feature strong metal-ligand 
bonds and that have geometric arrangements of binding sites that do not favour Cu(I) 
sequestration are advantageous for PAMC. 
As outlined previously in Chapter 2, the attempt to modify alkyne-terminated 
flexicate structures via PAMC failed to produce sufficiently pure species in the click 
reaction. In this chapter, PAMC with triplex systems are investigated and shown to be 
much more suited to this strategy. 
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3.2 PAMC of alkyne triplex metallohelices 
3.2.1 Synthesis of benzyl azide derivatives 
Benzyl azide derivatives have been chosen to validate PAMC reactions on the alkyne 
triplex metallohelices described in Chapter 2 due to their facile synthesis. In addition, 
the resulting structures allow us to elucidate whether bulky hydrophobic aromatic 
groups alter the biological activity of the metallohelices. Moreover, some benzyl azide 
derivative like 4-azidomethyl benzoic acid could offer even more powerful means of 
building functionalised complexes. 
 
Scheme 3-1 Synthesis of benzyl azide derivative 
The benzyl azide derivatives shown in Scheme 3-1 were prepared by the 
nucleophilic substitution of their benzyl bromide analogues (substituted by fluoro, 
methoxy, nitrile and carboxylic acid) with sodium azide in high yield.53, 54 
3.2.2 Synthesis of [Zn2L4a-d3][ClO4]4 triplexes via CuAAC  
(Azidomethyl)benzene (4.5 eq.), (Rc,ΔZn)-HHT-[Zn2L33][ClO4]4 (1 eq.) and copper (I) 
iodide (0.1 eq.) were heated at 65˚C under reduced pressure for 18h. The resulting 
suspension was filtered through celite to remove copper salts and the final product was 
isolated as a white/yellow solid upon the addition of ethyl acetate.  
 




Figure 3-4 1H NMR spectra (500 MHz, CD3CN, 298K) of (a) (Rc,ΔZn)-HHT-[Zn2L33][ClO4]4, (b) 
(Rc,ΔZn)-HHT-[Zn2L4a3][ClO4]4; 13C NMR spectra (125 MHz, CD3CN, 298K) of (c) (Rc,ΔZn)-HHT-
[Zn2L33][ClO4]4, (d) (Rc,ΔZn)-HHT-[Zn2L4a3][ClO4]4; 
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As can be seen in the 1H NMR spectra [Figure 3-4(a) and (b)], the three alkyne 
singlets of the zinc alkyne triplex starting material [Figure 3-4(a)] (Hj, between 3.0-
2.8 ppm) are absent in the spectrum of the (azidomethyl)benzene CuAAC triplex 
product [Figure 3-4(b)]. The three methylene protons Hi belonging to the pyridine-O-
CH2-R group shift to higher frequency i.e. from ca 4.9 ppm in the alkyne triplex 
[Figure 3-4(a)] to ca 5.2 ppm in the product triplex [Figure 3-4(b)]. Three new singlets 
Hk at 8.01, 7.92 and 7.81 ppm are observed in Figure 3-4(b) due to the triazole protons 
in three separate ligand environments. In addition, the three new singlets Hm found at 
5.61, 5.57, 5.48 ppm [Figure 3-4(b)] are assigned to the Ph-CH2-traziole groups. The 
three imine peaks Ha, three bipyridine singlets Hb and the phenyl ring protons are 
observed with negligible shift in both 1H NMR spectra, demonstrating that the 
structural integrity of the metallohelix was preserved during the click reaction. 
The 13C NMR spectra [Figure 3-4(c) and (d)] also confirm the completion of 
the click reaction due to the disappearance of alkyne carbon signals Cj and Cn [Figure 
3-4(c)] and presence of carbon Ph-CH2 peaks Cm at 54.2 and 54.1 (two signals) ppm 
[Figure 3-4(d)]. The three pyridine-O-CH2-R carbons Ci shift to higher frequency from 
ca 57 ppm to ca 63 ppm as the adjacent alkyne group is replaced with the more electric 
withdrawing group triazole. The new signals Cl found at ca 142 ppm are assigned to 
triazole C4 carbon [Figure 3-4(d)].  
Other similar triplex derivatives can be synthesised readily through 
substitution of the benzyl azide. (Rc,ΔZn)-HHT-[Zn2L4b][ClO4]4, (Rc,ΔZn)-HHT-
[Zn2L4c3][ClO4]4 and (Rc,ΔZn)-HHT-[Zn2L4d3][ClO4]4 were successfully synthesised 
via CuAAC with 1-(azidomethyl)-4-fluorobenzene, 4-(azidomethyl)benzonitrile and 
1-(azidomethyl)-4-methoxybenzene onto alkyne triplex (Rc,ΔZn)-HHT-
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[Zn2L33][ClO4]4 separately. The 
1H and 13C NMR spectra were similar to that of 
(Rc,ΔZn)-HHT-[Zn2L4a3][ClO4]4 (Figure 3-5). 
 
Figure 3-5 (a) Structure of L4d and (Rc,ΔZn)-[Zn2L4d3][ClO4]4; (b) 1H NMR (500 MHz, 298K, 
CD3CN) and (c) 13C NMR (125 MHz, 298K, CD3CN) spectra of (Rc,ΔZn)-[Zn2L4d3][ClO4]4. 
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3.2.3 Synthesis of water soluble iron(II) triplex systems via CuAAC 
 
Scheme 3-2 Synthesis of CuAAC derivative iron (II) triplex metallohelices 
In order to investigate the biological activities of the metallohelices, all the tested 
complexes must possess the solubility in aqueous media. As expected, the zinc 
perchlorate triplexes were insoluble in aqueous media but water-compatible triplexes 
were accessed by replacing zinc perchlorate with iron(II) chloride. Ten iron(II) triplex 
complexes ∆Fe/ΛFe-[Fe2L4a
-e
3]Cl4 (Scheme 3-2), were prepared via CuAAC reactions 
with benzyl azide derivatives onto the corresponding alkyne iron(II) triplex in 
methanol.  
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Figure 3-6 1H NMR spectra (400 MHz, MeOD, 298K) of (a) (Rc,ΔFe)-HHT-[Fe2L33]Cl4, (b) (Rc,ΔFe)-
HHT-[Fe2L4a3]Cl4; 13C NMR spectra (125 MHz, MeOD, 298K) of (c) (Rc,ΔFe)-HHT[Fe2L33]Cl4, (d) 
(Rc,ΔFe)-HHT-[Fe2L4a3]Cl4; 
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The 1H-NMR spectra of all iron(II) triplex complexes were similar but broader 
than their Zn(II) perchlorate counterparts. However, the progress of the CuAAC 
reaction could still be monitored by the changes in the spectra. As seen in Figure 3-6, 
the alkyne singlets Hc at 3.19, 3.12 ppm [Figure 3-6(a)] were no longer observable in 
the CuAAC product triplex spectra. The triazole protons were unable to be assigned 
as these signals overlap with other aromatic proton signals. Three singlets He at 5.77, 
5.72, 5.64 ppm [Figure 3-6(b)] appear upon completion of the reaction, and are 
assigned to the benzonitrile-CH2 protons. The 
13C NMR spectra [Figure 3-6(c) and (d)] 
are also consistent with the completion of the reaction supported by the disappearance 
of alkyne carbon signals Cc and Cf [Figure 3-6(c)] and presence of carbon Ph-CH2 
peaks Ce at 55 ppm (three signals) [Figure 3-6(d)]. In a similar fashion with the zinc(II) 
perchlorate counterparts, the three pyridine-O-CH2-R carbons Cd shift to higher 
frequency from ca 58 ppm to ca 63 ppm due to the adjacency of the more electron 
withdrawing triazole group.  
 
Figure 3-7 (a) CD spectra of alkyne triplex isomers [Fe2L33]Cl4 (0.1mg/ml) and 
(azidomethyl)benzene CuAAC product isomers [Fe2L4a3]Cl4 (0.1mg/ml) in methanol; (b) High 
resolution mass spectrometry for (Rc,ΔFe)-HHT-[Fe2L4a3]Cl4: top measured, below calculated. 
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The CD spectra of the enantiomers in methanol were found to be equal and 
opposite in signal [Figure 3-7(a)]. As expected, the spectral curves were similar to the 
unclicked parent alkyne triplexes as the additional aromatic rings cause little effect on 
the chiroptic properties of the structure. The successful synthesis of all complexes 
[Fe2L43]
4+ was also confirmed by high resolution electrospray mass spectrometry. For 
instance, (Rc,ΔFe)-HHT-[Fe2L4a3][Cl]4 gave a strong peak at m/z 463.9073 Da for the 
tetracationic molecular ion within 0.001 Da of the calculated value for 
C105H93Fe2N21O6 (m/z 463.9076 Da) [Figure 3-7(b)]. Inductively-Coupled Plasma 
Atomic Absorption (ICP-MS) analysis showed only trace amounts of copper 
(0.527±0.005%). The isolated compounds contain water of crystallisation; ca 16 
equivalents as has been consistently observed for this general class of compound.55 
The degree of hydration could not in most instances be determined directly by 
thermogravimetric analysis as the mass-loss traces contained no clear plateau. 
Microanalytical data are thus compared to computed figures at reasonable levels of 
hydration and while these gave excellent agreement for %C and N in all cases the 
figures for %H were consistently high (ca 1%). 
3.3 Biological activity of the new triplex metallohelices 
3.3.1 In vitro cytotoxicity assay 
The cytotoxicity and selectivity of both enantiomers of HHT-[Fe2L4a-e3]Cl4 were 
screened for potency against HCT116 p53++ (human colon carcinoma) cell lines and 
the human non-cancer retinal pigment epithelial cells (ARPE19). The alkyne parent 
compounds ∆Fe/ΛFe-[Fe2L33]Cl4 were treated as control to investigate the effect of 
benzyl triazole derivatives. All the compounds were found to be fully soluble in water 
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under assay conditions. The IC50 values obtained from triplicate measurements are 
given in Figure 3-8 and plotted in Table 3-1. 
 
Figure 3-8 IC50 values for triplex [Fe2L4a-e3]Cl4 and unclicked alkyne triplex [Fe2L33]Cl4 against: (a) 
HCT116 p53++ cancer cell line; (b) ARPE19 (noncancerous cell line) 
As seen in Table 3-1, all Ʌ [Fe2L4a-e3]Cl4 were more potent than the Δ 
enantiomers. The potency of these metallohelices was relatively unperturbed by the 
para substitution on the aromatic ring, except for the Δ-configured [Fe2L4e3]Cl4 
complex; the substitution of the carboxylate group on the Δ enantiomer reduced the 
potency by a factor of ca 5 with respect to Δ[Fe2L4a3]Cl4. The most potent compound 
is the Ʌ enantiomer of benzonitrile CuAAC product triplex [Fe2L4b3]Cl4 with IC50 = 
730 nM.  
While potency is an important factor, selectivity for cancer cells over “healthy” 
cells is crucial in potential treatments. The IC50 values obtained against the non-
cancerous cell line ARPE19 [Table 3-1 and Figure 3-8(b)] are all significantly higher 
than those for HCT116 p53++ and there was a considerable range (3 µM to 76 µM). 
Again, all Ʌ enantiomers were more toxic than Δ enantiomers. While ΛFe-[Fe2L4c3]Cl4 
and ΛFe-[Fe2L4d]Cl4 with IC50 3.08, 2.94 µM respectively were the most potent, all the 
Δ enantiomers had IC50 over 25 µM and there was no clear relationship between the 
substituent on the aromatic ring and the activity. 
 
University of Warwick | Page 74 
 
Selectivity Index (SI) is defined here as the mean IC50 for ARPE19 divided by 
IC50 against HCT116 p53
++. While as mentioned above the  compounds are most 
potent, the most selective compounds are the Δ enantiomers, with [Fe2L4a3]Cl4 and 
[Fe2L4c3]Cl4 having SI of ca 30 and 34 respectively, very close to that of the parent 
complex -[Fe2L33]Cl4 (Table 3-1).  
Table 3-1 Cytotoxicity and Selectivity index for triplex [Fe2L4a-e3]Cl4 and unclicked alkyne triplex 
[Fe2L33]Cl4 against HCT116 p53++ and ARPE-19 cell line 
 mean IC50 (µM) Selectivity 
Index HCT116 p53++ ARPE-19 
[Fe2L4a3]Cl4 Λ 0.91 ± 0.28 8.82 ± 1.04 10 
Δ 2.16 ± 0.97 65.58 ± 6.82 30 
[Fe2L4b3]Cl4 Λ 1.00 ± 0.19 6.88 ± 1.20 7 
Δ 1.94 ± 0.84 25.37 ± 1.94 13 
[Fe2L4c3]Cl4 Λ 0.73 ± 0.30 3.08 ± 0.15 4 
Δ 2.25 ± 0.96 76.14 ± 3.66 34 
[Fe2L4d3]Cl4 Λ 2.13 ± 2.10 2.94 ± 0.31 1 
Δ 3.13 ± 0.47 59.60 ± 5.60 19 
[Fe2L4e3]Cl4 Λ 1.63 ± 1.13 8.75 ± 0.63 5 
Δ 10.15 ± 2.12 72.23 ± 10.52 7 
[Fe2L33]Cl4 Λ 5.02 ± 0.21 73.81 ± 13.05 15 
Δ 2.87 ± 0.91 100.44 ± 4.67 35 
Due to their potency and selectivity towards the HCT116 p53++ and ARPE19 
cells, Δ-[Fe2L33]Cl4 and Δ-[Fe2L4a3]Cl4 were further assessed by Dr Viktor Brabec in 
Marsaryk University for activity against additional cell lines (Table 3-2). Cisplatin 
was included for comparison. 
As seen in Table 3-2, -[Fe2L33]Cl4 and -[Fe2L4a3]Cl4 each showed 
preferential cytotoxicity towards each of the different cancer cell lines tested (derived 
from different cancerous tissue) compared to two non-cancerous cell lines, ARPE19 
and MRC-5 pd30 (the latter is derived from fetal lung tissue). Comparing -
[Fe2L33]Cl4 and -[Fe2L4a3]Cl4, the post-assembly CuAAC addition of a benzyl had 
little effect on activity towards the HCT116 colon cancer cells but notably it increased 
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cytotoxicity towards the human ovarian and breast cancer cell lines by ~7 to 25 fold. 
In contrast, activity against the two non-cancer cell lines was only modestly increased 
{by ~1.5 fold (ARPE19) and ~2 fold (MRC-5 pd30)}. The benzyl triazole 
modification resulted in a ~3.75-fold increase in cytotoxicity towards the cisplatin-
resistant ovarian cancer cells (A2780cis) compared to the cisplatin-sensitive parental 
cells. For both ovarian cell lines -[Fe2L4a3]Cl4 was substantially more cytotoxic and 
showed comparable or improved selectivity than -[Fe2L33]Cl4 indicating the merits 
of post-assembly modification. 
Table 3-2. Cell viability (IC50 mean values, µM) of the investigated 
compounds. Cell survival was evaluated using the MTTa assay. 
 Compound 
Cell line -[Fe2L33]Cl4 -[Fe2L4a3]Cl4 cisPt 
A2780 
(ovarian cancer cells) 
6.1±0.8 0.9±0.2 3.3±0.2 
A2780cisR 
(ovarian cancer cells) 
6.1±0.3 0.24±0.02 20±3 
HeLa 
(cervical cancer cells) 
16±6 7.6±0.5 14.0±0.9 
MCF-7 
(breast cancer cells) 
±2 ±0.2 12.9±0.6 
MDA-MB-231 
(breast cancer cells) 
±1 ±0.2 22±2 
HCT116 p53+/+  
(colon cancer cells) 
2.9±0.9 b 2.2±1.0 b 3.3±0.4 b 
HCT116 p53-/-  
(colon cancer cells) 
3.4±0.2 b 3.3±0.3 b 7.5±0.7 b 
ARPE-19 
(non-cancer) 
100±5 b 66±7 b 3.4±0.5 b 
MRC-5 pd30 
(non-cancer) 
±5 ±5 11.6±0.8 
aThe experiments were performed in triplicate or quadruplicate. The cells 
were treated with the compounds for 72 h, unless otherwise stated. The results 
are expressed as mean values ± SD from three or four independent 
experiments; bCells were treated for 96 h. 
The p53 tumour suppressor gene is one of the most commonly mutated in 
cancer. Loss of this function commonly increases resistance to chemotherapeutic 
drugs, and for example cisplatin was found here to be >2 fold less active towards 
HCT116 p53-/- than p53+/+ (Table 3-2). Interestingly, the alkyne Δ-[Fe2L33]Cl4 and 
CuAAC derivative Δ-[Fe2L4a3]Cl4 showed similar activity towards both cell clones. 
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3.3.2 Cell cycle analysis  
The distribution of cell cycle during drug exposure can point to a mode of action. This 
work was conducted by Hannah Bridgewater. ARPE19 and HCT116 p53+/+ cells were 
incubated with the enantiomers of [Fe2L33]Cl4 and [Fe2L4a3]Cl4 at 2 × IC50 
concentration, respectively. After 24 h, cells were analysed by fluorescence-activated 
cell sorting (FACS).  
 
Figure 3-9 Cell cycle analysis by FACS assay using propidium iodide staining to analyse the percent 
population in stages of the cell cycle for untreated ARPE19 and HCT116 p53++ cells, and those 
incubated with the metallohelices shown for 24 h, at twice the IC50 concentration. 
In the HCT116 p53+/+ cell line, Λ-[Fe2L33]Cl4 resulted in a significant increase 
in G2/M cells, in comparison with the untreated (control) cells. However, the Δ-
[Fe2L33]Cl4 substantially increased the number of cells in the G1 phase, demonstrating 
a clear difference in cell response to the two enantiomers. In the similar fashion with 
Λ-[Fe2L33]Cl4, Λ-[Fe2L4a3]Cl4 evidently led to G2/M arrest in HCT116 p53
+/+ cells. 
Notably, the Δ-[Fe2L4a3]Cl4  only led to a marginal increase in the proportion of cells 
in the G2/M phase [Figure 3-9(a)]. For the non-malignant ARPE19 cell line, Λ-
[Fe2L33]Cl4 led to marginal increase in the S phase population [Figure 3-9(b)]. In 
contrast, it appears that Δ-[Fe2L33]Cl4 considerably increased the proportion of cells 
in the G1 phase. A significant increase in the G1 population was observed for Λ-
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[Fe2L4a3]Cl4 and a slight increase in the S phase population for Δ-[Fe2L4a3]Cl4. 
Therefore, the post-assembly modifications of parent [Fe2L33]Cl4  can dramatically 
alter the cell cycle effect in two different cell lines. Whilst effects on the cell cycle of 
both the enantiomer and post-assembly modifications are evident, at present the 
mechanisms responsible and how these relate to differential cytotoxicity and 
selectivity are unclear.  
3.3.3 Induction of apoptosis  
A hallmark of cancers is the evasion of apoptosis or programmed cell death, and the 
induction of this process in cancer cells is a target of many anticancer drug 
treatments.56-58 We found that HCT116 p53+/+ cells that had been incubated with 
[Fe2L3]Cl4 and [Fe2L4a 3]Cl4 at 2 × IC50 for 24 and 48 h showed no increase in 
membrane phosphatidylserine (PS)59 – a key feature and quantifiable marker of early 
apoptosis. After 96 h a slight elevation in PS was detected. This work was conducted 
by Dr Samantha Shepherd in Huddersfield University. 
3.3.4 Real-time cell growth and ATPase Activity 
Time-dependent cellular response profiles (TCRPs) produced by impedance-based 
monitoring reflect cellular responses to small biologically active compounds,60 and 
have been used to predict or compare the mechanism of action of small molecules.61-
63 The work below was conducted by collaborators at Marsaryk University. 
The TCRPs induced in A2780 cells by the metallohelices Δ-[Fe2L33]Cl4, Δ-
[Fe2L4a3]Cl4, and Δ-[Fe2LS3]Cl4 (the triplex without terminal alkyne group
55) were all 
distinct (Figure 3-10). For the parent metallohelix Δ-[Fe2LS3]Cl4 the initial rise is less 
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apparent than for other compounds and the period of signal elevation is the shortest. 
For the alkyne Δ-[Fe2L33]Cl4 the CI signal increases to ca 1.7 × that of the control and 
the peak is relatively broad, the signal decreasing steadily over the measurement 
period. For the benzyl triazole derivative Δ-[Fe2L4a3]Cl4 the CI signals reach a much 
sharper dose-dependent maximum. A TCRP profile database search indicated a 
similarity with that for compounds that inhibit Na+/K+ stimulated ATPases (mainly 
cardiotonics like strophanthidin, convallatoxin, gitoxin, digoxin and/or 
sarmetogenin).64 













































































Figure 3-10 TCRPs of A2780 treated with the growing concentrations of the investigated 
metallohelices. The medium containing the tested compounds was added after 27.5 h of incubation. 
(A) Δ-[Fe2LS3]Cl4; (B) Δ-[Fe2L33]Cl4 (C) Δ-[Fe2L4a3]Cl4. The concentrations of metallohelices were 
chosen to induce various inhibitory effects. 
The above profiling study suggests that the mechanism of action of the 
metallohelices may involve inhibition of the activity of Na+/K+ ATPase; a highly 
conserved integral cell membrane pump expressed in virtually all cells of higher 
organisms that maintains ionic concentration gradients. A rubidium based assay65 was 
subsequently used to evaluate Na+/K+ ATPase inhibition in A2780 and HCT116 p53+/+ 
cell lines by Δ-[Fe2LS3]Cl4, Δ-[Fe2L33]Cl4, Δ-[Fe2L4a3]Cl4 (10 μM) and ouabain. In 
order to secure cell viability and to mainly detect the upstream effects of the applied 
drug, a short incubation time (6 h) was used, after which the uptake of Rb+ (5.4 mM) 
was determined by ICPMS (Figure 3-11). Δ-[Fe2L4a3]Cl4 was found to inhibit 
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rubidium uptake under the given conditions by 35-47%, which is comparable to that 
of the known Na+/K+ ATPase inhibitor ouabain67 (39-57% inhibition). In contrast, Δ-
[Fe2LS3]Cl4 and Δ-[Fe2L33]Cl4 did not affect the rubidium uptake suggesting these 
compounds have a different mechanism of action to Δ-[Fe2L4a3]Cl4.  
 
Figure 3-11 Metallohelices induced Na+/K+ ATPase inhibition. A2780 and HCT116 p53++ cells were 
treated with metallohelices and ouabain (10 µM) for 6 h and then incubated with RbCl for 3 h. 
Rubidium content in cell lysates was determined with ICP-MS. All results are expressed as the mean 
± SD from three independent experiments. Stars indicate significant difference from untreated control 
(100%) with *p ˂ 0.001 calculated by using 2way ANOVA. 
3.3.5 Antimetastatic properties 
Colorectal cancer is one of the four most common causes of cancer deaths and in 90% 
of instances, mortality is ascribed to metastasis.68, 69 Notably, ouabain was reported to 
inhibit the migratory activities of various cancer cell lines,70-73 and the antimetastatic 
activity was in part downstream signalling effects of Na+/K+ ATPase inhibition.73 
Given the comparable performance of Δ-[Fe2L3a3]Cl4 in this regard, we set out to 
investigate the effect of metallohelices on cell migration and invasion which are 
important steps in the process of metastasis.74, 75  
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Figure 3-12 Antimetastatic activity of metallohelices against HCT116 p53++ cells: (a) resistance to 
trypsin detachment, cells were treated with Δ-metallohelices at 10 μM and 20 μM respectively for 3h, 
(b) cell re-adhesion, cells were treated with Δ-metallohelices at 10 μM for 3h, followed by trypsin 
detached and re-seeded for 30 min (c) invasion activity, cells were treated with Δ-metallohelices at 
equitoxic (2xIC50) concentration for 2h, followed by seeded and incubated for additional 96h. The 
results are expressed as the mean ± SD from three independent experiments. Stars indicate significant 
difference from untreated control (100%) with *p ˂ 0.05 or **p ˂ 0.001 calculated by using 2way 
ANOVA 
We modelled the detachment of cancer cells from a primary tumour by an 
assay of cell resistance to trypsinization. HCT116 p53++ cells grown in monolayer 
were treated with the investigated compounds for 3 h and then subjected to a diluted 
trypsin solution. The number of cells that resisted the treatment with trypsin (i.e. 
remained attached to the surface) was evaluated by the SRB assay. Treatment with Δ-
[Fe2LS3]Cl4 reduced detachment only at higher concentrations [Figure 3-12 (a)] and 
Δ-[Fe2L33]Cl4 had no significant effect. In contrast, Δ-[Fe2L4a3]Cl4 treatment of cells 
significantly impeded their detachment.  
 
University of Warwick | Page 81 
 
Re-adhesion of detached cells in a distant organ was modeled in a further assay. 
Cells were treated with 10 µM compound for 3 h, detached with trypsin and re-seeded 
at a density of 2 x 104 cells/well. The number of cells attached after 30 min incubation 
was determined with SRB assay [Figure 3-12 (b)]. While Δ-[Fe2L33]Cl4 did not 
measurably influence the ability of cells to re-attach to the new growth surface, Δ-
[Fe2LS3]Cl4 and Δ-[Fe2L4a3]Cl4 reduced cell re-adhesion by 24% and 58%, 
respectively.  
The effects of Δ-[Fe2LS3]Cl4, Δ-[Fe2L33]Cl4, and Δ-[Fe2L4a3]Cl4 on invasion 
activity were also assessed using a MatrigelTM transwell assay. HCT116 p53++ cells 
were treated with the investigated compounds at equitoxic (2×IC50) concentrations. 
The treatment of tumor cells for 2 h with Δ-[Fe2L4a3]Cl4 resulted in a significantly 
reduced invasion activity [Figure 3-12 (c)], whereas Δ-[Fe2L33]Cl4 had little or no 
potency to inhibit HCT116 p53++ invasiveness. Δ-[Fe2LS3]Cl4 and Δ-[Fe2L4a3]Cl4 
reduced the invasive ability by 35% and 58%, respectively. 
 
University of Warwick | Page 82 
 
 
Figure 3-13 Wound healing assay of metallohelices: (a) HCT116 p53+/+ cells were were treated with 
metallohelices at IC50 concentration. The shots were taken at times 0 h and 24 h. (b) the cells were 
treated in the complete medium (10% FBS, gentamycin), the shots were taken at times 0, 8.5 and 24 
h. The area of a gap at time 0 h was considered 100%. (c). after growing period, the cells were 
incubated overnight in starving medium (1% BSA, gentamycin) and were kept in the starving medium 
during the rest of the assay 
A wound healing assay (scratch gap closure) was also used to assess the overall 
ability of the compounds to influence cell migration and invasion (Figure 3-13). In 
complete medium, 24 h after scratching a monolayer of HCT116 p53+/+ cells, the gap 
in an untreated control sample was healed to 33%, while in the presence of Δ-
[Fe2LS3]Cl4 or Δ-[Fe2L4a3]Cl4 healing was more suppressed and 62% and 71% of the 
wound remained open respectively. Cells treated with Δ-[Fe2L33]Cl4 resembled the 
control [Figure 3-13 (a); (b)]. A qualitatively similar result was obtained in starving 
medium conditions [Figure 3-13 (c)] indicating that the suppression of wound-healing 
results at least in part from anti-migration/invasion rather than being due to cell 
proliferation resulting in closure of the scratch.  
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Collectively, these data show that in particular the metallohelix Δ-[Fe2L4a3]Cl4 
is capable of suppressing the cellular properties characteristic of metastatic 
progressions, such as invasiveness, migration, and re-adherence to a substrate. Thus, 
these properties predestine it for further biological testing as a potential antimetastatic 
drug. 
3.3.6 Growth-inhibitory effects on cancer stem cells (CSCs) 
CSCs76-78 have the ability to self-renew, differentiate, form secondary or tertiary 
tumors, exhibit up-regulated cellular defense mechanisms and are less susceptible to 
chemotherapy.79 Being thus more aggressive and linked to cancer relapse and 
metastasis, they are the primary target for chemotherapy.80 Recently, Qu and co-
workers demonstrated that a bimetallic nickel(II) helicate could effectively eradicate 
breast cancer stem cells, and this led us to investigate this feature in the current system, 
which, being based on a non-toxic metal, not requiring chemical separation of 
enantiomers, and being capable of derivatisation, has several advantages over the 
former.88  
We initially studied their effect on sphere formation from single cells; only 
self-renewing cells, stem or stem-like cells can survive and proliferate to form spheres 
when grown in serum-free media under low-attachment conditions. The inhibition of 
colonosphere formation81-83 was tested in HCT116 p53++ cells treated with Δ-
[Fe2LS3]Cl4 and Δ-[Fe2L4a3]Cl4 at their respective IC30 concentrations for 72 h. These 
data were compared with effects of salinomycin, which is known to have CSC-
selective potency.84-86 Both Δ-[Fe2LS3]Cl4 and Δ-[Fe2L4a3]Cl4 were found to inhibit 
colonosphere formation in the tested HCT116 p53++ cells, giving rise to decrease from 
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224±14 spheres/1000 cells and sphere diameter of 96±20 µm in the control cells, to 
134±15 spheres /1000 cells and sphere diameter of 86±18 µm (Δ-[Fe2LS3]Cl4 ) and 
94±22 spheres /1000 cells and sphere diameter of 82±16 µm (Δ-[Fe2L4a3]Cl4), both 
being more effective than salinomycin (142±14 spheres/1000 cells and sphere 
diameter of 76±17 µm) (Table 3-3).  
Table 3-3. Quantification of colonosphere formation in HCT116 p53++ cells untreated or 
treated with the investigated compounds at their respective IC30 values for 72 h.a 
HCT116 p53++ Spheres/1000cells Diameter (µm) 
Control 224 ± 14 96 ± 20 
Salinomycin 142 ± 14 76 ± 17 
-[Fe2LS3]Cl4 134 ± 15 86 ± 18 
-[Fe2L4a3]Cl4 94 ± 22 82 ± 16 
aThe results are expressed as mean ± SD of three independent experiments. 
To further study the anti-CSC potency of Δ-[Fe2LS3]Cl4 and Δ-[Fe2L4a3]Cl4, 
the inhibition of colonosphere formation in CSC-enriched HCT116.CD133+ was also 
investigated, as shown in Figure 3-14. 
Significant colonosphere inhibition was also observed in the CSC-enriched 
cells treated with both Δ-[Fe2LS3]Cl4 and Δ-[Fe2L4a3]Cl4 [Figure 3-14 (a-f)]. These 
data suggest that Δ-[Fe2LS3]Cl4 and Δ-[Fe2L4a3]Cl4 inhibits both the number and 
average size of colonospheres formed in CSC-enriched cells more effectively than 
salinomycin. 
Monolayer human solid-tumour cell-line screening is a useful technique to 
garner acute toxicity information, but in order to better indicate the efficacy of 
anticancer drugs to kill undifferentiated CSCs, it is important to investigate their 
effects on clonogenic activity. The clonogenic assay is a quantitative in vitro technique 
that examines the capability of a single cell to grow into a large colony through clonal 
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expansion, and is a sensitive indicator of CSCs.87 HCT116.CD133+ cells incubated for 
48 h with 30 µM Δ-[Fe2L4a3]Cl4, exhibited no surviving cells after being allowed to 
grow for 8 d; a comparable growth-inhibitory effect to that of conventional 
salinomycin. A more moderate growth inhibition was observed for cells treated with 
Δ-[Fe2LS3]Cl4 [Figure 3-14 (g)]. 
 
Figure 3-14 Growth inhibitory effects in HCT116.CD133+ cells Representative microscopy images of 
the HCT116.CD133+ colonospheres in the absence (a) and presence of salinomycin (b), Δ-[Fe2LS3]Cl4 
(c), and Δ-[Fe2L4a3]Cl4 (d), treated at their respective IC30 values for 6 days (scale bar: 100 µM). 
Quantification of colonosphere formation (e and f) under the same conditions. Clonogenic assay on 
the HCT116.CD133+ (g) showing the number of colonies counted after treatment with different 
concentrations of salinomycin, (grey circles), Δ-[Fe2LS3]Cl4 (black open circle), and Δ-[Fe2L4a3]Cl4 
(black squares) for 48h, following growth for 8 days. Data represent the mean value and SD from 
three independent experiments. p < 0.01, versus control. 
The cytotoxicity of Δ-[Fe2L4a3]Cl4 was also tested in isolated CD133
+ cells 
from the HCT116 p53+/+ cell line, and an IC50 of 1.21±0.25 µM was measured in 
HCT116.CD133+, using the SRB assay following a 72 h exposure (Table 3-4). This is 
ca 40% lower than the IC50 measured for HCT116p53
+/+ cells (2.11±0.41 µM) under 
the same conditions, suggesting that Δ-[Fe2L4a3]Cl4 has a strong growth-inhibitory 
 
University of Warwick | Page 86 
 
effect on the CSCs, in fact similar to that of salinomycin (IC50 {HCT116p53+/+} = 
1.48±0.21 µM, IC50 {HCT116.CD133+} = 1.12±0.23 µM). 
Table 3-4 IC50 values of the investigated compounds in CSC enriched HCT116.CD133+ 
cells determined with SRB assay.a 
IC50 (µM) HCT116.CD133+ HCT116p53++ 
Salinomycin 1.12 ± 0.23 1.48 ± 0.21 
-[Fe2LS3]Cl4 2.04 ± 0.39 3.28 ± 0.30 
-[Fe2L4a3]Cl4 1.21 ± 0.25 2.11 ± 0.41 
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3.4 Conclusion 
In this chapter, the post-assembly modification of optically pure alkyne triplex 
metallohelices [Fe2L33]Cl4 has been investigated via CuAAC reactions. Unlike the 
symmetric flexicate system [Fe2L13]Cl4 and [Fe2L23]Cl4 described in Chapter 2, the 
anti-parallel external alkyne functional sites of the HHT triplex metallohelices 
[Fe2L33]Cl4 offer greater geometric advantages in precluding the formation of copper(I) 
bonded three concurrent triazole rings,89 allow 100% CuAAC conversion of the alkyne 
groups with bulky aromatic azides and preserve the helical structure. A series of new 
substituted triplex systems [Fe2L4a
-e
3]Cl4 have been synthesized through the 
substitution of benzyl azide in high efficiency and yield, and characterised by NMR 
spectroscopy, microanalysis, mass spectrometry and circular dichroism spectroscopy. 
In vitro cytotoxicity assay demonstrated the high potency of all the new triplex 
systems against HCT116 p53++ with an average IC50 value 2.60 µM, similar with 
parent [Fe2L33]Cl4. A wide range of cytotoxicity (3 µM to 76 µM) was found towards 
noncancerous ARPE-19 cell line. Notably, the significantly enantiomeric difference 
was observed that all Δ enantiomers were more selective than the Ʌ enantiomers. The 
most promising compounds were -[Fe2L4a3]Cl4 and -[Fe2L4c3]Cl4 with SI ca 30 and 
34 respectively, close to the parent complex -[Fe2L33]Cl4. In further cytotoxicity 
assay, -[Fe2L4a3]Cl4 demonstrated high potency against multiple cancer cell lines. 
The cell cycle analysis revealed that the post-assembly modifications of parent 
[Fe2L33]Cl4 can dramatically alter the cell cycle effect in two different cell lines. The 
anticancer mechanism of Δ-[Fe2L4a3]Cl4 was also demonstrated significantly different 
from cisplatin. Annexin V assay showed no apoptosis was induced by [Fe2L4a3]Cl4 
enantiomers. In contrast, they interfere with the Na+/K+ ATPase activity with 
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comparable potency to that of the conventional inhibitor ouabain. Moreover, Δ-
[Fe2L4a3]Cl4 is the first metallohelix to show antimetastatic properties. It significantly 
reduces HCT116 p53++ cell detachment, inhibits cell re-adhesion and reduces the 
invasion activity. 
Remarkably, Δ-[Fe2L4a3]Cl4 reduces the proportion of CSCs within a 
heterogeneous colon cancer cell population and irreversibly inhibits the colonosphere 
formation in both CSC enriched cells to an similar extent to salinomycin, a natural 
product that targets CSCs. To our knowledge, Δ-[Fe2L4a3]Cl4 is the first metallohelix 
to exhibit selective toxicity for colon CSC-enriched cell populations. Given our 
findings and the urgent medical need for CSC-specific chemotherapies to overcome 
cancer relapse and metastases in the clinic, the anti-CSC properties of Δ-[Fe2L4a3]Cl4 
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Chapter 4  
Glycoconjugation of triplex metallohelices 
4.1 Introduction 
Cancer cells have significantly different metabolic requirements to most normal cells.1 
For instance, increased rates of glutaminolysis and lipid synthesis are observed in 
tumour tissue2 and mitogenic signals promote nutrient uptake and the synthesis of 
DNA, RNA and proteins.3 Such metabolic characteristics, which support high rates of 
cancer cell proliferation4 and resist programmed cell death signals,5 have raised 
interest in targeted metabolic enzymes and signalling pathways for cancer therapy.6  
The Warburg effect, one of the most remarkable metabolic phenotypes of 
cancerous cells, describes the phenomenon whereby metabolism of glucose by 
anaerobic glycolysis (fermentation) is increased, even in the presence of oxygen.1 This 
effect has been extensively studied as a hallmark of cancer over the past eight 
decades.7 Two therapeutic strategies have been developed to exploit the Warburg 
effect: (i) interference with the signalling pathways and inhibition of metabolic 
enzymes involved in glycolysis by using small molecules such as 2-deoxy-D-glucose8 
and phloretin;9 (ii) development of cytotoxins that are tethered to glucose or other 
sugar molecules via glycoconjugation in order to decrease the cytotoxicity and 
increase the anticancer selectivity versus the aglycone.12 Substantial research has been 
conducted to investigate the latter strategy of glycoconjugation; the most widely 
exploited glycoconjugated anticancer agent is glufosfamide,11 which demonstrated the 
comparable potency to that of its aglycone in vitro but less cytotoxicity in vivo. The 
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cellular uptake assay indicated that the entry of glufosfamide into cells was at least 
partially GLUT receptor-mediated.12 We have not however been able to find further 
literature examples where any selectivity or activity improvement following 
glycoconjugation is shown convincingly to be a result of receptor mediation. One 
presumes that there are unreported examples where glycoconjugation has deleterious 
effects. 
Nevertheless, the attempted use of glycoconjugation in cancer therapy – and 
the great challenge associated with synthesis of labile metal complexes with appended 
sugars – inspired us to design and synthesize such triplex metallohelices and explore 
the potential biological application. In this chapter, two different methodologies have 
been applied to achieve the glycoconjuation of metallohelix systems. The anticancer 
mechanism of activity for these compounds has been investigated both in vitro and in 
vivo. 
4.2 Glycoconjugation of alkyne triplex metallohelices 
 
Figure 4-1 Two strategies to anchor sugars onto the triplex metallohelices 
In this section, two methods for the assembly of sugar-appended triplex metallohelices 
are explored. (Figure 4-1). In Method 1, a sugar derivative of the single ligand strand 
component is synthesized initially, followed by subsequent self-assembly of the metal 
complex. This has the advantage of simplicity, but also some disadvantages: first, the 
hydroxyl or other oxygen/nitrogen donors within the sugar unit may bind to the metal 
 
University of Warwick | Page 95 
 
in competition with the intended diamine/bpy ligands, leading to mixtures of 
(paramagnetic) products; second, for each type of sugar that we wish to append to the 
metallohelix, a new ligand component must be synthesised. Both of these issues may 
be circumvented in Method 2, whereby a single triplex system synthesised by self-
assembly is derivatised with a range of sugars. This of course depends on the stability 
of the triplex under the post-assembly reaction conditions.  
4.2.1 Synthesis and self-assembly reactions of glyco-pyridine aldehydes (Method 
1) 
 
Scheme 4-1 Synthesis of glyco-pyridine aldehyde 
Classically, the conjugation of sugar units to other molecules can be achieved using 
amide, ether, ester, thioester or glycosidic linkers;13 such moieties are widely present 
in sugar-containing small organic units14, peptides15 and proteins.16 For our triplex 
system, following a method for the etherification of similar sugar halides,17 a prototype 
glycosylated sub-component was synthesised as shown in Scheme 4-1. Williamson 
ether synthesis using 5-(hydroxy)picolinaldehyde (7) and the C1-bromo peracetylated 
glucose derivative 16 in the presence of K2CO3 in acetonitrile gave 17. Acetyl 
deprotection with a catalytic amount of sodium methoxide in methanol gave 18; as far 
as we aware this is the first example of a glyco-pyridine aldehyde. Notably, 18 is 
soluble in water, and in the presence of methanol it is in equilibrium with the 
hemiacetal, as observed by 1H NMR spectroscopy. 
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Subsequently, both 17 and 18 were treated with the aminobipyridine 14 in the 
presence of metal salts in order to allow self-assembly of sugar-appended triplex 
metallohelices, as follows. 
Synthesis of [Zn2L53][ClO4]4 from acetyl-protected sugar derivative 17 
 
Scheme 4-2 Synthesis of the sugar appended (Rc,ΔZn)-HHT-[Zn2L53][ClO4]4 triplex 
We first attempted to synthesize zinc(II) sugar appended metallohelices since these 
will be rigorously diamagnetic, thus providing sharp NMR spectra in order to assist in 
validation of the method. The acetyl protected glycol-pyridine aldehyde was employed 
as it is soluble in acetonitrile. Following a similar procedure for the aglycones,18 (R)-
2-([2,2'-bipyridin]-5-ylmethoxy)-1-phenylethan-1-amine (14, 3 eq.) was added to 
peracetylated glyco-pyridine aldehyde 17 (3 eq.) and Zn(ClO4)2·6H2O (2 eq.) in 
acetonitrile at ambient temperature (Scheme 4-2).  
 
University of Warwick | Page 97 
 
 
Figure 4-2 1H NMR (500 MHz, CD3CN, 298K) and 13C (125 MHz, CD3CN, 298K) spectra of 
(Rc,ΔZn)-HHT-[Zn2L53][ClO4]4. 
1H and 13C NMR spectra are consistent with the highly selective formation of 
the asymmetric HHT triplex structure with three spectroscopically unique ligand 
environments (Figure 4-2). All the characteristic 1H and 13C peaks were assigned, 
including the presence of two bpy H resonances b at unusually low field indicating 
cross-helix H-bonding, and two sets of very high field shifted phenyl resonances c and 
d as a result of bifurcated -stacking with adjacent bpy units – note that e.g. only one 
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doublet is seen for nuclei Hc for each arene as a result of flipping of the -stack on this 
timescale.19 Twelve acetyl Me (i) and carbonyl units (h) are expected and while the 
former overlap, most of the latter are well resolved. We also investigated whether the 
self-assembly reaction could withstand elevated temperatures; essentially identical 1H 
and 13C NMR spectra were obtained after heating to reflux for 48 h. 
Synthesis of [Zn2L63][ClO4]4 from deprotected sugar derivative 18 
 
Scheme 4-3 Attempted synthesis of acetyl deprotect (Rc,ΔZn)-HHT-[Zn2L63][ClO4]4 
Due to the low solubility of glyco-pyridine aldehyde 18 in acetonitrile, the attempt to 
synthesize [Zn2L3][ClO4]4 from 18 and 14 in the presence of Zn(ClO4)2 was not 
achieved at ambient temperature (Scheme 4-3). However, following the heating of the 
reaction solution at reflux for 48 h, the [Zn2L63][ClO4]4 was separated as yellow 
crystals following the addition of ethyl acetate. 
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Figure 4-3 1H NMR (500 MHz, CD3CN, 298K) and 13C (125 MHz, CD3CN, 298K) spectra of 
(Rc,ΔZn)-HHT-[Zn2L63][ClO4]4 
The 1H and 13C NMR spectra were well resolved and very similar to the acetyl 
protected compound [Zn2L63][ClO4]4 (Figure 4-3). The hydroxyl groups of the sugar 
dramatically increase the solubility of the zinc perchlorate complex such that NMR 
spectra are readily measureable in D2O (Figure 4-4). This is the first example of a 
water-soluble zinc(II) metallohelix; perhaps the most astonishing aspect is that the 
cation in this perchlorate salt is not hydrolysed under these conditions in water, with 
no decomposition detected for at least one week. The prospect thus arises that we 
might be able to develop metallohelices for medicinal applications or biophysical 
studies based on colourless Zn(II) complexes rather than intensely coloured Fe(II) 
complexes.  
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These spectra (Figure 4-4) differ from those measured in CD3CN (Figure 4-3) 
in that the peaks associated with the phenyl rings are significantly broadened. We 
suggest that this is due to the slowing of -stack flipping in the more polar solvent. 
We previously noted that polar media promote the formation of -stacked isomers in 
a model system.20 
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Synthesis of [Fe2L53]Cl4 from acetyl-protected sugar derivative 17 
 
Scheme 4-4 The attempt to synthesis of the acetyl protect glucose appended (Rc,ΔFe)-[Fe2L53]Cl4 
triplex 
Following the successful self-assembly of the peracetylated glyco-pyridine aldehyde 
17 with zinc(II) and amine 14 (Scheme 4-2), we attempted the synthesis of the iron(II) 
analogue (Rc,ΔFe)-[Fe2L53]Cl4 (Scheme 4-4). Mixing appropriate proportions of 14, 17 
and FeCl2 in methanol led to the immediate formation of an intense purple solution. 
After heating for 48 h, the product was isolated as a semi crystalline purple solid 
following the addition of ethyl acetate.  
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Figure 4-5 The 1H NMR (500 MHz, MeOD, 298K) and 13C NMR(125 MHz, MeOD, 298K) spectra 
of the acetyl protect glucose appended (Rc,ΔFe)-[Fe2L53]Cl4 triplex 
In the region 10.0-9.2 ppm of the 1H NMR spectrum, rather than the expected 
five singlets we observed a more complex set of peaks (Figure 4-5). The 13C NMR 
spectrum is also more complicated than the zinc(II) perchlorate counterpart, notably 
with two clusters around 100 ppm arising from the sugar C1 centres, where only one 
is observed above. This suggests that the phenomenon responsible for the presence of 
more than one species is associated with the C1 centre. 
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Figure 4-6 ESI mass spectrum of [Fe2L53]Cl4 showing peaks for [L5+Na]+ and {[Fe2L53]Cl}3+  
Mass spectrometry shows the base peak of tricationic ion {[Fe2L53]Cl}
3+ at 
789.5, followed by the [L5+Na]+ at 763.4 (Figure 4-6). No tetracationic molecular ion 
[Fe2L53]
4+ was detected. The chloride ion is evidently not present in the inner 
coordination sphere since the NMR spectra indicate diamagnetism (vide infra).  
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Figure 4-7 The proposed structure of the (Rc,ΔFe)-[Fe2L53Cl]3+ cation showing the hydrogen bonding 
of the chloride ion 
On the basis that the tetracationic charge in the main triplex structure provides 
electrostatic binding, and that chelate H-bonding C1-H···Cl
- is feasible at one end of 
the triplex,21 we suggest that structures such as that shown in Figure 4-7 are 
responsible for the observations from mass spectrometry and the presence of 
unexpected species in the NMR spectra.  
In order to test this idea, we explored the effects of solvent and anion. While 
(Rc,ΔFe)-[Fe2L53]Cl4
 is not very soluble in CD3CN, leading to poor signal:noise, it is 
nevertheless clear that a similar mixture of species is present in this solvent. We were 
pleased to find that repeating the assembly reaction using Fe(ClO4)2 in the place of 
FeCl2 gave essentially a single species (Rc,ΔFe)-[Fe2L53][ClO4]4 according to 
1H and 
13C NMR spectra, which were very similar to those of (Rc,ΔZn)-[Zn2L53][ClO4]4 
(Figure 4-8). Unsurprisingly, no inclusion of perchlorate was detected by mass 
spectrometry.  
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Synthesis of [Fe2L63]Cl4 from deprotected sugar derivative 18 
 
Scheme 4-5 The attempt to synthesis of (Rc,ΔFe)-[Fe2L63]Cl4 triplex 
The self-assembly of glyco-pyridine aldehyde 18, with bipyphenylamine 14 
and FeCl2 was also investigated, which again led to the rapid formation of purple 
solution from which purple microcrystals were isolated following addition of ethyl 
acetate after 2 d (Scheme 4-5). 
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Figure 4-9 The 1H NMR (500 MHz, D2O, 298K) and 13C NMR spectra (125 MHz, D2O, 298K) of 
(Rc,ΔFe)-[Fe2L63]Cl4 triplex after 2 d reflux 
The 1H NMR spectrum (Figure 4-9) showed peaks in the low field region 
(9.80-8.70 ppm) consistent with the presence of two major and one minor HHT species. 
The 13C NMR spectrum also displayed several peaks around 100 ppm which were 
ascribed to the C1 carbon of various species. Coordination of Cl
- to the core triplex 
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tetracation is possible in the case of the deptrotected sugar via a number of modes – 
perhaps the above detected species differ for example in the facial coordination mode. 
However, the [Fe2L63Cl]
3+  ion was not detected by ESI mass spectrometry. 
Assembly of the same glyco-pyridine aldehyde 18 and bipyphenylamine 14 
with Fe(ClO4)2 led to the formation of (Rc,ΔFe)-[Fe2L63][ClO4]4. The 
1H spectrum 
shows principally five characteristic singlets at 9.5-9.0 ppm, as for the zinc analogue 
(Rc,ΔZn)-[Zn2L63][ClO4]4 (Figure 4-10). The tetracationic molecular ion [Fe2L63]
4+ was 
observed at 457.4 in the mass spectrum, whereas no tricationic ion [Fe2L53(ClO4)]
3+ 
was detected. Similar to the zinc(II) analogue, the presence of twelve hydroxyl groups 
improves the solubility of the structure, such that even as a perchlorate salt excellent 
NMR spectra could be obtained in D2O (Figure 4-11). The presence of a minor 
component of apparently HHH structure is indicated in the 1H NMR spectrum of 
Figure 4-10 measured in CD3CN although the appearance of the same sample in D2O 
is very different.  
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Figure 4-10 1H NMR (500 MHz, CD3CN, 298K) and 13C (125 MHz, CD3CN, 298K) spectra of 
(Rc,ΔFe)-HHT-[Fe2L63][ClO4]4 
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Figure 4-11 1H NMR (500 MHz, D2O, 298K) and 13C (125 MHz, D2O, 298K) spectra of (Rc,ΔFe)-
HHT-[Fe2L63][ClO4]4 
In conclusion for glycoconjugation strategy Method 1, the sugar ligand 
subcomponents i.e. glyco-pyridine aldehydes 17/18 have been synthesized. The acetyl 
protected [M2L
5
3][ClO4]4 (M = Zn, Fe) and acetyl deprotected [M2L
6
3][ClO4]4 




3][ClO4]4 exhibit substantial water solubility. 





due to the presence of intramolecular hydrogen bonding between Clˉ and C1 proton 
or OH.
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4.2.2 Method two: Synthesis of glycoconjugated triplex metallohelix via CuAAC 
The successful use of CuAAC chemistry to attach aromatic azides to the triplex 
metallohelices was described in Chapter 3. In this section, we attempt to click sugar 
azides onto pre-formed alkyne triplex metallohelices, using the same strategy. Due to 
their documented involvement in cancer cell metabolism, β-glucose23, β-galactose24, 
2-deoxy-D-glucose25, α-mannose26, β-N-acetylglucosamine27 and β-N-
acetylgalactosamine28 were selected as sugar moieties to click onto the alkyne triplex 
metallohelices via their azide derivatives. 
Synthesis of sugar azides 
 
Scheme 4-6 Synthesis of the sugar azides 
The synthesis of β-D-glucopyranosylazide was adapted from a literature procedure 
(Scheme 4-6).29,30 D-Glucopyranosyl pentaacetate (from D-glucose and acetic 
anhydride) in dry CH2Cl2 was treated dropwise with a solution of HBr in AcOH to 
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form D-glucopyranosyl bromide (16). This was converted quantitatively to 2,3,4,6-
tetra-O-acetyl-β-D-glucopyranosylazide (19) using sodium azide in DMSO. 
Deprotection using sodium methoxide was followed by neutralization using cationic 
ion-exchange resin (Dowex® 50WX4 hydrogen form), then filtration and evaporation 
afforded β-D-glucopyranosylazide (20) as a colourless oil. β-D-Galactopyranosylazide 
(23) was synthesised using the same method.30 β-D-Mannopyranosylazide cannot be 
synthesised with the same method, but α-D-mannopyranosylazide (25) was achieved 
via the following synthetic method:30 azidotrimethylsilane (TMSiN3), tin tetrachloride 
(SnCl4) and D-mannopyranosyl pentaacetate were added in dry CH2Cl2 solution under 
nitrogen to form 1,2,3,4,6-Penta-O-acetyl-α-D-mannopyranosylazide (24), which was 
deprotected with sodium methoxide to form 25. -N-acetylgalactosamine azide (26) 
and -N-acetylglucosamine azide (27) were provided by Dr Joji Tanaka from the 
Perrier group, Warwick University.31  
Synthesis of acetyl protect glucose [Zn2L7a3][ClO4]4 triplex via CuAAC 
β-D-Glucopyranosyl pentaacetate azide (19) (4.5 eq.) and (Rc,ΔZn)-HHT-
[Zn2L33][ClO4]4 (1 eq.) were dissolved in acetonitrile in the presence of copper(I) 
iodide (0.1 eq.). The solution was heated at 65˚C under reduced pressure for 18h. The 
resulting suspension was filtered through Celite to remove precipitated copper salts 
and the final product was isolated as a white/yellow solid upon the addition of ethyl 
acetate.  
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Figure 4-12 1H NMR spectra (500 MHz, CD3CN, 298K) of (a) (Rc,ΔZn)-HHT-[Zn2L33][ClO4]4, (b) 
(Rc,ΔZn)-HHT-[Zn2L7a3][ClO4]4; 13C NMR spectra (125 MHz, CD3CN, 298K) of (c) (Rc,ΔZn)-HHT-
[Zn2L33][ClO4]4, (d) (Rc,ΔZn)-HHT-[Zn2L7a3][ClO4]4; 
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As seen in the 1H NMR spectra [Figure 4-12(a); (b)], the three alkyne singlets 
Hh (3.0-2.8 ppm) are no longer observed following the click reaction. The three sharp 
singlets He at 4.85, 4.81, 4.72 ppm [Figure 4-12(a)], which were assigned to the CH2-
alkyne groups, shift to higher frequency and overlap with sugar protons at ca 5.30 ppm 
[Figure 4-12(b)]. The new multiple singlets Hi at 2.08-1.64 ppm [Figure 4-12(b)] 
overlapping with CD3CN peaks are due to acetyl groups of β-D-glucopyranosyl 
pentaacetate. The characteristic peaks such as three imine singlets Ha, three bpy 
singlets Hb and the phenyl ring protons Hc marginally shift in both 1H NMR spectra, 
indicating that the core triplex architecture is retained during the click reaction. 
The 13C NMR spectra [Figure 4-12(c); (d)] are also consistent with complete 
conversion of the sugar click reaction as shown by the disappearance of alkyne carbon 
signals Ch [Figure 4-12(c)] and presence of triazole C4 carbon Cj [ca 142 ppm Figure 
4-12(d)]. Multiple signals Ck at ca 170.0 ppm are sugar carbonyl groups, accompanied 
with strong methyl carbon signals Ci found at ca 20.0 ppm. The three pyridine-O-CH2-
R carbons Ce shifted to higher frequency from ca 56.9 ppm to ca 62.2 ppm as a result 
of conjugating with the triazole, a stronger electronic withdrawing group than the 
alkyne. The three imine carbons Ca and three bpy carbons Cb were unperturbed by the 
click reaction. 
Synthesis of CuAAC glycoconjugated Fe(II) triplex 
 
Scheme 4-7 Synthesis of CuAAC glycoconjugated Fe(II) triplex metallohelices 
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The Fe(II) sugar clicked triplex was synthesized in an analogous fashion to the 
Zn(II) sugar clicked triplex. β-N-Acetylgalatosmaine azide (4.5 eq.) and (Rc,ΔFe)-
HHT-[Fe2L33]Cl4 (1 eq.) were dissolved in methanol (20 ml) in the presence of copper 
(I) iodide (1 eq.) (Scheme 4-7). The reaction was heated at 65˚C under reduced 
pressure for 18h. After cooling, the suspension was filtered and the purple product was 
isolated by the addition of ethyl acetate. 
The 1H NMR spectra [Figure 4-13(a);(b)] confirm that the click reaction has 
proceeded to completion alkyne singlets Hg at 3.05, 2.84 and 2.79 ppm [Figure 4-13(a)] 
are no longer present and triazole signals Hh at 8.28, 8.17 and 8.06 ppm [Figure 
4-13(b)] appear. The multiplets Hi between 5.76-5.62 ppm [Figure 4-13(b)] are due to 
the C1 proton of β-N-acetylgalactosamine units overlapping with broad phenyl protons. 
The three singlets Hk at 1.71, 1.55, 1.51 ppm [Figure 4-13(b)] arise from methyl 
protons of the acetyl groups. 
The 13C NMR spectra [Figure 4-13(c);(d)] also confirm the completion of the 
click reaction through the absence of alkyne carbon signals Cg and Cf [Figure 4-13(c)] 
and the presence of the triazole carbon signal Cf at ca 142.0 ppm [Figure 4-13(d)]. The 
pyridine-O-CH2-R carbon signal Ce has shifted to higher frequency from ca 56.0 ppm 
to ca 60.9 ppm. The carbonyl signals Cj and methyl signals Ck of the acetyl group 
were found at ca 174.0 and ca 21.6 ppm, respectively. 
 
 
University of Warwick | Page 116 
 
 
Figure 4-13 1H NMR spectra (500 MHz, D2O, 298K) of (a) (Rc,ΔFe)-HHT-[Fe2L33]Cl4, (b) (Rc,ΔFe)-
HHT-[Fe2L7i3]Cl4; 13C NMR spectra (125 MHz, D2O, 298K) of (c) (Rc,ΔFe)-HHT-[Fe2L33]Cl4, (d) 
(Rc,ΔFe)-HHT-[Fe2L7i3]Cl4 
The CD spectra of the diastereomers [Fe2L7i3]Cl4 in methanol gave equal and 
opposite signals, and mimic the features of the aglyconic triplex isomers [Fe2L33]Cl4 
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[Figure 4-14(a)]. The sugar clicked compounds were found to be remarkably stable 
under aqueous conditions. (Rc,ΔFe)-HHT-[Fe2L7i3]Cl4 gave a high resolution 
electrospray mass spectrometry peak at m/z 548.9335 Da for the tetracationic 
molecular ion, which is within 0.001 Da of the calculated value (548.9325) for 
C108H114N24O21
56Fe2 [Figure 4-14(b)]; no chloride coordination was detected.  
 
Figure 4-14 (a) CD spectra for alkyne triplex isomers [Fe2L33]Cl4 and β-N-acetylgalatosmaine clicked 
isomers of [Fe2L7i3]Cl4 in methanol; (b) High resolution mass spectrometry for (Rc,ΔFe)-HHT-
[Fe2L7i3]Cl4: top measured, below calculated. 
Other sugar clicked triplex metallohelices were synthesised using the same 
procedure. CHN elemental analyses were also consistent with the proposed formula 
of each metallohelix. 
4.3 Biological activity of CuAAC glycoconjugated triplex 
metallohelices 
While to our delight all the above synthetic glycoconjugation strategies were 
successful, Method 2 was judged to give the greatest diversity most rapidly, and did 
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not suffer from the complication of Cl- coordination of some compounds from Method 
1. We thus chose this small library for further study.  
4.3.1 In vitro cytotoxicity assay 
 
Figure 4-15 Structure of glycoconjugation triplex compounds via CuAAC 
The 18 new CuAAC glycoconjugated Fe(II) triplex metallohelices of Figure 4-15 were 
screened alongside the alkyne triplex [Fe2L33]Cl4 for their activity and selectivity 
against cancer cell lines HCT116 p53++ (human colon carcinoma with wild-type p53) 
and the healthy cell line ARPE19 (human retinal pigment epithelial cells). This work 
was partially conducted by Dr Samantha Shepherd in Huddersfield University. The 
IC50 values obtained from triplicate measurements are given in Figure 4-16, Figure 
4-17, and are plotted in Table 4-1. 
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Cytotoxicity for HCT116 p53++ cancer cell line. The potency of all CuAAC 
glycoconjugated triplex metallohelices [Fe2L7a
-i
3]Cl4 varies from 630 nM to 10.70 μM 
(Figure 4-16). A significant difference in the potency was observed between 
diastereomers; Ʌ metallohelices were at least twice potent than the Δ enantiomers. The 
hydroxyl groups on the sugar significantly affect the drug potency as the cytotoxicity 
of the acetyl protected sugar compounds [Fe2L7a
-c
3]Cl4 decreased substantially relative 
to their deprotected counterparts [Fe2L7d
-f
3]Cl4. Investigations of structure-activity 
relationships revealed that the potency depended upon the sugar moiety, with activity 
decreasing in the following order: galactose L7d > glucose L7g > acetylglucosamine 
L7i > deoxy-glucose L7f > mannose L7e> three acetyl protect sugar clicked compounds 
(L7a-c)> acetylgalactosamine L7i. The most potent compound is the Ʌ enantiomer of 
the galactose clicked triplex [Fe2L7d3]Cl4 with IC50 630 nM.  
 
Figure 4-16 IC50 values of CuAAC glycoconjugated triplexes [Fe2L7a-i3]Cl4 and alkyne triplex 
[Fe2L33]Cl4 against HCT116 p53++ 
Cytotoxicity for ARPE19 noncancerous cell line. In a similar fashion to the HCT116 
p53++ cancer cell line, the cytotoxicity difference between the enantiomers is also 
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remarkable i.e. all Ʌ type of metallohelices (with average IC50 value at 10 µM) 
demonstrated over 5 fold increase in toxicity with respect to the Δ diastereomers 
(average IC50 value over than 55 µM) (Figure 4-17). Compared with alkyne 
[Fe2L33]Cl4, all Ʌ glycoconjugated metallohelices showed increased toxicity whereas 
Δ counterparts possess much more moderate and similar cytotoxicity. Among the 
glycoconjugated metallohelices, the IC50 of Δ[Fe2L7i3]Cl4 (acetylgalatosmaine 
clicked) was extraordinarily high at 315.35 µM, which is desirable in normal cells to 
reduce unwanted side effects. 
 
Figure 4-17 IC50 values of CuAAC glycoconjugated triplexes [Fe2L7a-i3]Cl4 and alkyne triplex 
[Fe2L33]Cl4 against ARPE19 (noncancerous cell line) 
Selectivity index. The selectivity index can be calculated by dividing the ARPE-19 
IC50 value with that of the HCT116 p53
++cells. In conclusion, all the Δ enantiomers 
have much better selectivity than Ʌ enantiomers (Table 4-1). Structure-activity 
relationships demonstrated that selectivity of the sugar metallohelices decreased in the 
following order: glucose L7g > acetylglucosamine L7h > galactose L7d > 
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acetylgalactosamine L7i> deoxy-glucose L7f > mannose L7e > all acetyl protected 
sugar clicked compounds L7a-c. The most potent compounds are Δ[Fe2L7g3]Cl4 
(glucose clicked) and Δ[Fe2L7h3]Cl4 (acetylglucosamine clicked) with selectivity 
index 43 and 37.37 respectively, slightly higher than Δ[Fe2L33]Cl4. 
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Table 4-1. Cytotoxicity and Selectivity index of sugar clicked triplex [Fe2L7a-i3]Cl4 and unclicked 
alkyne triplex [Fe2L33]Cl4 against HCT116 p53++ and ARPE-19 cell line 
 mean IC50 (µM) Selectivity 
Index HCT116 p53++ ARPE-19 
[Fe2L7a3]Cl4 Λ 3.53 ± 0.18 5.44  ± 3.01 2 
Δ 9.52 ± 0.10 63.17 ± 8.08 7 
[Fe2L7b3]Cl4 Λ 3.60 ± 0.23 11.04 ± 3.25 3 
Δ 10.70 ± 0.74 65.45 ± 1.44 6 
[Fe2L7c3]Cl4 Λ 3.28 ± 0.28 13.35 ± 5.85 4 
Δ 9.93 ± 0.92 57.90 ± 6.31 6 
[Fe2L7d3]Cl4 Λ 0.63 ± 0.02 2.96 ± 0.19 5 
Δ 1.68 ± 0.04 59.68 ± 5.44 36 
[Fe2L7e3]Cl4 Λ 0.72 ± 0.08 8.22 ± 0.19 11 
Δ 5.42 ± 1.16 89.31 ± 2.43 16 
[Fe2L7f3]Cl4 Λ 0.74 ± 0.08 10.18 ± 1.21 14 
Δ 4.54 ± 0.31 101.12 ± 12.91 22 
[Fe2L7g3]Cl4 Λ 1.05 ± 0.51 11.64 ± 1.98 11 
Δ 2.69 ± 1.71 115.55 ± 19.28 43 
[Fe2L7h3]Cl4 Λ 1.56 ± 0.23 16.56 ± 5.76 11 
Δ 2.08 ± 0.08 77.73 ± 5.28 37 
[Fe2L7i3]Cl4 Λ 12.16 ± 0.74 79.64 ± 10.67 7 
Δ 10.62 ± 5.42 315.35 ± 29.78 30 
[Fe2L33]Cl4 Λ 5.02 ± 0.21 73.81 ± 13.05 15 
Δ 2.87 ± 0.91 100.44 ± 4.67 35 
4.3.2 Pseudo-Hypoxic assay 
Most cancer cells utilise anaerobic glycolysis, an inefficient way to generate energy 
for cellular processes.1 This altered metabolism is due to the micro-environmental 
stresses of hypoxia,33,34 which upregulates the hypoxia-inducible factor 1 (HIF1)35 and 
increases the expression of glucose transporters GLUT136 and GLUT3.37 We 
postulated that the activity and selectivity of CuAAC glycoconjugated triplex were 
related to glucose transporters. To validate the hypothesis, CoCl2, a chemical 
stabilising HIF1 to mimic hypoxia conditions,38 was added into cell culture medium, 
followed by the normal MTT protocol. We expected the IC50 value to decrease after 
adding CoCl2 compared with normoxic conditions, as more sugar triplex would be 
transported into cells. This work was conducted by Dr Samantha Shepherd in 
Huddersfield University. 
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Table 4-2 Cytotoxicity of CuAAC glycoconjugated triplexes against HCT116 p53++ with and without 
CoCl2 exposure 
 
mean IC50 (µM) 
HCT116 p53++ HCT116 p53++ with CoCl2 
ΔFe,HHT-[Fe2L7d3]Cl4 1.68 ± 0.04 58.34 ± 15.14 
ΔFe,HHT-[Fe2L7e3]Cl4 5.42 ± 1.16 58.44 ± 14.44 
ΔFe,HHT-[Fe2L7g3]Cl4 2.69 ± 1.71 53.15 ± 7.09 
ΔFe,HHT-[Fe2L7h3]Cl4 2.08 ± 0.08 56.28 ± 12.45 
ΔFe,HHT-[Fe2L7i3]Cl4 10.62 ± 5.42 >100 
As we can see in Table 4-2, the IC50 of the glycoconjugated triplex increased 
dramatically after adding CoCl2. The overexpression of glucose transporters did not 
improve the activity of the sugar triplex. One of the reasons for this might be that 
hypoxia can induce drug resistance34, 39 by effluxing xenobiotics and reducing drug 
retention in the cells.40 Or, more free glucose was competitively uptaken into cells and 
reduced the interaction between sugar triplex and glucose transporter. Further 
investigations are required to verify these hypotheses. 
4.3.3 In vivo Xenograft Studies 
Based on the excellent cytotoxicity of this new series of sugar conjugated 
metallohelices against HCT116 p53++ in vitro, the ΔFe,HHT-[Fe2L7g3]Cl4 (SI>40) was 
chosen to evaluate the efficacy of this compound a the inhibiting tumour growth in 
vivo. Human colorectal tumour xenograft models were injected intravenously (iv) with 
ΔFe,HHT-[Fe2L7g3]Cl4 (1.75 mg/Kg). Cisplatin (6mg/Kg) was iv administrated for 
comparison. These studies were conducted by Dr. Steve Shnyder at the University of 
Bradford.  
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Figure 4-18 In vivo antitumor effect of ΔFe,HHT-[Fe2L7g3]Cl4 on HCT116 xenograft models: Mice 
were administrated with ΔFe,HHT-[Fe2L7g3]Cl4 (1.75mg/Kg) or cisplatin (6mg/Kg) for one dose by iv 
injection. (a) Mean relative tumour volumes; and (b) mean relative bodyweight were measured at 
different time points and plotted, and expressed with + standard error; the significance p value < 0.01 
was considered to be statistically significant. 
As shown in Figure 4-18(a), ΔFe,HHT-[Fe2L7g3]Cl4 exhibited statistically 
significant tumour growth delay (4.3 days), similar to cisplatin (4.7 days). More 
importantly, no side effects of weight loss were observed during the treatment of 
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ΔFe,HHT-[Fe2L7g3]Cl4, which was consistent with the high selectivity observed in 
vitro. In contrast, cisplatin showed serious toxicity as indicated by up to 6% loss of 
body weight on day two [Figure 4-18(b), Table 4-3]. Considering that this preliminary 
result was obtained for only one dose injection, the antitumour activity of ΔFe,HHT-
[Fe2L7g3]Cl4 is very promising. Multiple-dose investigation of this compound is in 
progress.  
Table 4-3 Anti-tumour effect of ΔFe,HHT-[Fe2L7g3]Cl4 and cisplatin against HCT 116 p53-/- tumour in 
vivo 






Control 4.2 - - 2.0 (day 6) 
ΔFe,HHT-
[Fe2L7g3]Cl4 
8.5 4.3 p<0.01 6.0 (day 2) 
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4.4 Conclusion 
Motivated by the Warburg effect, we attempted to make glycoconjugation of 
metallohelices in two different methodologies and evaluate the hypothesis that sugar 
appended complexes enhance the targeting and anticancer activity compared with the 
aglycone.  
For Method 1, glyco-pyridine 17/18 were made as the ligand precursors to 
assemble with aminobipyridine 14 and metal salt in proportional ratio. For the first 
time, we made water soluble glyco-metallohelices [M2L63][ClO4]4 (M = Zn, Fe) with 
regard to the perchlorate salt. Whereas, the same ligand components gave a mixture 
of species [Fe2L53]Cl4 and [Fe2L63]Cl4, presumably due to the presence of 
intramolecular hydrogen bonding between Cl- and C1 proton or OH.  
For Method 2, based on the success of CuAAC click post-assembly 
modification described in Chapter 3, the sugar azides were employed to substitute the 
aromatic azide. Following the same protocol, a series of sugar azides have been clicked 
onto the alkyne triplex [Fe2L33]Cl4 in high yield. These new CuAAC glyco-
metallohelices [Fe2L7a
-i
3]Cl4 demonstrated the high anticancer activity and selectivity 
against HCT116p53++ cell line and noncancerous ARPE19 cell line in vitro. In 
particular, (Rc,ΔFe)-HHT-[Fe2L7g3]Cl4 displayed similar inhibition to the growth of 
human tumour xenografts, but reduced side effects compared to cisplatin. 
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Chapter 5   
Triplex metallohelices containing triazole ligand units 
5.1 Introduction 
Polypyridines, such as bipyridine, terpyridine or pyridine-imine, are the most 
frequently employed units in discrete multinuclear coordination structures e.g. 
helicates,1-3 cages,4-6 and grids.7-9 However, the limitations of pyridine-containing 
ligands, such as cumbersome syntheses involving toxic reagents10 and lack of 
functionalization impede access to diversity.11 Other N-heterocycles such as pyrazoles, 
imidazoles and pyrazines have also been used, but these suffer from similar problems. 
Alternatively, 1,2,3-triazole moieties, can in principle be much more readily 
functionalised than pyridines, due to the discovery of CuAAC chemistry.12 
In addition to the synthetic advantages, 1,2,3-triazole moieties also exhibit 
interesting coordination behaviour. The three nitrogen atoms of the 1,2,3-triazole give 
rise to its distinct chemical and physical properties (e.g. high degree of aromaticity,13 
large polarization of electronic distribution,14 the increased CH- acidity15 and 
decreased base strength)16 and offer two different N-donor (N2 and N3)17 and one C-
donor (C5) coordination modes.18 In either monodentate or bidentate ligand systems, 
coordination through the more electron-rich (and more basic) N3 nitrogen atom is 
most commonly observed. Intriguingly, the isoelectronic replacement of a methine 
group by nitrogen leads to weaker σ-donor and π-acceptor strength of the N3-
coordinated triazole ligand, with respect to pyridine.17 These electronic differences 
have received considerable attention as the replacement of the pyridine by triazole 
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varies the photophysical,19-21 electrochemical,22-27 thermodynamic28-30 and kinetic31 
properties of the metal complexes.  
1,2,3-triazole ligands therefore open up an excellent route for new ligand 
design and can be employed in multidentate ligand systems in which the motif is 
treated as the pyridyl surrogate e.g. bidentate bis-triazole or pyridine-triazole ligands, 
and tridentate bis-triazole-pyridine ligands.17, 32-34 A growing number of examples in 
the literature of coordination complexes with traziole-containing ligands are exploited 
for their applications in biology and medicine,35-42 catalysis,43-47 photoactive 
devices,48-53 host-guest chemistry54-57 and molecular machines.58-61  
 
Figure 5-1 The formation of M2L3 helicate from bis-(2-pyridyl-1,2,3-triazole) ligands35 
In 2012, Petitjean and co-workers first synthesized a family of M2L3 (M = 
Fe2+and Ni2+) helicates containing bis-(2-pyridyl-1,2,3-triazole) ligands and exploited 
the applications of magnetism and self-selection.1,62 Crowley and co-workers 
employed the analogue ligand to form Fe(II) helicates and examined the biological 
activity. Unfortunately, no antifungal activity was observed as the complexes are not 
soluble in aqueous solution and decomposed instantaneously in DMSO.36 In order to 
improve the solubility and stability of triazole metallohelices, the same group 
substituted the Fe(II) with the more inert metal Co(III); antimicrobial studies showed 
no activity.37 In 2015, the same group reported a triazole-derived quadruply-stranded 
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helicate of Pd(II) which was 7-fold more active than cisplatin.63 However, the complex 
has no selectivity towards non-malignant cells.  
The majority of the triazole-containing ligands employed to date are end-to-
end symmetric and contain bulky (aromatic) groups, consequently leading to 
symmetric, racemic, rigid and low functionality structures. More importantly, the 
ability to readily functionalise the triazole unit has not been exploited to its full 
potential to construct more flexible and asymmetric discrete metallohelices. 
In this chapter, we describe the synthesis of a new directional ligand class 
(Figure 5-2) based on the bipyridine-imine system studied in earlier chapters, but 
which is derived from new triazole aldehydes. A new series of asymmetric 
metallohelicates is established with a range of substituents at the triazole i.e. on the 
external faces the framework. The investigations of the chemical and biological 
properties of these new metallohelices are also detailed.  
 
Figure 5-2 New triazole-imine/bipyridine ligand developed in this chapter.  
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5.2 Synthesis of benzylic triazole aldehydes 29a-e 
 
Scheme 5-1 Synthesis of aromatic triazole aldehyde 
Benzyl triazole aldehyde derivatives have been reported as key intermediates for 
catalysis,64,65 switchable materials,66 antibacterial compounds,67,68 
immunostimulants,69 anti-inflammatory compounds and anticancer drugs.70,71 
Following a literature example to make benzyl triazole aldehyde 29a (Scheme 5-1),72 
the benzyl azide derivatives 15a-e (1 eq.) were first treated with propargyl alcohol (1 
eq.) in the present of copper iodide (0.1 eq.) to afford the respective benzyl triazole 
methanol derivatives 28a-e. These derivatives were subsequently oxidised with 
activated manganese dioxide (3 eq.) to obtain the benzyl triazole aldehyde derivatives 
29a-e, as white solids. Of this series, 29c and 29e are new compounds but since 
characterisation of some other examples is incomplete in the literature, full data was 
acquired here. 
5.3 Synthesis of triazole Zn(II) triplex metallohelices 
 
Scheme 5-2 Synthesis of benzyl triazole derivate Zn (II) triplex metallohelice 
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The bimetallic metallohelix (Rc,ΔZn)-[Zn2L8a3][ClO4]4 was synthesised by mixing (R)-
2-([2,2'-bipyridin]-5-ylmethoxy)-1-phenylethan-1-amine (14, 3 eq.) with benzyl 
triazole aldehyde 29a (3 eq.) and Zn(ClO4)2·6H2O (2 eq.) in acetonitrile solution at 
ambient temperature (Scheme 5-2). After 4 h, the pure complex was isolated by 
dropwise addition of ethyl acetate and filtration of the microcrystalline solid formed.  
The triazole-containing metallohelix (Rc,ΔZn)-HHT-[Zn2L8a3][ClO4]4 has an 
asymmetric configuration evidenced by the three spectroscopically unique ligand 
environments in the 1H NMR spectrum (Figure 5-3). The characteristic signals of the 
imine proton Ha, bpy protons Hb and triazole protons Hc were observed at low fields 
(9.4-8.4 ppm) (Figure 5-3a). Two sets of phenyl ring protons Hd and He, found at 6.80–
5.90 ppm, experience strong through-space shielding from the bpy unit of an adjacent 
ligand. The benzylic CH protons Hg were detected at 5.43, 4.88 and 4.79 ppm along 
with the adjacent diasterotopic CH2 groups protons Hi observed at 4.30-4.00 ppm and 
3.70-3.42 ppm. The clusters at 5.30-5.10 ppm and 4.55-4.40 ppm were assigned to 
bipyridine-CH2 protons Hh. Benzyl-CH2 atoms Hf were analysed at 5.62-5.40 ppm. 
The 13C NMR spectrum (Figure 5-3b) was also consistent with three unique ligand 
environments. Three imine carbon peaks Ca were found at 157.1-156.1 ppm, and three 
bpy carbon peaks Cb were observed at 150.4-149.9 ppm. The three benzylic carbon 
peaks Cg were detected at 69.7, 69.5 and 67.8 ppm. Bipyridine-CH2 carbon peaks Ch 
were found at 70.0, 69.9 and 69.1 ppm. Benzyl-CH2 carbon peaks Cf were assigned at 
55.5-50.1 ppm.  
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Figure 5-3 1H (500 MHz, CD3CN, 298K) and 13C (125 MHz, CD3CN, 298K) NMR spectra of 
(Rc,ΔZn)-HHT-[Zn2L8a3][ClO4]4 
Other aromatic triazole triplex metallohelices (Scheme 5-2) were easily 
accessed through use of the aldehydes shown in Scheme 5-1. The 1H and 13C NMR 
spectra (Figure 5-4) were similar to that of (Rc,ΔZn)-HHT-[Zn2L8a3][ClO4]4  
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Figure 5-4 1H (500 MHz, CD3CN, 298K) and 13C (125 MHz, CD3CN, 298K) NMR spectra of 
(Rc,ΔZn)-HHT-[Zn2L8b3][ClO4]4 
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5.5 Synthesis of water soluble triazole triplex metallohelices 
of Fe(II). 
 
Scheme 5-3 Synthesis of triazole Fe (II) triplex metallohelices  
Water soluble complexes of this class (Rc,ΔFe)-HHT-[Fe2L8a-e3]Cl4 were accessed by 
heating (R)-2-([2,2'-bipyridin]-5-ylmethoxy)-1-phenylethan-1-amine (14, 3 eq.), the 
appropriate benzyl triazole aldehydes 29a-e (3 eq.) and FeCl2 (2 eq.) in methanol for 
48 h (Scheme 5-3).  
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Figure 5-5 Variable temperature 1H NMR spectra of (Rc,ΔFe)-HHT-[Fe2L8a3]Cl4 (600 MHz, MeOD) 
Compared with the Zn(II) counterparts, the 1H NMR signals for the -stacked 
phenyl rings (e.g. Hd/d', Figure 5-5) were much broader at 293 K, presumably as a 
result of relatively slow rotation since on increasing the temperature the signals 
sharpened. These broad signals were also observed in the 1H spectra of other iron(II) 
pyridine triplexes. 
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Figure 5-6 1H-13C HSQC/HMBC (500 MHz, MeOD, 298K) spectra of (Rc,ΔFe)-HHT-[Fe2L8a3]Cl4 
In a similar fashion to the Zn(II) counterpart, nine sharp singlets were observed 
in the down field region of the 1H NMR spectrum of (Rc,ΔFe)-HHT-[Fe2L8a3]Cl4 , 
between 9.70-8.00 ppm, which are identified as the three imine protons H1, three bpy 
protons H2 and three triazole protons H3. These assignments were confirmed by 
HSQC and HMBC NMR spectroscopy (Figure 5-6).  
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Figure 5-7 (a) High resolution mass spectrum for (Rc,ΔFe)-HHT-[Fe2L8a3]Cl4: top measured, below 
calculated; (b) CD spectra of HHT-[Fe2L8a3]Cl4 
The formation of (Rc,ΔFe)-HHT-[Fe2L8a3][Cl]4 was also confirmed by high 
resolution electrospray mass spectrometry, with the tetracationic molecular ion being 
observed at m/z 383.8799 Da (calculated 383.8803 Da) [Figure 5-7 (a)]. The CD 
spectra of the two enantiomers of [Fe2L8a3]Cl4 in methanol were equal and opposite 
[Figure 5-7 (b)].  
Other triazole triplex systems were synthesized using the same method. 
Microanalysis was also consistent with the proposed formulation. To our knowledge, 
this series of [M2L8a-d3]
4+ (M= Zn2+ and Fe2+) was the first example of optically pure 
and asymmetric metallohelices containing triazole chelate group. 
We have noted that the selectivity for HHT-isomers over HHH in our 
previously reported triplex systems is ca 99%, but peaks consistent with the presence 
of the HHH isomer can nevertheless be detected (see Chapter 2 section 2.3.2). It is 
striking that in the 1H NMR spectra of the new triazole triplex systems in this chapter, 
no such HHH isomer was detected. In other words, there seems to be a still stronger 
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preference for a mixed ligand bpy/triazole-imine metal centres over the homoleptic 
tris(bpy) or tris(triazole-imine).  
5.6 Synthesis and self-assembly reactions of glyco-triazole 
aldehydes  
Based on the synthetic success of benzyl triazole triplex system, we attempted to 
synthesize a small series of glyco-triazole aldehydes 34-39 (Scheme 5-4) and 
investigate their subsequent self-assembly reactions with bpy-phenylamine 14. 
 
Scheme 5-4 Synthesis glyco-triazole aldehyde 
Following some literature precedent on glyco-triazole derivatives,76,77 the 
CuAAC reaction of β-D-pentaacetato sugar azides 19/22/30 (see Section 4.2.2) with 
propargyl alcohol using CuSO4·5H2O as a catalyst at 70 ºC was investigated. 
Overnight reactions successfully led to the formation of alcohols 31-33 in ca 80% 
yield. While to our knowledge the oxidation of such compounds has not previously 
been achieved, we found that the use of pyridinium chlorochromate at ambient 
temperature gave the corresponding acetyl-protected triazole aldehydes 34-36 very 
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smoothly, and these were subsequently deprotected using MeONa in methanol to give 
37-39 in excellent overall yield. 




Scheme 5-5 Synthesis of glyco-triazole derivate Zn (II) triplex metallohelice 
Treatment with bipyphenylamine 14 (3 eq.), glyco-triazole derivative 34-36 (3 eq.) 
and Zn(ClO4)2 (2 eq.) led to the rapid self-assembly of the triplex metallohelix in 
acetonitrile solution at ambient temperature (Scheme 5-5).  
The 1H NMR spectrum of the glyco-triazole zinc(II) metallohelix clearly 
shows three inequivalent ligand environments, indicating the formation of the 
asymmetric HHT configuration (Figure 5-8). For instance, the (Rc,ΔZn)-HHT-
[Zn2L9a3][ClO4]4 displayed three imine resonances Ha, two bpy Hb resonances and two 
triazole Hc resonances at 9.40-8.70 ppm. The phenyl ring protons Hd and He were 
found at 7.00–6.00 ppm. The two benzylic environments Hf were observed at 4.92 and 
4.80 ppm, while the third Hf overlapped with sugar protons. Three diasterotopic CH2 
protons Hg adjacent to benzylic centres were clustered at 3.75-3.45 ppm 
(approximately doublets of doublets). The twelve sugar acetyl CH3 singlets Hh overlap 
with one another at high field (2.50-1.50 ppm) and were also masked slightly by the 
solvent peak. In the 13C NMR spectrum, the acetyl C=O carbons Ci were detected 
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around 170.0 ppm, followed by the three imine carbon peaks Ca observed at 157.3-
156.0 ppm. Three bpy carbon peaks Cb were found at 150.5-149.9 ppm. The acetyl 
CH3 carbons Ch were assigned at 20.0 ppm. The 
1H and 13C NMR spectra of other 
glyco-trizole zinc(II) metallohelices i.e. (Rc,ΔZn)-HHT-[Zn2L9b3][ClO4]4 and (Rc,ΔZn)-
HHT-[Zn2L9c3][ClO4]4 were similar with [Zn2L9a3][ClO4]4 (See Figure 5-9; Figure 
5-10). 
 
Figure 5-8 1H (500 MHz, CD3CN, 298K) and 13C (125 MHz, CD3CN, 298K) NMR spectra of 
(Rc,ΔZn)-HHT-[Zn2L9a3][ClO4]4 
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Figure 5-9 1H (500 MHz, CD3CN, 298K) and 13C (125 MHz, CD3CN, 298K) NMR spectra of 
(Rc,ΔZn)-HHT-[Zn2L9b3][ClO4]4 
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Figure 5-10 1H (500 MHz, CD3CN, 298K) and 13C (125 MHz, CD3CN, 298K) NMR spectra of 
(Rc,ΔZn)-HHT-[Zn2L9c3] [ClO4]4 
Synthesis of water soluble triazole triplex metallohelix [Fe2L103]Cl4 
 
Scheme 5-6 Synthesis of no acetyl protect glucose-triazole triplex metallohelices (Rc,ΔFe)-
[Fe2L103]Cl4 
The use of three equivalents of (R)-2-([2,2'-bipyridin]-5-ylmethoxy)-1-
phenylethan-1-amine (14) in a one-pot synthesis with three equivalents of the 
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deprotected glucose-triazole aldehyde derivative 37 and two equivalents of FeCl2 led 
to the immediate formation of the intense orange solution (Scheme 5-6). After heating 
for 48 h, the pure bright orange product was isolated via the addition of ethyl acetate 
to the methanol solution.  
The 1H NMR spectrum of this product was consistent with the target triplex 
structure but contained relatively broad signals. The 13C NMR spectrum was well-
resolved and confirmed the presence of three inequivalent ligand environments 
(Figure 5-11). In the 1H spectrum, three imine singlets Ha were observed at 9.75, 9.54 
and 9.18 ppm, followed by two bpy Hb signals at 9.48 and 9.40 ppm. Two triazole 
singlets Hc were found at 9.54 and 9.26 ppm and two sets of the phenyl protons Hd 
were detected at 6.79 and 6.62 ppm. In the 13C spectrum, three imine carbon peaks Ca 
were detected at 164.9, 164.8 and 164.0 ppm with three bpy carbon signals Cb at 159.3, 
158.7 and 157.0 ppm. The triazole quaternary carbon peaks Ce were seen at 151.2, 
151.1 and 150.7 ppm. Unlike the glyco-pyridine complex [Fe2L53]Cl4 and [Fe2L63]Cl4 
(Chapter 4, section 4.2.1), no tricationic ion [Fe2L103Cl]
3+or similar were observed 
here, presumably because the geometry of the triazole unit is less well-disposed the 
Cl- coordination. A dicationic molecular ion peak at m/z 910.2362 Da was observed in 
the high resolution electrospray mass spectrum of (Rc,ΔFe)-HHT-[Fe2L103]Cl4, within 
0.001 Da of the calculated value (m/z 910.2376).  
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Figure 5-11 1H (500 MHz, MeOD, 298K) and 13C (125 MHz, MeOD, 298K) NMR spectra of 
(Rc,ΔFe)-HHT-[Fe2L103]Cl4 
5.7 Stability study in aqueous solution 
In advance of evaluation of the compounds in biological applications, the stability of 
(Rc,ΔFe)-HHT-[Fe2L8a3]Cl4 in aqueous solution was assessed using UV-vis 
spectroscopy.  
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Figure 5-12 Monitoring MLCT absorption of (Rc,ΔFe)-HHT-[Fe2L8a3]Cl4 in HCl/KCl buffer at pH 1.5 
(green line), phosphate buffered saline (pH 7.0, black line) and DMSO λmax= 485 nm (red line), 
concentration 0.02 mg/mL 
Time-dependent photoabsorbance measurements of (Rc,ΔFe)-HHT-
[Fe2L8a3]Cl4 solutions were observed at 485 nm (within the MLCT band of the 
complex) in HCl/KCl buffer (pH 1.5), phosphate buffer saline (pH 7.0) and in DMSO. 
At pH 7.0, a gradual decrease in the absorbance was observed indicating (Rc,ΔFe)-
HHT-[Fe2L8a3]Cl4 is decomposing in neutral solution; the corresponding t½ was 
calculated to be 21 h. As expected, under acidic conditions (pH 1.5) the complex 
decomposed more quickly (t½ 4 h) and is rather unstable in DMSO (t½ 36 min). It thus 
appears that the triaozle-imine/bpy triplex system (Rc,ΔFe)-HHT-[Fe2L8a3]Cl4 is far 
less stable than the otherwise identical pyridine system; the compound (Sc,ΛFe)-HHT-
[Fe2L33]Cl4 for example has t½ of over 16 d in PBS at pH 7. 
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5.8 Biological activity of triazole iron (II) triplex 
metallohelices 
5.8.1 In vitro cytotoxicity assay 
 
Figure 5-13 IC50 values of triazole derived iron (II) triplex [Fe2L8a-e3]Cl4 against: (a) HCT116 p53++ 
cancer cell line; (b) ARPE19 (noncancerous cell line) 
The potencies of all triazole derived iron(II) triplexes [Fe2L8a-e3]Cl4 were evaluated 
against the HCT116 p53++ colon cancer cell line. As can be seen in Figure 5-13(a), 
with the exception of the tricarboxylic acid [Fe2L8e3]Cl4 (vide infra), this triplex series 
demonstrated excellent activity with IC50 values all lower than 500 nM with little 
effect of the para substituent. The Ʌ enantiomers were marginally more potent than 
the Δ enantiomers; the most potent compound was Ʌ-[Fe2L8a3]Cl4 with IC50 191 ± 10 
nM. 
Notably, the para substitution with a carboxylate group reduces the overall 
charge and solubility of the [Fe2L8a3]Cl4 in aqueous solution, but no stability decrease 
was observed. The Δ-[Fe2L8e3]Cl4 appears to reduce the potency to HCT116 p53
++ by 
a factor of ca 5 with respect to the parent R = H compound Δ-[Fe2L8a3]Cl4, while the 
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same effect is not found in the Ʌ compound which has a similar IC50 (300 ± 100 nM) 
to the other compounds.  
The compounds were also tested against the non-cancerous retinal pigment 
epithelial cell line ARPE19. Significant enantiomeric differences in toxicity were 
observed in the ARPE19 cells; the Ʌ enantiomers (average IC50 value at 1.5 µM) were 
more cytotoxic than the Δ enantiomers (average IC50 value 6.8 µM) [Figure 5-13(b)].  
Table 5-1 Cytotoxicity and selectivity index of triazole triplex [Fe2L8a-e3]Cl4 against HCT116 p53++ 
and ARPE-19 cell line 
 mean IC50 (µM) Selectivity 
Index HCT116 p53++ ARPE-19 
[Fe2L8a3]Cl4 Λ 0.19 ± 0.01 0.97 ± 0.25 5 
Δ 0.32 ± 0.14 6.31 ± 0.78 20 
[Fe2L8b3]Cl4 Λ 0.20 ± 0.02 1.83 ± 0.80 9 
Δ 0.35 ± 0.20 9.88 ± 3.82 28 
[Fe2L8c3]Cl4 Λ 0.20 ± 0.01 2.22 ± 0.58 11 
Δ 0.23 ± 0.02 7.97 ± 1.18 34 
[Fe2L8d3]Cl4 Λ 0.20 ± 0.01 1.92 ± 0.43 10 
Δ 0.40 ± 0.30 6.89 ± 1.94 17 
[Fe2L8e3]Cl4 Λ 0.30 ± 0.10 0.72 ± 0.11 2 
Δ 1.72 ± 0.07 3.05 ± 1.29 2 
A selectivity index (SI) is defined as the mean IC50 of ARPE19 divided by IC50 
of HCT116 p53++. Except for [Fe2L8e3]Cl4, significant enantiomeric selectivity was 
observed, with the Δ enantiomers exhibiting substantially better selectivity (SI 17-34) 
than Λ enantiomers (5-10). 
5.8.2 Cytotoxicity of the precursor compounds 
As described above, the aqueous stability of this metallohelix series is lower than that 
of other compounds described in this thesis, with t½ for 21 h at pH 7 being rather 
shorter than the 96 h dosing time period of the MTT assay used in the IC50 values 
(Table 5-1). We thus investigated the cytotoxicity of the ligand sub-components of 
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[Fe2L8a3]Cl4 under similar conditions; low solubility necessitated dissolution in 
DMSO prior to dilution. 
Table 5-2 Cytotoxicity of precursor compounds vs triazole triplex [Fe2L8a3]Cl4 (given per mole of 
ligand) against HCT116 p53++ and ARPE-19 cell line. a These figures are derived from those of Table 
5-1 by multiplying by 3 in order to allow direct comparison with ligand sub-components. 
 mean IC50 (µM) Selectivity 
Index HCT116 p53++ ARPE-19 
14 S 1.13 + 0.37 2.34 + 0.33 2 
14 R 2.29 + 0.57 9.66 + 3.61 4 
29a  > 73.2 > 89.1 - 
[Fe2L8a3]Cl4 Λ (S) 0.57a 2.91a  5 
Δ (R) 0.96a  18.93a  20 
As seen in Table 5-2, the triazole aldehyde precursor 29a has minimal 
cytotoxicity (IC50 > 70 μM) towards both HCT116 p53
++ and ARPE19 cells. Although 
the two amine enantiomers 14 (R/S) are both less toxic than their respective helical 
triplex metallohelix (by a factor of ca 2 per mole of ligand), they are both potent 
compounds against HCT116 p53++cells. However, they are both more toxic towards 
ARPE-19 noncancerous cells than the metallohelix per mole of ligand. The Δ-
[Fe2L8a3]Cl4 architecture has 5 times the selectivity than its amine precursor, over a 
96 h dosing period, with the added advantage of being water-soluble. Further time-
dependent cytotoxicity studies are on-going to see whether the selectivity and potency 
of the drug changes over time as it decomposes.  
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5.8 Conclusion 
We initially synthesized a series of benzyl triazole aldehydes 29a-e and 
investigated the self-assembly reaction with the aminobipyridine 14. A new 
asymmetric HHT triazole bimetallic system was isolated and characterised. The highly 
stereoselective configuration is ascribed to the maximal presentation of π-stacking 
between the phenyl rings and triazole-imine/bpy. In vitro MTT assays revealed that 
these triazole containing iron(II) triplexes [Fe2L8a-e3]Cl4 possess excellent anticancer 
activity against the HCT116 p53++ cell line with IC50 values under 2 μM and high 
selectivity towards ARPE19 cell line, whereas the precursors have moderate 
anticancer activity and lower selectivity.  
Since the 1,2,3-triazole moiety is relatively easy to functionalise, we have 
synthesized glycolconjugated metallohelices from a new sugar triazole aldehyde. We 
developed a synthetic protocol to form a small series of sugar triazole aldehydes 34-
39 and validated the assembly reaction with aminobipyridine 14. The 1H and 13C NMR 
spectra confirmed the asymmetric arrangement of glyco-triazole triplex, and no 
intramolecular Cl- coordination was observed.  
Despite this class of triazole-imine chelated triplex architectures being less 
stable than previously designed pyridine-imine analogues, we demonstrate greater 
stability than other reported triazole metallohelice such as Crowley’s pyridine-triazole 
systems which are racemic, decomposed instantaneously in DMSO and reported no 
biological activity.36 This new class of structures have intermediate stability (t½ 21 h), 
and it is therefore possible that the intact metallohelix can be uptaken by cells, but are 
expected to decompose over 24 h. We envisage that these ‘metastable’ triplex systems 
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have the potential to help deliver active compounds to the cells, and can even be used 
to ‘mask’ aldehydes as imines, for release within a cell. 
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6.1 Chemicals and solvents 
All solvents and chemicals purchased from commercial sources (Sigma-Aldrich, 
Acros, Fisher Scientific or Alfa Aesar) were used without further purification unless 
otherwise stated. Sodium hydride dispersions in mineral oil were placed in a Schlenk 
vessel under an inert atmosphere and washed three times with diethyl ether to remove 
the oil. The sodium hydride powder was then dried and stored in an MBraun glove 
box at <5 ppm O2. Necessary solvents were dried by heating to reflux for 3 d under 
dinitrogen over the appropriate drying agents (potassium for tetrahydrofuran, and 
calcium hydride for acetonitrile, pyridine, diisopropyl amine and triethylamine) and 
degassed before use. Tetrahydrofuran and diethyl ether were additionally pre-dried 
over sodium wire. All dried and degassed solvents were stored in glass ampoules under 
argon. Deuterated solvents were purchased from Sigma-Aldrich or Cambridge Isotope 
Laboratories Inc and pre-dried over molecular sieves (3A for methanol, dimethyl 
sulfoxide and acetonitrile; 4A for chloroform), for 24 h prior to use. 
6.2 Equipment and instrumentation 
All glassware and cannulae were stored in an oven at > 375 K. Where appropriate, 
reactions were carried out under argon using a dual manifold argon/vacuum line and 
standard Schlenk techniques or using an MBraun  glove box at <5 ppm O2.  
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NMR spectra were recorded on Bruker Spectrospin 300/400/500/600 
spectrometers and Bruker AV II DRX-300/500 spectrometers. Routine NMR 
assignments were confirmed by 1H-1H (COSY) and 13C-1H (HMQC) correlation 
experiments where necessary. The spectra were internally referenced using the 
residual protio solvent (CDCl3, CD3CN etc.) resonance relative to tetramethylsilane (δ 
= 0 ppm). ESI mass spectra were recorded on Bruker Esquire 2000 or Bruker 
MicroTOF spectrometers. Infra-Red spectra were measured using a Bruker Alpha-P 
FTIR spectrometer. Elemental analyses were performed by MEDAC Ltd. Chobham, 
Surrey GU24, 8JB, UK. 
UV-Visible absorbance spectra were recorded using a Jasco V-660 
spectrometer. Measurements were collected in a 1 cm path-length quartz cuvette using 
the following standard parameters: bandwidth 1 nm, response time 1 sec, wavelength 
scan range 200 – 800 nm, data pitch 0.2 nm, scanning speed 200 nm/min and 
accumulation 1. CD spectra were measured on a Jasco J-815 spectrometer. 
Measurements were collected in a 1 cm path-length quartz cuvette using the following 
standard parameters: bandwidth 1 nm, response time 1 sec, wavelength scan range 200 
– 800 nm, data pitch 0.2 nm, scanning speed 100 nm/min and accumulation 10. 
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6.3 Ligand components 
(S)-2-(prop-2-ynyloxy)-1-phenylethanamine1 (1) 
 
(S)-2-Phenylglycinol (0.50 g, 3.6 mmol) was dissolved in dry THF (15 ml) and added 
to a stirred suspension of sodium hydride (0.17 g, 7.3 mmol, 2.0 eq.) in dry THF (10 
ml). The solution was stirred for 1 h at ambient temperature, followed by addition of 
propargyl bromide (0.43 ml, 3.8 mmol, 1.05 eq.). The solution was stirred for 1 h at 
ambient temperature then heated to reflux (65°C) under partial vacuum overnight. 
After cooling to ambient temperature, the solution was poured into brine (30 ml). The 
crude product was extracted with diethyl ether (4 × 50 ml), dried over sodium sulfate 
and isolated under reduced pressure. This crude product was purified by flash 
chromatography (DCM/MeOH/Triethylamine, 500:5:2; Rf = 0.50) to furnish (S)-2-
(prop-2-ynyloxy)-1-phenylethanamine as a yellow oil. 
Yield 0.70 g, 55%. 
1H NMR (400 MHz, 298 K, CDCl3) δH ppm 7.52-7.19 (5H, m, Ph), 4.30-4.19 (3H, m, 
CH, CH2), 3.72 (1H, dd, 
3JHH = 9.0 Hz, 
4JHH = 3.7 Hz), 3.50 (1H, t, 
3JHH = 9.0 Hz, 
CH2), 2.46 (1H, t, 
4JHH = 2.4 Hz, C≡H), 1.76 (2H, s, NH2). 
13C {1H} NMR (100 MHz, 298 K, CDCl3) δC ppm 142.26, 128.48, 127.50, 126.84 
(Ph), 74.58 (CH), 58.45 (CH2), 55.39 (CH). 
MS (ESI) m/z 176 [M+H]+ 
 




5-(Hydroxy)picolinaldehyde (1.23 g, 10.0 mmol) was dissolved in acetonitrile (40 ml), 
followed by the addition of potassium carbonate (1.45 g, 10.5 mmol) and propargyl 
bromide (80 wt% in toluene, 1.17 ml). The solution was stirred at reflux (ca. 85°C) 
overnight, cooled to ambient temperature and filtered through a short column of silica. 
The solvent was removed under reduced pressure to leave the crude product as a dark 
orange solid. The pure product was recrystalised from n-hexane/dichloromethane 
(80:20 v/v).  
Yield = 0.45 g, 80%. 
1H NMR (400 MHz, 298 K, DMSO) δH ppm 9.90 (1H, s, HC O), 8.54 (1H, d, 
4JHH = 
2.8 Hz), 7.98 (1H, d, 3JHH = 8.7 Hz), 7.64 (1H, dd, 
3JHH = 8.7 Hz, 
4JHH = 2.8 Hz, Py), 
5.05 (2H, d, 4JHH = 2.3 Hz, CH2–C≡C), 3.71 (1H, t, 
4JHH = 2.3 Hz, C≡CH).  
13C {1H} NMR (100 MHz, 298 K, DMSO) δC ppm 192.50 (CO), 157.22, 146.69, 
139.40, 123.85, 122.27 (Py), 79.96 (C≡CH), 78.45 (C≡CH), 56.80 (CH2). 
MS (ESI) m/z 162 [M+H]+ 
IR ʋ cm−1 3210 w, 1690 s, 1570 s, 1485 w, 1380 w, 1305 m, 1276 w, 1260 s, 1200 s, 
1005 s, 970 m, 914 w, 830 s, 802 s, 730 m, 693 s, 661 s.  
Elemental Analysis found (Calculated for C9H7NO2) % C 66.75 (67.08), H 4.32 (4.38), 
N 8.61 (8.69). 
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(R,R)-4,4'-bis[(2-amino-2-phenylethoxy)methyl]-diphenyl ether3 (3) 
 
(R)-2-phenylglycinol (0.66 g, 4.8 mmol, 2.1 eq.) and 15-crown-5 (0.67 g, 3.0 mmol, 
1.3 eq.) were dissolved in dry THF (30 ml) under inter atmosphere and was added 
dropwise to a stirred suspension of sodium hydride (0.25 g, 10.4 mmol, 4.6 eq.). The 
reaction mixture was stirred under partial vacuum for 1 h at ambient temperature. This 
was followed by dropwise addition of the bis-4-(bromomethyl)phenyl ether (0.8 g, 2.3 
mmol, 1.0 eq.) in dry THF (30 ml). The solution was then heated to reflux (65˚C) for 
4h. After cooled to ambient temperature, the reaction was quenched with brine (20 
ml). The product was extracted into diethyl ether (3 × 100 ml), dried over sodium 
sulphate and the solvent was removed under reduced pressure to leave a yellow oil. 
The pure product was obtained by Kügelrohr distillation to remove unreacted excess 
(R)-2-phenylglycinol and 15-crown-5 at 155 ˚C under high vacuum, to give a yellow 
oil.  
Yield: 0.85 g, 78% 
1H NMR (300 MHz, 298 K, CDCl3) δH 7.42-7.29 (14H, m, Ph), 7.00 (4H, d, 
3JHH = 
8.5 Hz, Ph), 4.55 (4H, s, CH2Ph), 4.27 (2H, dd, 
2JHH = 9.0 Hz,
 3JHH = 4.0 Hz,CHPh), 
3.65 (2H, dd, 2JHH = 9.0 Hz,
 3JHH = 4.0 Hz, CH2CHPh), 3.49 (2H, t, 
2JHH/
 3JHH = 9.0 
Hz, CH2CHPh), 1.80 (4H, s, NH2) 
13C {1H} NMR (75 MHz, 298K, CDCl3) δC 156.3, 141.9, 132.5, 128.8, 127.8, 126.8, 
126.2, 118.1 (Ph), 76.0 (CH2CHPh), 72.3 (CH2Ph), 55.0 (CHPh) 
ESI-MS (+) m/z 469.2 [M+H]+ , 491.2 [M+Na]+ 
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IR ʋ (cm−1): 3028 w, 2850 w, 1603 m, 1500 s, 1450 w, 1355 w, 1238 s, 1160 w, 1077 
s, 1015 w, 874 m, 760 s, 700 s.  
Elemental Analysis found (Calculated for C30H32N2O3) % C 76.47 (76.90), H 7.14 
(6.88), N 5.65 (5.98). 
5-hydroxy-2-methylpyridine-1-oxide4 (4). 
 
5-Hydroxy-2-mehylpyridine (25.0 g, 0.23 mol) was suspended in a solution of m-
chlorperbenzoic acid (43 g, 0.23 mol) in chloroform (250 ml) and heated to reflux for 
2 h. After cooling down to ambient temperature and stirred for a further 2 h, the 
solvents were removed under reduced pressure. The crude product was washed with 
ethyl acetate, isolated by filtration and dried to give the pure compound as a pale 
yellow solid.  
Yield 15.6 g, 54% 
1H NMR (400 MHz, 298 K, DMSO) δH ppm 10.22 (1H, s, OH), 7.81 (1H, d, 
4JHH = 
2.3 Hz, Py), 7.24 (1H, d, 3JHH = 8.5 Hz, Py), 6.77 (1H, dd, 
3JHH = 8.5 Hz, 
4JHH = 2.3 
Hz, Py), 2.23 (3H, s, Me).  
13C {1H} NMR (75 MHz, 298 K, DMSO) δC ppm 153.97, 138.96, 127.33, 126.07, 
113.64 (Py), 16.26 (CH3).  
MS (ESI) m/z 126 [M+H]+ 148 [M+Na]+.  
IR ʋ cm-1 2360 m, 1623 w, 1571 m, 1526 m, 1456 m, 1385 m, 1308 m, 1273 w, 1227 
m, 1163 m, 1114 s, 963 w, 859 s, 822 s, 775 m, 741 w, 690 w. 
 
University of Warwick | Page 163 
 
6-(acetoxymethyl)pyridin-3-yl acetate4 (5). 
 
5-Hydroxy-2-methylpyridine-1-oxide (4) (15.60 g, 0.13 mol) was suspended in acetic 
anhydride (400 ml) and heated to reflux for 4 h. After cooling down to ambient 
temperature, the solvent was removed under reduced pressure to give the titular 
product as a black oil which was suitable for use without further purification.  
Yield 24.8, 95% 
1H NMR (400 MHz, 298 K, DMSO) δH ppm 8.39 (1H, d, 
4JHH = 2.5 Hz, Py), 7.66 (1H, 
dd, 3JHH = 8.5 Hz, 
4JHH = 2.5 Hz, Py), 7.50 (1H, d, 
3JHH = 8.5 Hz, Py), 5.14 (2H, s, 
CH2), 2.31 (3H, s, CH3) 2.12 (3H, s, CH3).  
13C {1H} NMR (75 MHz, 298 K, DMSO) δC ppm 170.0 (C=O), 169.1 (C=O) 152.9, 
146.4, 142.8, 130.2, 122.4 (Py), 65.6 (CH2), 20.7 (CH3), 20.6 (CH3).  
MS (ESI) m/z 232 [M+Na]+. 
6-(hydroxymethyl)pyridine-3-ol4 (6) 
 
6-[(Acetyloxy)methyl]pyridine-3-yl acetate (5) (26.40 g, 0.13 mol) was dissolved in 
concentrated hydrochloric acid (36%, 100 ml) and stirred at reflux (110 °C) for 24 h. 
The volatile was removed under reduced pressure to 20 ml and the solution was 
neutralised with sodium hydroxide solution (1 M, 50 ml) to pH7. The solvent was 
removed under reduced pressure to yield a brown solid which was dried in vacuo (50 
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oC). The crude compound was dissolved in acetonitrile (3 × 150 ml) and heated reflux 
for 1 h, filtered hot and the solvent was removed under reduced pressure to yield a 
brown/yellow solid.  
Yield: 9.26 g, 59%. 
1H NMR (400 MHz, 298 K, DMSO): δH ppm 10.15 (s, br, 1H, PyOH), 8.03 (d, 1H, 
4JHH = 2.7 Hz, Py), 7.26 (d, 1H, 
3JHH = 8.4 Hz, Py), 7.13 (dd, 1H, 
3JHH = 8.4 Hz, 
4JHH 
= 2.7 Hz, Py), 4.44 (s, 1H, CH2).  
13C {1H} NMR (100 MHz, 298K, DMSO): δC ppm 152.42, 151.87, 136.44, 122.54, 
120.97 (Py), 63.92 (CH2). 
MS (ESI) m/z 126 [M+H]+ 
IR ʋ cm-1 2845 w, 2366 br, 1760 w, 1570 m, 1491 m, 1455 m, 1336 w, 1269 m, 1208 
s, 1128 w, 1117 w, 1070 s, 1026 m, 893 w, 858 w, 829 s, 760 w, 715 w, 658 s.  
5-(hydroxyl)picolionaldehyde4 (7) 
 
6-(Hydroxymethyl)pyridine-3-ol (6) (9.26 g, 74 mmol) was dissolved in isopropanol 
(200 ml). Activated manganese dioxide (16.10 g, 185 mmol) was added and the 
solution was heated at reflux (100oC) for 4 h and stirred for a further 18 h at ambient 
temperature. The reaction mixture was filtered through celite and the solvent was 
removed under reduced pressure. The pure product was recrystalised from boiling 
water (50 ml).  
Yield: 1.82 g, 20%. 
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1H NMR (300 MHz, 298 K, DMSO): δH ppm 11.07 (s, br, 1H, OH), 9.83 (s, 1H, CHO), 
8.32 (d, 1H, 4JHH = 2.6 Hz, Py), 7.85 (d, 1H, 3JHH = 8.5 Hz, Py), 7.33 (dd, 1H, 
3JHH = 
8.5 Hz, 4JHH = 2.7 Hz), 3.38 (s, br, 1H, PyOH). 
13C {1H} NMR (100 MHz, 298 K, DMSO): δC ppm 192.34 (CHO), 158.41, 145.21, 
139.25, 124.22, 122.86 (Py). 
MS (ESI) m/z 124 [M+H]+ 
IR ʋ cm-1 2885 w, 2840 w, 1570 s, 1485 m, 1460 w, 1370 w, 1320 w, 1205 s, 1116 
m, 1071 s, 1026 m, 886 w, 850 w, 756 w. 
L-phenylglycinol5 (8) 
 
L-phenylglycine (20.0 g, 0.13 mol) was suspended in dry tetrahydrofuran (100 ml) 
under argon and was added drop-wise to a stirred solution of lithium aluminium 
hydride (10 g, 0.26 mol) in dry tetrahydrofuran (100 ml) at 0°C. The suspension was 
allowed to warm to ambient temperature and then heated at reflux (70°C) for 16 h. 
After cooling to 0°C, the reaction mixture was quenched by drop-wise addintion of 
saturated potassium carbonate solution (250 ml). The solid was filtered off to obtain a 
yellow solution. The solvent was removed under reduced pressure to give a yellow 
solid, which was recrystallized from hot toluene to give the pure product as a white 
crystalline solid.  
Yield: 15.6 g, 87%. 
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1H-NMR (400 MHz, 298 K, CDCl3): δH ppm 7.31 (m, 5H, Ph), 4.04 (dd, 1H, 
3JHH = 
8.3Hz, 4JHH = 4.4 Hz, CH), 3.74 (dd, 2H, 
3JHH = 10.8 Hz, 
4JHH = 4.4Hz, CH2), 3.55 (dd, 
2H, 3JHH = 10.7 Hz, 
4JHH = 8.3 Hz, CH2), 2.04 (s, 2H, NH2). 
13C {1H} NMR (101 MHz, 298 K, CDCl3): δC ppm 142.74, 128.65, 127.52, 126.47 
(Ph), 68.04 (CH2), 57.35 (CH). 
MS (ESI) m/z 138 [M+H]+ 
IR ʋ cm−1: 3325 w, 2833 s, 1600 m, 1495 m, 1450 m, 1195 w, 1071 m, 1043 m, 970 
m, 876 m, 750 s, 701 s. 
Elemental analysis found (Calculated for C8H11NO) % C 70.16 (70.04) H 8.12 (8.08) 
N 10.13 (10.21) 
(E)-5,5'-(but-2-ene-1,4-diylbis(oxy))dipicolinaldehyde (9) 
 
9 was synthesised using the procedure described for 2, substituting propargyl bromide 
for 1,4-trans-dibromobut-2-ene with 1 equivalent more 5-(hydroxy)picolinaldehyde 
added. The resulting beige solid was recrystalised from mixture solvent: methanol/ n-
hexane (10:90 v/v). 
Yield = 2.24 g, 75%. 
1H NMR (300 MHz, 298 K, CD3CN) δH ppm 9.93 (2H, s, CHO), 8.47 (2H, d, 
3JHH = 
2.5 Hz), 7.94 (2H, d, 3JHH = 10 Hz), 7.46 (2H, dd, 
3JHH = 8.7 Hz, 
4JHH = 2.3 Hz, Py), 
6.16 (2H, m CH), 4.80 (4H, m, CH2). 
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13C {1H} NMR (75 MHz, 298 K, CD3CN) δC ppm 192.61 (CHO), 139.64, 128.81, 
123.68, 121.71 (Py), 68.71 (CH2). 
MS (ESI) m/z 321 [M+Na]+ 
IR ʋ cm−1 2842 w, 1705 m, 1551 m, 1270 s, 1124 s, 801 m, 610 m. 
1-(2-pyridylacetyl)pyridinium iodide6 (10) 
 
2-Acetylpyridine (26.65 g, 25 ml, 220mmol) was added via syringe to a solution of 
iodine (56.50 g, 220 mmol) in dry pyridine (225 ml) in a 500 ml round bottomed 
Schlenk vessel. The round bottomed Schlenk was fitted with a condenser and a N2 
bubbler. The reaction mixture was stirred and heated at reflux (130oC) for 2 h and then 
cooled to to 0oC using an ice/water bath. A 9:1 mixture of diethyl ether/ethanol (20 
ml) was then added into the solution. The resulting black precipitate was filtered off, 
washed with a 9:1 mixture of diethyl ether/ethanol (20 ml), and dried in air. The 
precipitate was then dissolved in boiling methanol (250 ml) with activated charcoal 
(30 g) and stirred at reflux for 30 min. The solution was filtered through hot celite in 
a fritted funnel and the solvent was removed under reduced pressure to leave the crude 
product. Recrystallisation from hot methanol (100 ml) resulted the final product in 
light brown crystal which was filtered, washed with cold methanol (25 ml), and dried 
in vacuo.  
Yield = 36.25 g, 50%. 
1H NMR (400 MHz, 298 K, DMSO) δH ppm 9.02 (2H, d, 
3JHH = 5.7 Hz, Py), 8.88 (1H, 
d, 3JHH = 4.7 Hz, Py), 8.74 (1H, t, 
3JHH = 7.8 Hz, Py), 8.29 (2H, m, Py), 8.15 (1H, td, 
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3JHH = 7.7 Hz, 
4JHH = 1.4 Hz, Py), 8.08 (1H, d, 
3JHH = 7.7 Hz, Py), 7.85 (1H, m, Py), 
6.52 (2H, s, CH2).  
13C {1H} NMR (100 MHz, 298 K, DMSO) δC ppm 191.46 (C=O), 150.42, 149.54, 
146.32, 146.28, 138.13, 129.12, 127.69, 122.01 (Py), 66.63 (CH2).  
MS (ESI) m/z 199 [M]+ 
IR ʋ cm−1 3040 w, 1703 m, 1475 m, 990 m, 785 m, 760 m, 695 m, 670 m, 565m. 
5-methyl-2,2'-bipyridine7 (11) 
 
1-(2-Pyridylacetyl)pyridinium iodide (36.25 g, 110 mmol) and ammonium acetate 
(21.43g, 280 mmol) were dissolved in formamide (250 ml) in argon condition. Freshly 
distilled methacrolein (7.79 g, 9.17 ml, 110 mmol) was then added via syringe and the 
solution was heated at 80°C for 6 h. After cooled to ambient temperature, water (150 
ml) and DCM (3 × 250 ml) were added into the reaction mixture. The organic layer 
was collected, dried over sodium sulphate and the solvent was removed under reduced 
pressure to leave a yellow liquid. Distillation under vacuum at 110˚C gave the pure 
product as a pale yellow oil.  
Yield = 11.4 g, 61%. 
1H NMR (400 MHz, 298 K, CDCl3) δH ppm 8.67 (1H, d, 
3JHH = 4.6 Hz, Py), 8.52 (1H, 
s,  Py), 8.36 (1H, d, 3JHH = 8.0 Hz, Py), 8.29 (1H, d, 
3JHH = 8.1 Hz, Py), 7.80 (1H, t, 
3JHH = 7.7 Hz, Py), 7.63 (1H, d, 
3JHH = 8.1 Hz, Py), 7.29 (1H, t, 
3JHH = 6.1 Hz, Py), 
2.40 (3H, s, CH3).  
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13C {1H} NMR (100 MHz, 298K, CDCl3) δC ppm 155.67, 153.00, 149.02, 148.50, 
136.84, 136.25, 132.80, 122.76, 120.16, 119.97 (Py), 17.74 (CH3).  
MS (ESI) m/z 171 [M+H]+, 193 [M+Na]+, 
IR ʋ cm−1 3000 w, 1455 s, 1430 s, 1375 m, 788 s, 741s. 
5-((trimethylsilyl)methyl)-2,2'-bipyridine8 (12) 
 
A Schelnk vessel was charged with dry THF (30 ml), diisopropylamine (14.13 ml, 
100.8 mmol) and the solution was cooled to -78˚C, at which point n-butyllithium 
(31.20 ml, 80.7 mmol) was added and the resulting solution was stirred for 10 min 
before being warmed to 0˚C for a further 10 min. The reaction mixture was then cooled 
again to -78˚C and a solution of 5-methyl-2,2'-bipyridine(11.44 g, 67.21 mmol) in dry 
THF was added dropwise. The resulting maroon solution was stirred for 1 h at -78˚C. 
Chlorotrimethylsilane (10.22 ml, 80.63 mmol) was then added rapidly to the solution 
and after 1 min the reaction was quenched by the rapid addition of absolute ethanol. 
The resulting pale yellow/green solution was allowed to warm up to room temperature 
before a saturated solution of NaHCO3 (150 ml) was added and the reaction mixture 
was extracted into DCM (3 x 75 ml). The organic fractions were combined, washed 
with brine, dried over sodium sulphate, filtered and solvents removed under reduced 
pressure to yield the titular product as a white solid that was used without purification.  
Yeild = 13.0 g 80% 
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1H NMR (400 MHz, 298 K, CDCl3) δH ppm 8.69 (1H, dq, 
3JHH = 4.7 Hz, 
4JHH = 0.9 
Py), 8.41 (2H, m, Py), 8.33 (1H, d, 3JHH = 8.3 Hz, Py), 7.78 (1H, td, 
3JHH = 7.8 Hz, 
4JHH = 2.0 Hz, Py), 7.46 (1H, dd, 
3JHH = 8.0 Hz 
4JHH= 2.5, Hz Py), 7.25 (1H, ddd, 
3JHH 
= 7.5 Hz 3JHH = 4.7 Hz 
4JHH = 1.2, Py), 2.14 (2H, s, CH2), 0.05 (9H, s, SiMe3). 
13C {1H} NMR (100 MHz, 298K, CDCl3) δC ppm 155.74, 151.54, 148.44, 147.86, 
136.93, 136.29, 135.52, 122.58, 120.24, 120.03 (py), 23.39 (CH2), 2.65 (SiCH3). 
MS (ESI) m/z 243 [M+H]+ 
IR ʋ cm−1 3051 w, 1590 m, 1256 s, 1430 s, 1270 w, 1150 w, 870m. 
5-(chloromethyl)-2,2'-bipyridine8 (13) 
 
5-((Trimethylsilyl)methyl)-2,2'-bipyridine (22.53 g, 93 mmol), hexachloroethane 
(44.08 g, 186.18 mmol) and caesium fluoride (28.28 g, 186.12 mmol) were suspended 
in dry acetonitrile (75 ml) and heated at 60˚C for 4 h. The reaction mixture was cooled 
to ambient temperature, followed by addition of water (100 ml) and ethyl acetate (3x 
150 ml). The organic fractions were combined, washed with brine, dried over sodium 
sulphate, filtered and solvents were removed under reduced pressure. The product was 
purified by flash chromatography (petroleum ether/EtOAc/triethylamine, 20:5:1 v/v/v; 
Rf = 0.50) to furnish the pure product as a white crystal (1.77 g, 4.76 mmol, 98%).  
Yield = 16.0 g, 84 %. 
1H NMR (300 MHz, 298 K, CDCl3) δH ppm 8.69 (2H, d,
 3JHH = 4.3 Hz Py), 8.43 (2H, 
t, 3JHH = 7.7 Hz Py), 7.92-7.77 (2H, m, Py), 7.38-7.29 (1H, m, Py), 4.66 (2H, s, CH2).  
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13C {1H} NMR (75 MHz, 298K, CDCl3) δC ppm 156.22, 155.58, 149.26, 149.02, 
137.19, 137.00, 133.18, 123.96, 121.24, 121.01 (py), 43.11 (CH2). 
MS (ESI) m/z 205 [M+H]+ 
IR ʋ cm−1 3000 w, 2696 w,1600 m, 1493 w, 1458 m, 1430 m, 1391 m, 1262 m, 1091 
w, 990 w, 855 w, 675s. 
(S)-2-(2,2'-bipyridin-5-ylmethoxy)-1-phenylethanamine9 (14) 
 
(S)-Phenylglycinol (1.00 g, 7.3 mmol) was dissolved in dry THF (20 ml) and added 
dropwise to a stirred suspension of sodium hydride (0.36 g, 15.0 mmol) in dry THF 
(10 ml). The solution was stirred for 1 h at room temperature. A solution of 5-
(bromomethyl)-2,2'-bipyridine (1.82 g, 7.3 mmol) in dry THF (20 ml) was added 
dropwise and stirred for 1 h at room temperature before heated to reflux (65˚C) for a 
further 2 h. The reaction mixture was cooled to ambient temperature followed by 
addition of brine (40 ml). The product was extracted with diethyl ether (4 × 60 ml), 
dried over sodium sulphate and the solvent was removed to leave a dark yellow oil. 
The crude product was purified by flash chromatography (petroleum 
ether/EtOAc/triethylamine, 8:8:1 v/v/v) to furnish the (S)-2-(2,2'-bipyridin-5-
ylmethoxy)-1-phenylethanamine as a white solid. Rf = 0.45, (petroleum 
ether/EtOAc/triethylamine 8:4:1 v/v/v).  
Yield 1.8 g, 98%. 
1H NMR (300 MHz, CDCl3) δH ppm 8.72-8.65 (m, 1H, Ar-H), 8.63 (d, 
4JHH = 1.3 Hz, 
1H, Ar-H), 8.38 (dd, 2H, 3JHH = 8.0 Hz, 
4JHH = 3.9 Hz, Ar-H), 7.86-7.74 (m, 2H, Ar-
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H), 7.43-7.23 (m, 6H, Ar-H), 4.62 (s, 2H, OCH2), 4.26 (dd, 1H, 
3JHH = 8.6 Hz, 
4JHH = 
3.8 Hz, CH), 3.65 (dd, 1H, 3JHH = 9.1 Hz, 
4JHH = 3.9 Hz, CH2), 3.52 (t, 1H, 
3JHH = 8.8 
Hz, CH2). 
13C {1H} NMR (75 MHz, 298 K, CDCl3) δC ppm 155.97, 155.72, 149.22, 148.57, 
142.32, 136.95, 136.40, 133.65, 128.49, 127.52, 126.82, 123.73, 121.10, 120.83 (Ar), 
77.35 (CH2), 70.67 (CH2), 55.60 (CH). 
MS (ESI) m/z 306 [M+H]+ 
IR ʋ cm−1: 3295 w, 3050 w, 3023 w, 2900 w, 2845 w, 1568 w, 1570 w, 1563 w, 1495 
w, 1445 m, 1430 w, 1412 w, 1385 w, 1253 m, 1096 m, 1035 w, 1018 m, 988 w, 933 
w. 
Elemental Analysis found (Calculated for C19H19N3O) % C 74.53 (74.73), H 6.24 
(6.27), N 13.57 (13.75). 
(azidomethyl)benzene10 (15a) 
 
Sodium azide (1.64 g, 25.2 mmol, 1.5 eq.) was added to a solution of benzyl bromide 
(2.0 ml, 16.8 mmol, 1.0 eq.) in DMSO (25 mL). The reaction mixture was stirred at 
80˚C overnight, followed by addition of water (75 mL) and diethyl ether (3 × 150 ml). 
The combined diethyl ether layers were washed with brine (2 × 150 ml) and water (2 
× 200 ml), dried over sodium sulphate and the solvent removed under reduced pressure. 
The pure product was obtained as a clear colourless oil. 
Yield 1.7g, 74%. 
1H NMR (400 MHz, 298 K, CDCl3): δH ppm 7.36 (m, 5H, Ph), 4.34 (s, 2 H, CH2).  
 
University of Warwick | Page 173 
 
13C {1H} NMR (100 MHz, 298 K, CDCl3) δC ppm 135.38, 128.86, 128.33, 128.24 
(Ph), 54.83 (CH2). 
MS (ESI) m/z 289.2 [2M+Na]+ 
1-(azidomethyl)-4-fluorobenzene (15b) 
 
15b was synthesised using the procedure described for 15a, substituting benzyl 
bromide for 1-(bromomethyl)-4-fluorobenzene. 
Yield = 1.6 g, 73% 
1H NMR (300 MHz, 298 K, CDCl3): δH ppm 7.32 (t, 2H, 
3JHH = 6.2 Hz, Ph), 7.10(t, 
2H, 3JHH = 8.0 Hz, Ph), 4.34 (s, 2 H, CH2).  
13C {1H} NMR (75 MHz, 298 K, CDCl3) δC ppm 164.30, 161.03, 130.08, 129.97, 
115.94, 115.66 (Ph), 54.07 (CH2). 
MS (+) m/z 303.2 [2M+H]+. 
4-(azidomethyl)benzonitrile11 (15c) 
 
15c was synthesised using the procedure described for 15a, substituting benzyl 
bromide for 4-(bromomethy)benzonitrile. 
Yield 0.7 g, 88%. 
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1H NMR (400 MHz, 298 K, CDCl3): δH ppm 7.68 (d, 2H, 
3JHH = 7.5 Hz, Ph), 7.44(d, 
2H, 3JHH = 7.6 Hz, Ph), 4.45 (s, 2 H, CH2). 
13C {1H} NMR (100 MHz, 298 K, CDCl3) δC ppm 140.77, 132.65, 128.50 (Ph), 118.43 
(CN), 112.21 (Ph), 54.05 (CH2). 
MS (ESI) m/z 181.2 [M+Na]+ 
1-(azidomethyl)-4-methoxybenzene12 (15d) 
 
15d was synthesised using the procedure described for 15a, substituting benzyl 
bromide for 1-(bromomethy)-4-methoxybenzene. 
Yield 1.1g 93%. 
1H NMR (300 MHz, 298 K, CDCl3): δH ppm 7.27 (d, 2H, 
3JHH = 7.4 Hz, Ph), 6.94 (d, 
2H, 3JHH = 7.4 Hz, Ph), 4.30 (s, 2H, CH2), 3.84 (s, 3H, CH3). 
13C {1H} NMR (75 MHz, 298 K, CDCl3) δC ppm 159.65, 129.77, 127.41, 114.22 (Ph), 
55.31 (CH3), 54.41(CH2). 
MS (ESI) m/z 365.4 [2M+K]+ 
4-azidomethyl Benzoic acid13 (15e) 
 
15e was synthesised using the procedure described for 15a, substituting benzyl 
bromide for 4-chloromethyl benzoic acid. 
Yield 0.9 g, 84%.  
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1H NMR (300 MHz, 298 K, CDCl3): δH ppm 8.16 (d, 2H, 
3JHH = 7.6 Hz, Ph), 7.47 (d, 
2H, 3JHH = 7.5 Hz, Ph), 4.48 (s, 2H, CH2). 
13C {1H} NMR (75 MHz, 298 K, CDCl3) δC ppm 171.10 (CO), 141.45, 130.79, 129.11, 
128.03 (Ph), 54.29 (CH2). 
ESI-MS(+) m/z 176.1 [M-H]-. 
2,3,4,6-tetra-O-acetyl-α-D-glucopyranosyl bromide14 (16) 
 
D-glucopyranosylpentaacetate (2.5 g, 6.4 mmol) was dissolved in 33% HBr/AcOH (20 
mL) solution and stirred for 3 h. The reaction mixture was then diluted with ethyl 
acetate (25 mL), cooled to 0 °C, and the solution was neutralized carefully with 10% 
aqueous NaOH (50 mL) and saturated NaHCO3 solution (5 mL). The solution was 
extracted with ethyl acetate (3 × 25 mL) after which the organic layer was dried over 
anhydrous magnesium sulfate, filtered, and evaporated under reduced pressure to a 
clear syrup that was essentially pure glycosyl bromide.  
Yield 2.6 g, 99%. 
(2R,3R,4S,5R,6S)-2-(acetoxymethyl)-6-((6-formylpyridin-3-yl)oxy)tetrahydro-2H-
pyran-3,4,5-triyl triacetate (17) 
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Potassium carbonate (0.59 g, 4.26 mmol) was added to a solution of 5-
(hydroxy)picolinaldehyde (0.50 g, 4.06 mmol) in acetonitrile (40 ml), followed by the 
addition of acetyl protected α-D-glucosyl bromide (1.67g, 4.06mmol). The solution 
was stirred at reflux (ca. 85 °C) overnight, cooled to ambient temperature and passed 
a short column of silica. The solvent was removed under reduced pressure to leave the 
product as a white solid.  
Yield = 1.5 g, 84%. 
1H NMR (500 MHz, 298 K, DMSO) δH 9.92 (1H, s, CHO), 8.53 (1H, d, 
4JHH =2.6 Hz), 
7.99 (1H, d, 3JHH =8.7 Hz), 7.66 (1H, dd, 
3JHH = 8.5 Hz, 
4JHH =2.6 Hz), 5.86 (1H, d, 
3JHH =7.9Hz, H1Glu), 5.41 (1H, t, 
3JHH =9.6 Hz, H5Glu), 5.16 (1H, dd, 
3JHH = 9.7 Hz, 8.0 
Hz, H2Glu), 5.06 (1H, t, 
3JHH =9.8 Hz, H4Glu), 4.35-4.32 (1H, m, H3Glu), 4.21 (1H, dd, 
3JHH =12.4 Hz, 5.5 Hz, H6Glu), 4.11 (1H, dd, 
3JHH =12.3 Hz, 2.2 Hz, H6Glu), 2.04 (3H, 
s, COCH3), 2.03 (3H, s, COCH3), 2.01 (3H, s, COCH3), 1.99 (3H, s, COCH3).
 
13C {1H} NMR (125 MHz, 298 K, DMSO) δC 192.54 (CHO), 170.43, 170.08, 169.77, 
169.59 (OCOCH3), 156.02, 147.91, 139.82, 124.09, 123.87 (Py), 96.90 (C1Glu), 
72.26(C5Glu), 71.65 (C3Glu), 70.86 (C2Glu), 68.22 (C4Glu), 61.93 (C6Glu), 20.92, 20.85, 
20.79, 20.74 (COCH3). 
MS (ESI) m/z 476.2 [M+Na]+ 
Elemental Analysis found (Calculated for C20H23NO11) % C 52.70 (52.98), H 5.01 
(5.11), N 2.94 (3.09). 
 





The catalytic amount of sodium methoxide (110 μL, 1M in MeOH, 0.1 eq.) was added 
to a stirring solution of 2,3,4,6-tetra-O-acetyl-β-D-glucopyridealdehyde (500 mg, 1.10 
mmol, 1.0 eq) in dry MeOH (6 mL) until pH 9-10 (110 μL). The reaction mixture was 
stirred at ambient temperature for 24 h. The solution was then neutralized by addition 
of ion-exchange resin (Dowex® 50WX4 hydrogen form) until pH 7, filtered, and the 
solvent was removed under reduced pressure to afford the fully acetyl deprotected 
derivative as a colorless solid. 
Yield = 274 mg, 99% 
1H NMR (500 MHz, 298 K, D2O) δH 9.80 (1H, s, CHO), 8.43 (1H, d, 
4JHH =2.4 Hz), 
7.99 (1H, d, 3JHH =8.7 Hz), 7.65 (1H, dd, 
3JHH = 8.7 Hz, 
4JHH =2.5 Hz), 5.23 (1H, d, 
3JHH =7.2Hz, H1Glu), 5.41 (1H, t, 
3JHH =9.6 Hz, H5Glu), 3.87 (1H, dd, 
3JHH =12.3 Hz, 1.7 
Hz, H6Glu), 3.74-3.48 (4H, m, H2,3,4,6Glu ). 
13C {1H} NMR (125 MHz, 298 K, D2O) δC 193.25 (CHO), 156.62, 153.19, 139.93, 
126.39, 124.02 (Py), 99.55 (C1Glu), 76.29(C5Glu), 75.37 (C3Glu), 72.78 (C2Glu), 69.20 
(C4Glu), 60.34 (C6Glu). 
MS (ESI) m/z 308.2 [M+Na]+; 593.3 [2M+Na]+ 
Elemental Analysis found (Calculated for C12H15NO7·MeOH) % C 48.81 (49.21), H 
5.65 (6.04), N 4.37 (4.41). 
 




The α-D-glucosyl bromide (2.60 g, 6.32 mmol) was dissolved in a 5:1 acetone and 
water mixture (70 mL). Sodium azide (1.95 g, 25.0mmol) was added and the solution 
was stirred overnight at room temperature or until TLC (hexanes: ethyl acetate, 1:1) 
showed the complete consumption of starting material. The acetone was removed by 
heating the solution at 50 °C in a water bath, and the remaining slurry was then 
partitioned between water and ethyl acetate (50 mL each). The organic layer was 
removed and the aqueous layer was extracted with ethyl acetate (2 x 50 mL). The 
combined organic extracts were dried over anhydrous magnesium sulfate, filtered, and 
evaporated to a white solid which was subsequently crystallized from hot methanol or 
isopropanol to give acetyl-β-D-glucopyranosylazide as a colourless crystalline solid.  
Yield 2.2 g, 95%. 
1H NMR (400MHz, 298 K, CDCl3) δH ppm 5.22 (t, 1H, 
3JHH =9.5 Hz), 5.11 (t, 1H, 
3JHH = 9.5Hz), 4.96 (t, 1H, 
3JHH = 9.6Hz), 4.65(d, 1H, 
3JHH = 8.8 Hz), 4.28 (dd, 1H, 
3JHH = 12.5 Hz,
 4JHH = 4.8 Hz), 4.17 (dd, 1H, 
3JHH = 12.4 Hz,
 4JHH = 2.0 Hz), 3.80 (ddd, 
1H, 3JHH = 10.0 Hz,
 4JHH = 4.7 Hz,
 4JHH = 2.2 Hz), 2.11-2.01 (4 × s, 12H, CH3). 
13C {1H} NMR (100 MHz, 298 K, CDCl3) δC ppm 170.62, 170.14, 169.32, 169.22 
(CO), 87.92 (C1), 74.03 (C5), 72.61(C3), 70.64 (C2), 67.89 (C4), 61.66 (C6), 20.70, 
20.57, 20.55 (CH3). 
MS (ESI) m/z 396.2 [M+Na]+ 
 




A solution of sodium methoxide (1M in MeOH, 120 μL) was added to a stirring 
solution of 2,3,4,6-tetra-O-acetyl-β-D-glucopyranosylazide (500 mg, 1.34 mmol, 1.0 
eq) in dry MeOH (6 mL) until pH 9-10. The reaction mixture was stirred at r.t. for 24 
h. The solution was then neutralized by addition of ion-exchange resin (Dowex® 
50WX4 hydrogen form) until pH 7, filtered, and the solvent was removed under 
reduced pressure to afford the fully acetyl deprotected derivative as a colourless syrup.  
Yield 254.2 mg, 93%. 
1H NMR (400MHz, 298 K, MeOD) δH ppm 4.51 (d, 1H, 
3JHH = 8.6 Hz), 3.90 (d, 1H, 
3JHH = 12.1 Hz), 3.70 (dd, 1H, 
3JHH = 12.1 Hz,
 4JHH = 5.5 Hz), 3.43-3.28 (m, 3H), 3.15 
(t, 1H, 3JHH = 8.8 Hz). 
13C {1H} NMR (100 MHz, 298 K, MeOD) δC ppm 92.12 (C1), 80.21 (C5), 78.11 
(C3), 74.78 (C2), 71.12 (C4), 62.55 (C6) 
MS (ESI) m/z 433.2 [2M+Na]+ 
2,3,4,6-Tetra-O-acetyl-β-D-galactopyranosyl bromide15 (21) 
 
D-galactopyranosylpentaacetate (2.5 g, 6.4 mmol) was dissolved in 33% HBr/AcOH 
(20 mL) solution and stirred for 3 h. The reaction mixture was then diluted with ethyl 
acetate (25 mL), cooled to 0 °C, and the solution was neutralized carefully with 10% 
aqueous NaOH (50 mL) and saturated NaHCO3 solution (5 mL). The mixture was 
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extracted with ethyl acetate (3 × 25 mL) after which the organic layer was dried over 
anhydrous magnesium sulfate, filtered, and evaporated under reduced pressure to a 
clear syrup that was essentially pure glycosyl bromide.  
Yield 2.2 g, 82 %. 
2,3,4,6-Tetra-O-acetyl-β-D-galactopyranosylazide15.(22) 
 
Sodium azide (0.38 g, 5.84 mmol, 1.2 eq.) was added to a solution of 2,3,4,6-tetra-O-
acetyl-β-D-galactopyranosyl bromide (2.00 g, 4.86 mmol, 1.0 eq.) in dry DMSO (10 
mL) and the reaction was allowed to stir at ambient temperature for 30 min. The 
reaction mixture was then diluted with water (50 mL) and extracted with EtOAc (100 
mL). The organic layer was dried over Na2SO4 and evaporated to dryness. The residue 
was purified by flash chromatography (EtOAc/petroleum ether: 1:2) to achieve the 
desired 2,3,4,6-tetra-Oacetyl-β-D-galactopyranosylazideas a white solid. Rf = 0.50, 
hexanes/ethyl acetate: 1:1. 
Yield 1.8 g, 98 %. 
1H NMR (400MHz, 298 K, CDCl3) δH ppm 5.44 (dd, 1H, 
3JHH = 3.3 Hz,
 4JHH = 0.8 Hz), 
5.18 (m, 1H), 5.06 (m, 1H), 4.62(d, 1H, 3JHH = 8.7 Hz), 4.19 (dd, 2H, 
3JHH = 6.5 Hz,
 
4JHH = 3.8 Hz), 4.03 (m, 1H) 2.19-2.01 (4 × s, 12H, CH3). 
13C {1H} NMR (100 MHz, 298 K, CDCl3) δC ppm 170.38, 170.12, 170.01, 169.37 
(CO), 88.32 (C1), 72.88 (C5), 70.74 (C3), 68.07 (C2), 66.85 (C4), 61.23 (C6), 20.68, 
20.67, 20.62, 20.53 (CH3). 
MS (ESI) m/z 396.6 [M+Na]+ 
 




A solution of sodium methoxide (1M in MeOH) was added to a stirring solution of 
2,3,4,6-tetra-O-acetyl-β-D-galactopyranosylazide (1.00 g, 2.68 mmol,1.0 eq) in dry 
MeOH (12 mL) until pH 9-10 (250μL). The reaction mixture was stirred at ambient 
temperature for 24 h. The solution was then neutralized by addition of ion exchange 
resin (Dowex® 50WX4 hydrogen form) until pH 7, filtered, and the solvent was 
removed under reduced pressure to yield the fully deprotected derivative as a 
colourless oil.  
Yield 489mg, 89%. 
1H NMR (400MHz, 298 K, D2O) δH ppm 4.61 (d, 1H, 
3JHH = 8.7 Hz), 3.91 (d, 1H, 
4JHH 
= 2.0 Hz), 3.78-3.68 (m, 3H), 3.63 (dd, 1H, 3JHH = 9.9 Hz,
 4JHH = 2.4 Hz), 3.46 (t, 1H, 
3JHH = 9.3 Hz) 
13C {1H} NMR (100 MHz, 298 K, MeOD) δC ppm 92.64 (C1), 78.95 (C5), 74.96 (C3), 
71.98 (C2), 70.23 (C4), 62.47 (C6) 
MS (ESI) m/z 228.1 [M+Na]+ 433.3 [2M+Na]+ 
2,3,4,6-tetra-O-acetyl-α-D-mannopyranosylazide15 (24) 
 
Azidotrimethylsilane (TMSiN3, 11 mL, 9.6 mmol, 4.00 equiv.) and tin tetrachloride 
(SnCl4, 1M in CH2Cl2, 0.62 mL, 0.62 mmol, 0.26 equiv.) were added to a solution of 
D-mannopyranosylpentaacetate (930 mg, 2.4 mmol, 1.0 eq.) in dry CH2Cl2 (3 mL) 
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under dinitrogen atmosphere and mixture was stirred at ambient temperature. The 
reaction was monitored by TLC (hexanes/toluene/ethyl acetate: 3:3:4) until complete 
disappearance of the starting material. DCM (15 mL) was then added and the solution 
was washed with a saturated aqueous NaHCO3 (10 mL), water (10 mL) and brine (10 
mL). The organic phase was dried with Na2SO4 and after the evaporation of the solvent, 
the resulting crude product was purified by flash chromatography (hexanes/ethyl 
acetate: 3:1) to give 2,3,4,6-tetra-O-acetyl-α-D-mannopyranosylazideas a colorless oil. 
Yield 276 mg, 96%. 
1H NMR (400MHz, 298 K, CDCl3) δH ppm 5.20 (s, 1H), 5.08 (m, 2H), 4.96 (s, 1H), 
4.12 (dd, 1H, 3JHH = 12.5 Hz,
 4JHH = 5.6 Hz), 3.97 (m, 1H), 1.98-1.81 (4 × s, 12H, 
CH3). 
13C {1H} NMR (100 MHz, 298 K, CDCl3) δC ppm 170.65, 169.92, 169.81, 169.67 
(CO), 87.45 (C1), 70.59 (C5), 69.16 (C2), 68.22 (C3), 65.56 (C4), 62.12 (C6), 20.86, 
20.75, 20.70, 20.65 (CH3). 
MS (ESI) m/z 396.4 [M+Na]+ 
α-D-mannopyranosylazide15 (25) 
 
A solution of sodium methoxide (1M in MeOH) was added to a stirring solution of 
2,3,4,6-tetra-O-acetyl-α-D-mannopyranosylazide (500 mg, 1.34 mmol, 1.0 eq) in dry 
MeOH (6 mL) until pH 9-10 (120 μL). The reaction mixture was stirred at ambient 
temperature for 24 h. The solution was then neutralized by addition of ion-exchange 
resin (Dowex® 50WX4 hydrogen form) until pH 7, filtered, and the solvent was 
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removed under reduced pressure to afford the fully deprotected derivative as a 
colorless syrup.  
Yield 264.6 mg, 96%.  
1H NMR (400MHz, 298 K, D2O) δH ppm 5.42 (s, 1H), 3.86 (m, 2H), 3.73 (m, 3H), 
3.61 (t, 1H, 3JHH = 9.4 Hz). 
13C {1H} NMR (100 MHz, 298 K, D2O) δC ppm 89.68 (C1), 74.56 (C5), 69.74 (C3), 
69.69 (C2), 66.32 (C4), 60.74 (C6). 
MS (ESI) m/z 244.5 [M+K]+ 
(1-benzyl-1H-1,2,3-triazol-4-yl)methanol16 (28a) 
 
(Azidomethyl)benzene (0.238g, 1.79mmol) was dissolved into methanol, followed by 
the addition of propargyl alcohol (0.1g, 1.79mmol) and CuI (0.034g, 0.18mmol). The 
reaction mixture was heated at 60 ℃ overnight while being protected from light. After 
cooling to ambient temperature, the solution was filtered to remove CuI salt and the 
solvent was removed under reduced pressure to give a white solid. 
Yield 0.30 g, 90% 
1H NMR (300 MHz, 298 K, DMSO) δH ppm 8.01 (s, 1H, TRZ), 7.34 (dd, 5H, 
3JHH = 
15.5 Hz, 4JHH = 6.7 Hz, Ph), 5.57 (s, 2H, Ph-CH2), 5.15 (t,
 1H, 3JHH = 5.3 Hz, OH), 
4.50 (d, 2H, 3JHH = 5.0 Hz, CH2OH). 
13C {1H} NMR (75 MHz, 298 K, DMSO) δC ppm 136.70 (C=CH (TRZ)), 129.18, 
128.55, 128.40 (Ph), 132.32 (C=CH (TRZ)), 55.50 (Ph-CH2), 53.16 (CH2OH). 
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Elemental Analysis found (Calculated for C10H11N3O) % C 63.56 (63.48), H 5.81 
(5.86), N 22.43 (22.20). 
MS (ESI) m/z 212.2 [M+Na]+, 401.3 [2M+Na]+ 
(1-(4-fluorobenzyl)-1H-1,2,3-triazol-4-yl)methanol (28b) 
 
28b was synthesised using the procedure described for 28a, substituting 1-
(azidomethyl)-4-fluorobenzen for (azidomethyl)benzene.  
Yield 0.58 g, 92%. 
1H NMR (300 MHz, 298 K, DMSO) δH ppm 8.02 (s, 1H, TRZ), 7.39 (d, 2H, 
3JHH = 
8.2 Hz, Ph), 7.21 (d, 2H, 3JHH = 8.2 Hz, Ph), 5.56 (s, 2H, Ph-CH2), 5.16 (t,
 1H, 3JHH = 
5.5 Hz, OH), 4.50 (d, 2H, 3JHH = 5.4 Hz, CH2OH). 
13C {1H} NMR (75 MHz, 298 K, DMSO) δC ppm 163.94 (F-Ph), 160.70 (C=CH 
(TRZ)), 132.98, 130.76, 130.65 (Ph), 123.24 (C=CH (TRZ)), 116.16, 115.87 (Ph), 
55.50 (Ph-CH2), 52.35 (CH2OH). 
4-((4-(hydroxymethyl)-1H-1,2,3-triazol-1-yl)methyl)benzonitrile (28c) 
 
28c was synthesised using the procedure described for 28a, substituting 4-
(azidomethyl)benzonitrile for (azidomethyl)benzene. 
Yield 0.50 g, 90%. 
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1H NMR (300 MHz, 298 K, DMSO) δH ppm 8.08 (s, 1H, TRZ), 7.86 (d, 2H, 
3JHH = 
7.5 Hz, Ph), 7.45 (d, 2H, 3JHH = 7.6 Hz, Ph), 5.70 (s, 2H, Ph-CH2), 5.18 (t,
 1H, 3JHH = 
5.3 Hz, OH), 4.52 (d, 2H, 3JHH = 5.4 Hz, CH2OH). 
13C {1H} NMR (75 MHz, 298 K, DMSO) δC ppm 142.19 (C=CH (TRZ)), 133.18, 
129.10 (Ph), 123.72 (C=CH (TRZ)), 119.02 (CN), 111.32 (Ph), 55.48 (Ph-CH2), 52.52 
(CH2OH). 
MS (ESI) m/z 237.2 [M+Na]+, 451.3 [2M+Na]+ 
(1-(4-methoxybenzyl)-1H-1,2,3-triazol-4-yl)methanol (28d) 
 
28d was synthesised using the procedure described for 28a, substituting 1-
(azidomethyl)-4-methoxybenzene for (azidomethyl)benzene.  
Yield 0.51 g, 85% 
1H NMR (300 MHz, 298 K, CDCl3) δH ppm 7.43 (s, 1H, TRZ), 7.27 (d, 2H, 
3JHH = 7.4 
Hz, Ph), 6.92 (d, 2H, 3JHH = 7.4 Hz, Ph), 5.47 (s, 2H, Ph-CH2), 4.78 (s, 2H, CH2OH), 
3.83 (s, 3H, OCH3). 
13C {1H} NMR (75 MHz, 298 K, CDCl3) δC ppm 129.74, 126.43, 114.52 (Ph), 56.66 
(Ph-CH2), 55.36 (OCH3), 53.79 (CH2OH). 
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4-((4-(hydroxymethyl)-1H-1,2,3-triazol-1-yl)methyl)benzoic acid (28e) 
 
28e was synthesised using the procedure described for 28a, substituting 4-azidomethyl 
benzoic acid for (azidomethyl)benzene. 
Yield 0.46 g, 87%. 
1H NMR (300 MHz, 298 K, DMSO) δH ppm 13.01 (s, 1H, COOH), 8.04 (s, 1H, TRZ), 
7.94 (d, 2H, 3JHH = 5.2 Hz, Ph), 7.40 (d, 2H, 
3JHH = 5.0 Hz, Ph), 5.67 (s, 2H, Ph-CH2), 
5.19 (t, 1H, 3JHH = 5.0 Hz, OH), 4.52 (d, 2H, 
3JHH = 5.0 Hz, CH2OH). 
13C {1H} NMR (75 MHz, 298 K, DMSO) δC ppm 141.45 (C=CH (TRZ)), 128.61 (Ph), 
55.50 (Ph-CH2), 52.73 (CH2OH). 
1-benzyl-1H-1,2,3-triazole-4-carbaldehyde16 (29a) 
 
(1-Benzyl-1H-1,2,3-triazol-4-yl)methanol (0.15g, 0.79mmol) was dissolved into 2-
propanol, followed by addition of activated manganese dioxide (0.23 g, 2.6 mmol). 
The reaction mixture was heated at 100℃ overnight. After cooling to ambient 
tempearture, the solution was filtered to remove MnO2. The solvent was removed 
under reduced pressure and the residue was purified by flash chromatography 
(DCM/MeOH: 100:1 v/v) furnish the 1-benzyl-1H-1,2,3-triazole-4-carbaldehyde as a 
white solid (0.136 g, 0.73 mmol). Rf = 0.50, DCM/MeOH =100:5 v/v.  
Yield 0.14 g 92%. 
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1H NMR (300 MHz, 298 K, DMSO) δH ppm 10.01 (s, 1H, CHO), 8.97 (s, 1H, TRZ), 
7.42-7.32 (m, 5H, Ph), 5.70 (s, 2H, Ph-CH2). 
13C {1H} NMR (75 MHz, 298 K, DMSO) δC ppm 185.42 (CHO), 135.81 (C=CH 
(TRZ)), 129.33, 128.86, 128.57 (Ph), 53.66 (Ph-CH2). 
Elemental Analysis found (Calculated for C10H9N3O) % C 64.20 (64.16), H 4.69 
(4.85), N 22.29 (22.44). 
MS (ESI) m/z 397.6 [2M+Na]+ 
1-(4-fluorobenzyl)-1H-1,2,3-triazole-4-carbaldehyde (29b) 
 
29b was synthesised using the procedure described for 29a, substituting ((1-(4-
fluorobenzyl)-1H-1,2,3-triazol-4-yl)methanol for (1-benzyl-1H-1,2,3-triazol-4-
yl)methanol. 
Yield 0.36 g, 86%. 
1H NMR (300 MHz, 298 K, DMSO) δH ppm 10.01 (s, 1H, CHO), 8.96 (s, 1H, TRZ), 
7.45 (t, 2H, 3JHH = 8.2 Hz, Ph), 7.23 (t, 2H, 
3JHH = 8.2 Hz, Ph), 5.69 (s, 2H, Ph-CH2). 
13C {1H} NMR (75 MHz, 298 K, DMSO) δC ppm 185.42 (CHO), 164.11 (F-Ph), 
147.52 (C=CH (TRZ)), 132.03, 131.07, 130.95 (Ph), 128.69 (C=CH (TRZ)), 116.32, 
116.03 (Ph), 52.87 (Ph-CH2). 
Elemental Analysis found (Calculated for C10H8FN3O) % C 58.37 (58.54), H 3.78 
(3.93), N 20.02 (20.47). 
MS (ESI) m/z 433.5 [2M+Na]+ 
 




29c was synthesised using the procedure described for 29a, substituting 4-((4-
(hydroxymethyl)-1H-1,2,3-triazol-1-yl)methyl)benzonitrile for (1-benzyl-1H-1,2,3-
triazol-4-yl)methanol.  
Yield 0.41g, 88%.  
1H NMR (300 MHz, 298 K, DMSO) δH ppm 10.03 (s, 1H, CHO), 9.01 (s, 1H, TRZ), 
7.87 (d, 2H, 3JHH = 7.6 Hz, Ph), 7.51 (d, 2H, 
3JHH = 7.6 Hz, Ph), 5.82 (2H, s, Ph-CH2). 
13C {1H} NMR (75 MHz, 298 K, DMSO) δC ppm 185.41 (CHO), 141.15 (C=CH 
(TRZ)), 133.28, 129.38 (Ph), 129.20 (C=CH (TRZ)), 118.94 (CN), 111.64 (Ph), 53.03 
(Ph-CH2). 
Elemental Analysis found (Calculated for C11H8N4O) % C 61.86 (62.26), H 3.93 
(3.80), N 25.79 (26.39). 
MS (ESI) m/z 447.5 [2M+Na]+ 
1-(4-methoxybenzyl)-1H-1,2,3-triazole-4-carbaldehyde (29d) 
 
29d was synthesised using the procedure described for 29a, substituting (1-(4-
methoxybenzyl)-1H-1,2,3-triazol-4-yl)methanol for (1-benzyl-1H-1,2,3-triazol-4-
yl)methanol.  
Yield 0.55 g, 87%. 
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1H NMR (300 MHz, 298 K, DMSO) δH ppm 10.00 (1H, s, CHO), 8.92 (s, 1H, TRZ), 
7.35 (d, 2H, 3JHH = 7.5 Hz, Ph), 6.94 (d, 2H, 
3JHH = 7.4 Hz, Ph), 5.61 (s, 2H, Ph-CH2), 
3.74 (s, 3H, OCH3). 
13C {1H} NMR (75 MHz, 298 K, DMSO) δC ppm 185.42 (CHO), 159.78, 130.29(Ph), 
128.42 (C=CH (TRZ)), 127.70, 114.68 (Ph), 55.63 (OCH3), 53.23 (Ph-CH2). 
Elemental Analysis found (Calculated for C11H11N3O2) % C 60.40 (60.82), H 4.99 
(5.10), N 19.21 (19.33). 
MS (ESI) m/z 457.5 [2M+Na]+ 
4-((4-formyl-1H-1,2,3-triazol-1-yl)methyl)benzoic acid (29e) 
 
29e was synthesised using the procedure described for 29a, substituting 4-((4-
(hydroxymethyl)-1H-1,2,3-triazol-1-yl)methyl)benzoic acid for (1-benzyl-1H-1,2,3-
triazol-4-yl)methanol.  
Yield 0.25 g, 50%. 
1H NMR (300 MHz, 298 K, DMSO) δH ppm 13.09 (s, 1H, COOH), 10.03 (s, 1H, CHO), 
9.00 (s, 1H, TRZ), 7.95 (d, 2H, 3JHH = 7.4 Hz, Ph), 7.44 (d, 2H, 
3JHH = 7.5 Hz, Ph), 
5.80 (s, 2H, Ph-CH2). 
13C {1H} NMR (75 MHz, 298 K, DMSO) δC ppm 185.42 (CHO), 167.34 (COOH), 
147.52 (C=CH (TRZ)), 140.48, 131.19, 130.29 (Ph), 129.08 (C=CH (TRZ)), 128.57 
(Ph), 53.21 (Ph-CH2). 
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Elemental Analysis found (Calculated for C11H9N3O3) % C 56.57 (57.14), H 3.77 
(3.92), N 18.00 (18.17). 
MS (ESI) m/z 485.4 [2M+Na]+ 
acetamido-3,4,6-tri-O-acetyl-2-deoxy-β-D-glucopyranosyl azide.17 (30) 
 
Acetamido-3,4,6-tri-O-acetyl-2-deoxy-β-D-glucopyranosyl chloride (1.01 g 2.74 
mmol) was dissolved in DMF (14 mL). Sodium azide (0.5 g, 7.69 mmol) was added 
slowly and the reaction mixture was heated at 70oC for 3h. Ethyl acetate (50 mL) and 
water (2 x 50 mL) were then added to the solution. The organic layer was dried with 
Na2SO4 and solvent removed under reduced pressure. The pure product was achived 
using column chromatography ethyl acetate: petromleum ether (4:1 v/v) to yield a 
white solid.  
Yield: 0.53 g, 52%. 
1H NMR (400 MHz, 298 K, CDCl3) δH ppm 5.57 (1H, d, 
3JHH = 9.0 Hz, NH), 5.29 
(1H, t, 3JHH = 9.0 Hz, H-C3), 5.11 (1H, t, 
3JHH = 10.0, H-C4), 4.76 (1H, d, 
3JHH = 9.0 
Hz, H-C1), 4.27 (1H, dd, J = 12.5, 5.0 Hz, H-C6), 4.14 (1H, m, H-C6), 3.91 (1H, dd, J 
= 19.5, 3JHH = 9.0 Hz, H-C2), 3.79 (1H, m, H-C5), 2.10-2.00 (s, 4 x CH3)  
13C NMR (100 MHz, 298 K, CDCl3) δc ppm 171.1, 170.6, 170.4 169.4 (4 x C=O), 88.3 
(C1), 73.8 (C5), 71.9 (C3), 67.9 (C4), 61.7 (C6) 53.9 (C2), 23.3, 20.7, 20.6 (4x CH3) 
MS (ESI) m/z 395.2 [M+Na]+ 
IR v cm-1 2117 s, 1752 s, 1731 s, 1368 m, 1236 s, 1211 s, 1056 s, 1037 s, 905 m, 890 
m, 878 m 
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(2R,3R,4S,5R,6R)-2-(acetoxymethyl)-6-(4-(hydroxymethyl)-1H-1,2,3-triazol-1-
yl)tetrahydro-2H-pyran-3,4,5-triyl triacetate18 (31) 
 
2,3,4,6-Tetra-O-acetyl-β-D-glucopyranosylazide (0.25 g, 6.70 mmol) was dissolved in 
1:1 tBuOH: water (6 mL). CuSO4.5H2O (0.008 g, 0.03 mmol) and sodium adsorbate 
(0.02 g, 0.10 mmol) were added to the reaction mixture, followed by the addition of 
propargyl alcohol (0.07 mL, 1.08 mmol). The solution was refluxed at 70oC for 24 h. 
The solvent was removed under reduced pressure and the residue was dispersed in 
ethyl acetate (50 mL) and water (30 mL). The organic layer was dried with Na2SO4 
and solvent removed under reduced pressure, to yield a white solid.  
Yield 0.60 g, 90%. 
1H NMR (300 MHz, 298 K, CDCl3) δH ppm 7.79 (1H, s, TRZ), 5.88 (1H, d, 
3JHH = 
8.1 Hz), 5.51-5.35 (2H, m), 5.24 (1H, t, 3JHH = 9.0 Hz), 4.79 (2H, s, CH2), 4.29 (1H, 
dd, 3JHH = 12.6 Hz; 
4JHH = 4.6 Hz), 4.14 (1H, d, 
3JHH = 12.6 Hz), 4.06-3.92 (1H, m), 
2.07-1.87 (12H, s, 4 × CH3). 
13C {1H} NMR (75 MHz, 298 K, CDCl3) δC ppm 170.53, 169.94, 169.93, 169.05 (4 × 
CO), 148.45 (C=CH (TRZ), 120.09 (C=CH (TRZ)), 85.74 (C1), 75.10 (C5), 72.64 (C3), 
70.32 (C2), 67.69 (C4), 61.54 (C6), 56.55 (CH2), 20.68, 20.54, 20.52, 20.19 (4 × CH3). 
IR v cm-1 3514 m, 1730 s, 1369 m, 1204 s, 1101 m, 1030 s, 912 m, 846 m, 871 m, 598 
m, 505 m 
MS (ESI) m/z 452.3 [M+Na]+ 
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Elemental analysis found (Calculated for C17H23N3O10) % C 47.50 (47.55) H 5.38 
(5.40) N 9.51 (9.78) 
(2R,3S,4S,5R,6R)-2-(acetoxymethyl)-6-(4-(hydroxymethyl)-1H-1,2,3-triazol-1-
yl)tetrahydro-2H-pyran-3,4,5-triyl triacetate. (32) 
 
32 was synthesised using the procedure described for 31, substituting 2,3,4,6-tetra-O-
acetyl-β-D-glucopyranosylazide for 2,3,4,6-tetra-O-acetyl-β-D-galactopyranosylazide. 
Yield: 0.12 g, 41%. 
1H NMR (400 MHz, 298 K, CDCl3) δH ppm 7.89 (1H, s, TRZ), 5.88 (1H, d, 
3JHH = 
9.5 Hz, H-C1), 5.55 (2H, m, H-C3/4), 5.27 (1H, t,
 3JHH = 9.5 Hz, H-C2), 4.79 (2H, s, 
CH2-OH), 4.26 (1H, m, H-C5), 4.15 (2H, s, H-C6), 2.21-1.98 (s, 4 x CH3)  
13C NMR (100 MHz, 298 K, CDCl3) δc ppm 170.4, 170.0, 169.8, 169.2, (4 x CO), 
120.4 (CH, TRZ), 86.2 (C1), 73.9 (C5), 70.6 (C2), 68.0 (C3), 66.8 (C4) 61.0 (C5), 56.1 
(CH2-OH), 21.0, 20.6, 20.5, 20.2 (4x CH3) 
MS (ESI) m/z 452.2 [M+Na]+ 
IR v cm-1 3518  w, 3128 w, 2941 w, 1739 s, 1367 m, 1208 s, 1042 s, 921 m, 589 m 
Elemental analysis found (Calculated for C19H25N3O12) % C 47.39 (46.82) H 5.87 
(5.17) N 8.49 (8.62) 
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(2R,3S,4R,5R,6R)-5-acetamido-2-(acetoxymethyl)-6-(4-(hydroxymethyl)-1H-1,2,3-
triazol-1-yl)tetrahydro-2H-pyran-3,4-diyl diacetate.19 (33) 
 
33 was synthesised using the procedure described for 31 substituting 2,3,4,6-tetra-O-
acetyl-β-D-glucopyranosylazide for acetamido-3,4,6-tri-O-acetyl-2-deoxy-β-D-
glucopyranosyl azide. 
Yield: 0.12 g, 41%. 
1H NMR (400 MHz, 298 K, CDCl3) δH ppm 7.91 (1H, s, HC=C), 6.69 (1H, d, J = 8.0 
Hz, NH), 6.05 (1H, d, 3JHH = 9.5 Hz, H-C1), 5.42 (1H, t, 
3JHH = 9.5 Hz, H-C3), 5.19 
(1H, t, 3JHH = 9.5 Hz, H-C4), 4.73 (2H, s, CH2-OH), 4.54 (1H, m, H-C2), 4.23 (1H, dd 
2JHH = 12.5 Hz, 
3JHH = 4.0 Hz, H-C6), 4.09 (1H, d, 
2JHH = 12.5 Hz, H-C6), 4.01 (1H, d, 
3JHH = 7.0 Hz, H-C5), 2.10 (s, 4 x CH3)  
13C NMR (100 MHz, 298 K, CDCl3) δc ppm 171.1, 170.6, 170.4 169.4 (4 x C=O), 88.3 
(C1), 73.8 (C5), 71.9 (C3), 67.9 (C4), 61.7 (C6) 53.9 (C2), 23.3, 20.7, 20.6 (4x CH3) 
MS (ESI) m/z 451.3 [M+Na]+ 
IR v cm-1 3270 w, 2926 w, 1741 s, 1664 m, 1369 m, 1218 s, 1101 m, 1034 s, 924 m, 
598 m 
Elemental analysis found (Calculated for C17H24N4O9) % C 48.03 (47.66) H 5.70 (5.65) 
N 10.73 (10.41) 
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(2R,3R,4S,5R,6R)-2-(acetoxymethyl)-6-(4-formyl-1H-1,2,3-triazol-1-yl)tetrahydro-
2H-pyran-3,4,5-triyl triacetate (34) 
 
Pyridinium chlorochromate (15.07 mg, 1.2 eq.) was added into the solution of β-
glucose-triaozle alchol 31 (25 mg, 1.0 eq.) in DCM. The reaction mixture was stirred 
at room temperature for 1 h, followed by addition of DCM (3 × 20 mL) and brine (2 
× 20 mL). The organic layer was dried over anhydrous Na2SO4 and concentrated under 
reduced pressure. The pure product was obtained by silica gel column chromatography 
(DCM/MeOH: 20/1 v/v) as white solid. 
Yield 23.0 mg, 92%. 
1H NMR (400 MHz, 298 K, CDCl3) δH ppm 10.15 (1H, s, CHO), 8.37 (1H, s, TRZ), 
5.94 (1H, d, 3JHH = 9.0 Hz), 5.43 (2H, m), 5.26 (1H, t,
 3JHH = 9.6 Hz), 4.32 (1H, dd, 
3JHH = 12.7 Hz; 
4JHH = 4.9 Hz), 4.17 (1H, d, 
3JHH = 12.6 Hz), 4.04 (1H, dd, 
3JHH = 
10.0 Hz, 4JHH = 3.0 Hz), 2.10-1.91 (12H, s, 4 × CH3). 
13C {1H} NMR (100 MHz, 298 K, CDCl3) δC ppm 184.44 (CHO), 170.45, 169.87, 
169.30, 168.91 (4 × CO), 147.97 (C=CH (TRZ), 124.17 (C=CH (TRZ)), 86.01 (C1), 
75.45 (C5), 72.25 (C3), 70.56 (C2), 67.50 (C4), 61.36 (C6), 20.66, 20.52, 20.49, 20.11 
(4 × CH3). 
IR v cm-1 2125 s, 1735 s, 1374 s, 1210 s, 1081 s, 1046 m, 951 m 
MS (ESI) m/z 450.3 [M+Na]+ 
Elemental analysis found (Calculated for C17H21N3O10) % C 47.59 (47.8) H 4.79 (4.95) 
N 9.81 (9.83) 
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(2R,3S,4S,5R,6R)-2-(acetoxymethyl)-6-(4-formyl-1H-1,2,3-triazol-1-yl)tetrahydro-
2H-pyran-3,4,5-triyl triacetate (35) 
 
35 was synthesised using the procedure described for 34, substituting β-glucose-
triaozle alchol 31 for β-galactose-triaozle alchol 32. 
Yield: 0.11 g, 35%.  
1H NMR (400 MHz, 298 K, CDCl3) δH ppm 10.1 (1H, s, H-C=O), 8.35 (1H, s, TRZ), 
5.83 (1H, d, 3JHH = 9.5 Hz, H-C1), 5.50 (1H, d, 
3JHH = 3.0 Hz, H-C3), 5.42 (1H, t,
 3JHH 
= 9.5 Hz, H-C2), 5.23 (1H, dd, J = 10.5 Hz, 
3JHH = 3.0 Hz, H-C4), 4.15 (3H, m, H-C5/6), 
2.16-1.86 (s, 4 x CH3)  
13C NMR (100 MHz, 298 K, CDCl3) δc ppm 185.0 (C=O, Aldehyde), 170.3, 169.9 
169.8, 161.1 (4 x C=O), 124.2 (TRZ), 86.5 (C1), 74.3 (C5), 70.4 (C4), 68.1 (C2), 66.7 
(C3) 61.2 (C6), 20.6, 20.5, 20.2 (4x CH3) 
MS (ESI) m/z 450.2 [M+Na]+ 
IR v cm-1 2124 s, 1736 s, 1374 s, 1211 s, 1081 s, 1045 m, 951 m 
Elemental analysis found (Calculated for C17H22N4O9) % C 47.39 (47.89) H 5.12 (5.20) 
N 11.39 (13.13). 
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(2R,3S,4R,5R,6R)-5-acetamido-2-(acetoxymethyl)-6-(4-formyl-1H-1,2,3-triazol-1-
yl)tetrahydro-2H-pyran-3,4-diyl diacetate (36) 
 
36 was synthesised using the procedure described for 34, substituting β-glucose-
triaozle alchol 31 for β-acetylglucosamine-triaozle alchol 33. 
Yield: 0.15 g, 62%. 
1H NMR (400 MHz, 298 K, CDCl3) δH ppm 10.1 (1H, s, H-C=O), 8.49 (1H, s, TRZ), 
6.50 (1H, s, NH), 6.12 (1H, s, H-C1), 5.47 (1H, s, H-C3), 5.20 (1H, s, H-C4), 4.55 (1H, 
s, H-C2), 4.23 (1H, m, H-C6) 4.10 (2H, d, 
3JHH = 10.5 Hz, H-C5/6), 2.01-1.73 (s, 4 x 
CH3) 
13C NMR (100 MHz, 298 K, CDCl3) δc ppm 184.4 (C=O), 170.9, 170.6, 169.4 (4 x 
C=O), 147.7 (TRZ), 86.4 (C1), 75.2 (C5), 72.3 (C4), 67.9 (C3) 61.6 (C6), 53.8 (C2), 
22.8, 20.7, 20.6 (4x CH3) 
IR v cm-1 3280 w, 2932 w, 2117 w, 1741 s, 1696 m, 1535 m, 1367 m, 1218 s, 1034 s, 
922 w, 759 w, 597 m 
MS (ESI) m/z 449.3 [M+Na]+ 
Elemental analysis found (Calculated for C17H22N4O9) % C 47.39 (47.89) H 5.12 (5.20) 
N 11.39 (13.13)  
  
 





Sodium methoxide (120 μL, 1M in MeOH, 0.1 eq.) was added to a stirring solution of 
34 (500 mg, 1.17 mmol, 1.0 eq) in dry MeOH (6 mL) until pH 9-10. The reaction 
mixture was refluxed at 85oc for 24 h. The solution was then neutralized by addition 
of ion-exchange resin (Dowex® 50WX4 hydrogen form) until pH 7, filtered, and the 
solvent was removed under reduced pressure to afford the fully deprotected triazole 
derivative as a colorless solid.  
Yield: 36 mg, 64%. 
1H NMR (400 MHz, 298 K, DMSO) δH ppm 10.05 (1H, s, CHO), 9.13 (1H, s, TRZ), 
5.65 (1H, d, 3JHH = 9.0 Hz), 5.55-5.16 (3H, m, 3 x OH), 4.64 (1H, s, OH), 3.87-3.67 
(2H, m), 3.51-3.23 (4H, m). 
13C {1H} NMR (100 MHz, 298 K, DMSO) δC ppm 185.39 (CHO), 147.24 (C=CH 
(TRZ), 128.37 (C=CH (TRZ)), 88.34 (C1), 80.63 (C5), 77.14 (C3), 72.55 (C2), 69.90 
(C4), 61.19 (C6). 
MS (ESI) m/z 282.2 [M+Na]+ 
IR v cm-1 3318 (broad), 2878 w, 1692 s, 1459 w, 1247 w, 1038 s, 897 m, 767 m 
Elemental analysis found (Calculated for C9H13N3O6) % C 41.63 (41.70) H 5.37 (5.05) 
N 15.33 (16.20) 
 





38 was synthesised using the procedure described for 37, substituting acetyl protected 
β-glucose triazole aldehyde 34 for acetyl protected β-galactose triazole aldehyde 35. 
Yield: 0.10 g, 77%.  
1H NMR (400 MHz, 298 K, CDCl3) δH ppm 10.1 (1H, s, H-C=O), 8.24 (1H, s, TRZ), 
5.63 (1H, d, H-C1), 4.16 (1H, dd, 
3JHH = 8.5 Hz, H-C2), 3.96 (1H, m, H-C5), 3.83 (1H, 
m, H-C4), (3H, 3.77, m, H-C3/6) 
13C NMR (100 MHz, 298 K, CDCl3) δc ppm 184.4 (C=O), 147.4 (C=CH TRZ), 120.9 
(C=CH TRZ), 89.0 (C1), 78.5 (C4), 74.5 (C3), 70.1 (C2), 69.0 (C5), 61.0 (C6) 
MS (ESI) m/z 282.2 [M+Na]+ 
IR v cm-1 3262 (broad), 2834 w, 1695 m, 1011 s, 884 m 
  
 





39 was synthesised using the procedure described for 37, substituting acetyl protected 
β-glucose triazole aldehyde 34 for acetyl protected β- acetylglucosamine triazole 
aldehyde 36. 
Yield: 0.09 g, 64%. 
1H NMR (400 MHz, 298 K, CDCl3) δH ppm 10.0 (1H, s, aldehyde proton), 8.56 (1H, 
s, TRZ), 5.80 (1H, m, H-C1), 5.49 (1H, s, NHAc), 4.23 (1H, dd, J = 16.5 Hz, 
3JHH = 
10.0 Hz, H-C2), 3.92 (1H, d, 
3JHH = 11.5 Hz, H-C6), 3.74 (2H, dd, J = 22.5 Hz, 
3JHH = 
10.0 Hz, H-C4/6), 3.58 (2H, d, 
3JHH = 10.0 Hz, H-C3/5), 1.80 (1H, s, CH3)  
13C NMR (100 MHz, 298 K, CDCl3) δc ppm 183.4 (C=O Aldehyde), 169.2 (C=O, 
NHAc), 134.4 (C=CH, TRZ), 121.2 (C=CH, TRZ), 86.4 (C1), 79.9 (C4), 74.5 (C5), 
69.9 (C3), 61.7 (C6), 55.6 (C2), 20.8 (CH3) 
IR v cm-1 3269 (broad), 2927 w, 2381 (broad), 1585 s, 1350 m, 1096 m, 1040 s, 767 
w 
MS (ESI) m/z 325.2 [M+Na]+ 
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6.4 Synthesis of complexes 
Synthesis of Rc,ΔZn,[Zn2L13][ClO4]4 
3 
 
5-(Prop-2-yn-1-yloxy)picolinaldehyde (2) (81 mg, 0.50 mmol, 6.0 eq.), and (R,R)-4,4'-
bis[(2-amino-2-phenylethoxy)methyl]-diphenyl ether (3) (95 mg, 0.25 mmol, 3 eq.) 
were dissolved in acetonitrile (30 ml) and stirred at ambient temperature for 2 h. 
Zinc(II) perchlorate hexahydrate (63 mg, 0.17 mmol, 2 eq.) was added and the yellow 
solution was stirred for a further 2 h. Upon addition of a few drops of ethyl acetate to 
the solution, the pure product was precipitated out and isolated by filteration. The off-
white crystals were then vacuum filtered and washed with ethyl acetate before drying 
overnight. 
Yield: 0.18 g, 75%  
1H NMR (500 MHz, 298 K, CD3CN) δH 8.70 (6H, s, HC=N), 7.47 (12H, d, 
3JHH = 
8.0Hz, PhO), 7.39 (12H, m, py), 7.33 (12H, d, 3JHH = 8.5 Hz, Ph), 7.07 (6H, t, 
3JHH = 
7.5Hz, Ph), 6.95 (12H, t, 3JHH = 7.5Hz, Ph), 6.75 (12H, d, 
3JHH = 8.5Hz, PhO), 6.66 
(12H, d, 3JHH = 8.0Hz, Ph), 5.73 (6H, m, CH), 4.97 (6H, d, 
2JHH= 12.0Hz, OCH2Ph), 
4.77 (12H, t, 4JHH = 2.0, CH2C≡C), 4.44 (6H, d, 
3JHH = 12.0Hz, OCH2Ph), 4.19 (6H, 
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t, JHH = 11.0Hz, OCH2CH), 3.37 (6H, dd, 
2JHH= 11.0Hz, 
3JHH= 2.5Hz, OCH2CH), 2.92 
(6H, t, 4JHH = 2.0, C≡CH). 
13C {1H} NMR (125 MHz,298 K, CD3CN) δC 161.3 (HC=N), 156.8 (q, py), 156.4 (q, 
PhO), 139.7 (q, py), 137.2 (py), 135.2 (q, Ph), 133.2 (q, PhO), 130.5 (py), 128.5 
(Ph/PhO), 128.1 (Ph), 126.1 (Ph), 124.8 (py), 118.3 (PhO), 77.6 (C≡CH), 76.5(q, 
C≡CH), 71.9 (OCH2Ph), 71.6 (OCH2CH), 66.7 (OCH2CH), 56.4 (CH2C≡CH);  
ESI-MS (+) m/z 755.4 [L+H]+, 777.4 [L+Na]+  
Elemental Analysis found (Calculated for C144H126Cl4N12O31Zn2·4H2O) % C 60.32 
(60.36), H 4.55 (4.71), N 5.70 (5.87). 
IR v cm-1 3259 (br, m), 2866 (br, m), 1572 (m), 1501 (m), 1223 (m), 1080 (s), 1006 




Zn(ClO4)2·6H2O (0.11 g, 0.30 mmol) was added to a stirred solution of the 5-
(propargyloxy)picolinaldehyde (2) (71 mg, 0.44 mmol) and (S)-2-(2,2'-bipyridin-5-
ylmethoxy)-1-phenylethanamine (14) (0.135 g, 0.44 mmol) in acetonitrile (20 ml) at 
ambient temperature and stirred for 4 h. The resulting yellow solution yielded the 
desired product as a yellow crystalline solid on the addition of ethyl acetate. 
Yield 0.23 g, 72 %. 
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1H NMR (500 MHz, 298 K, CD3CN) δH 9.26 (1H, s, HC=N), 9.23 (1H, s, bpy), 
9.17(1H, s,HC=N), 9.17 (1H, s, bpy), 8.81 (1H, s, HC=N), 8.54 (1H, d, 3JHH = 8.0 Hz, 
bpy), 8.49 (1H, d, 3JHH = 8.0 Hz, bpy), 8.39 (1H, s, bpy), 8.30 (1H, d, 
3JHH = 9.0 Hz, 
py), 8.28-8.19 (3H, m, py/bpy), 8.13-7.90 (8H, m, bpy), 7.89-7.74 (5H, m, py/bpy), 
7.71 (1H, d, 4JHH = 2.5 Hz, py), 7.59-7.45 (6H, m, py/bpy), 7.23-7.14 (2H, m, Ph/py), 
7.11 (2H, t, 3JHH = 7.5 Hz, Ph), 7.03 (1H, t, 
3JHH = 7.5 Hz, Ph), 6.97 (2H, d, 
3JHH = 7.5 
Hz, Ph), 6.91 (1H, t, 3JHH = 7.5 Hz, Ph), 6.72 (2H, t, 
3JHH = 7.5 Hz, Ph), 6.58 (2H, t, 
3JHH = 7.5 Hz, Ph), 6.11 (2H, d, 
3JHH = 7.5 Hz, Ph), 5.99 (2H, d, 
3JHH = 7.5 Hz, Ph), 
5.48 (1H, dd, 2JHH = 11.5 Hz, 
3JHH  = 3.0 Hz, CHPh), 5.22 (1H, d, 
2JHH=13 Hz, OCH2-
bpy) 5.21 (1H, d, 2JHH=13 Hz, OCH2-bpy), 5.16 (1H, d, 
2JHH=13 Hz, OCH2-bpy), 4.97 
(1H, dd, 3JHH = 11.5 Hz,
3JHH =3.5 Hz,CHPh), 4.88 (2H, d, 
4JHH = 2.0 Hz, CH2-CCH), 
4.84-4.78 (3H, m, CH2-CCH/CHPh), 4.75 (2H, d, 
4JHH = 2.0 Hz, CH2-CCH), 4.54 (1H, 
d, 2JHH=13 Hz, OCH2-bpy), 4.52 (1H, d, 
2JHH=13 Hz, OCH2-bpy), 4.48 (1H, d, 
2JHH=13 Hz, OCH2-bpy), 4.30 (1H, t, JHH = 11.0 Hz, CH2-CHPh), 4.18 (1H, t, JHH = 
11.0 Hz, CH2-CHPh), 4.10 (1H, t, JHH = 11.0 Hz, CH2-CHPh), 3.64 (1H, dd, 
2JHH = 
10.5 Hz, 3JHH = 3.5 Hz, CH2-CHPh), 3.54 (1H, dd, 
2JHH = 10.5 Hz, 
3JHH = 3.5 Hz, 
CH2-CHPh), 3.48 (1H, dd, 
2JHH = 10.5 Hz, 
3JHH = 3.5 Hz, CH2-CHPh), 3.03 (1H, t, 
4JHH = 2.0 Hz, C≡CH), 2.92 (1H, t, 
4JHH = 2.0 Hz, C≡CH), 2.83 (1H, t, 
4JHH = 2.2 Hz, 
C≡CH);  
13C {1H} NMR (125MHz, 298 K, CD3CN) δC 163.2/ 162.8/ 162.3 (HC=N), 158.6/ 
158.2/ 157.8 (q, py), 150.7/ 150.5/ 149.7 (bpy), 149.5/ 149.4/ 149.3 (q, bpy), 148.9(q)/ 
148.6/ 148.5(q)/ 148.5/ 148.3/ 148.0 (q, bpy), 143.4/ 143.1/ 143.0 (bpy), 142.3/ 141.9/ 
141.8 (bpy), 140.7/ 140.7/ 140.6 (q, py), 138.4/ 138.3/ 138.3 (py), 137.8/ 137.4/ 137.2 
(q, bpy), 135.1/ 134.2/ 133.8 (q, Ph), 132.3/132.0/ 131.2 (py), 129.2/ 129.1/ 129.1/ 
129.0/ 129.0/ 128.9 (Ph), 127.8/ 127.6/ 127.4 (bpy), 127.2/ 126.5/ 126.4 (Ph), 125.5/ 
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125.5/ 125.3 (py), 124.0/ 123.8/ 123.6/ 123.5/ 123.0/ 122.9 (bpy), 78.4/ 78.4/ 78.3 
(C≡CH), 77.1/ 76.9/ 76.9 (q, C≡CH), 70.1/ 70.0 (CH2-bpy), 69.5 (CHPh), 69.4 (CH2-
bpy), 69.3 (CHPh), 69.3/ 69.0/ 68.9 (CH2-CHPh), 67.5 (CHPh), 57.3/ 57.2/ 57.1 (CH2-
C≡CH);  
ESI-MS (+) m/z 449.3 [L+H]+, 471.3 [L+Na]+, 478.4 [L+K]+  
Elemental Analysis found (Calculated for C84H72Cl4N12O22Zn2·4H2O) % C 52.23 
(51.84), H 3.72 (4.14), N 8.53 (8.64). 
IR v cm-1 3568 (br, m), 1572 (m), 1475 (w), 1440 (w), 1220 (m), 1077 (s), 1008 (s), 
932 (m), 860 (w), 752 (w), 698 (w), 620 (s). 
General procedure for the synthesis of complexes Sc,ɅZn,HHT-[Zn2L
4a-d
3][ClO4]4 
The aromatic azide (4.5 eq.) and [Zn2L
3
3][ClO4]4 (1 eq.) was addition in acetonitrile 
(20 ml), followed by the addition of copper (I) iodide (1 eq.). The solution was stirred 
under partial vacuum and heated at 65 ˚C overnight. After cooling to ambient 
temperature, the solution was filtered to remove copper salt. The resulting pale yellow 
solution yielded the desired product as a white or yellow crystalline solid on the 
addition of ethyl acetate. 
 





Yield 0.18 g, 82%. 
1H NMR (500 MHz, 298 K, CD3CN) δH 9.25 (1H, s, HC=N), 9.20 (1H, s, bpy), 9.14 
(1H, s, bpy), 9.11 (1H, s, HC=N), 8.75 (1H, s, HC=N), 8.52 (1H, d,3JHH = 8.0, bpy), 
8.48 (1H, d,3JHH = 8.0, bpy), 8.36 (1H, s, bpy), 8.28 (1H, d,
3JHH = 9.0 Hz, py), 8.24-
7.71 (23H, m, Ph/bpy/py/TRZ), 7.59 (1H, d,4JHH = 2.5 Hz, py), 7.57-7.23 (27H, m, 
Ph/bpy/py), 7.10-6.87 (5H, m, Ph/py), 6.82 (1H, d,3JHH = 8.0 Hz, Ph) 6.70 (2H, t, 
3JHH 
= 8.0 Hz, Ph), 6.56 (2H, t, 3JHH = 8.0 Hz, Ph), 6.09 (2H, d, 
3JHH = 8.0 Hz, Ph), 5.96 
(2H, d, 3JHH = 8.0 Hz, Ph), 5.60 (2H, s, PhCH2TRZ), 5.57 (2H, s, PhCH2TRZ), 5.48 
(2H, s, PhCH2TRZ), 5.42 (1H, dd, 
2JHH= 11.0Hz, 
3JHH= 3.0, CHPh), 5.32-5.09 (10H, 
m, TRZ-CH2O/OCH2-bpy), 4.94 (1H, dd, 
2JHH = 11.0Hz, 
3JHH = 3.0, CHPh), 4.80 (1H, 
dd, 2JHH = 11.0Hz, 
3JHH = 3.0, CHPh), 4.53 (2H, d, 
2JHH= 13.0 Hz, OCH2-bpy), 4.46 
(1H, d, 3JHH = 13.0 Hz, OCH2-bpy), 4.29 (1H, t, JHH = 11.0 Hz, CH2-CHPh), 4.15 (1H, 
t, JHH = 11.0 Hz, CH2-CHPh), 4.07 (1H, t, JHH = 11.0 Hz, CH2-CHPh), 3.60 (1H, dd, 
2JHH= 10.0Hz,
3JHH= 3.5, CH2-CHPh), 3.52 (1H, dd, 
2JHH= 11.0 Hz,
3JHH= 3.0, CH2-
CHPh), 3.45 (1H, dd, 2JHH= 11.0Hz, 
3JHH= 3.5, CH2-CHPh). 
13C {1H} NMR (125 MHz, 298 K, CD3CN) δC 163.3/ 163.0/ 162.3(HC=N), 159.6/ 
159.3/ 158.7 (q, py), 150.8/ 150.6/ 149.8 (bpy), 149.7/ 149.6/ 149.4/ 149.2 (q, bpy), 
148.7/ 148.3 (bpy), 148.1 (q, bpy), 143.5/ 143.1/ 143.1 (q, bpy), 142.5/ 142.3 (q, TRZ), 
142.0/, 141.7 (bpy), 140.4/ 140.3 (q, py), 138.9/ 138.7/138.4 (py) 137.8/ 137.5/137.2 
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(q, bpy), 136.2/ 136.1 (q, PhCH2), 135.3/ 134.4/ 134.0 (q, Ph), 132.5/ 132.3/131.3 (py), 
129.6/ 129.5/129.5/ 129.3/ 129.2/ 129.1/ 129.1/ 129.0/ 129.0/128.8/ 128.7, 128.6 
(Ph/bpy),127.2/ 126.6/126.5 (bpy)/ 126.1 (py), 125.3/ 125.4/ 125.1 (TRZ), 124.3/ 
124.0/ 123.8/ 123.7/ 123.1/ 123.1 (bpy), 70.2/ 70.2/ 69.6 (CH2-bpy), 69.6 (CHPh), 
69.4 (CH2-bpy), 69.4 (CHPh), 69.1/ 69.0 (CH2-CHPh), 67.5 (CHPh), 62.8/ 62.7 
(TRZCH2O),54.2/ 54.1/ 54.0 (Ph-CH2-TRZ). 
ESI-MS (+) m/z 582.4 [L+H]+, 604.3 [L+Na]+ 
Elemental Analysis found (Calculated for C105H93Cl4N21O6Zn2·30H2O) % C 49.03 
(49.30), H 3.63 (6.03), N 11.37 (11.50). 
IR v cm-1 3519 (br, m), 3039 (br, m), 1570 (m), 1216 (m), 1076 (s), 933 (w), 794 (w), 




Yield 0.23 g, 66 %. 
1H NMR (500 MHz, 298 K, CD3CN) δH 9.24 (1H, s, HC=N), 9.20 (1H, s, bpy), 9.14 
(1H, s, bpy), 9.10 (1H, s, HC=N), 8.74 (1H, s, HC=N), 8.52 (1H, d,3JHH = 8.0 hZ, bpy), 
8.49 (1H, d, 3JHH = 8.0 hZ, bpy), 8.36 (1H, s, bpy), 8.28 (1H, d, 
3JHH = 9.0 Hz, py), 
8.23-8.17 (4H, m, bpy/py), 8.08-7.74 (20H, m, Ph/py/TRZ), 7.62-7.26 (18H, m, 
Ph/py/bpy), 7.24-6.99 (11H, m, Ph/py/bpy),6.94-6.85 (3H, m, Ph/bpy), 6.78 (2H, d, 
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3JHH = 8.0 Hz, Ph), 6.71 (2H, t, 
3JHH = 8.0 Hz, Ph), 6.56 (2H, t, 
3JHH = 8.0 Hz, Ph), 
6.09 (2H, d, 3JHH = 8.0 Hz, Ph), 5.96 (2H, d, 
3JHH = 8.0 Hz, Ph), 5.59 (2H, s, 
PhCH2TRZ), 5.55 (2H, s, PhCH2TRZ), 5.46 (2H, s, PhCH2TRZ), 5.42 (1H, dd, 
2JHH 
= 11.0 Hz, 3JHH = 3.0, CHPh), 5.31-5.08 (10H, m, TRZ-CH2O/OCH2-bpy), 4.94 (1H, 
dd, 2JHH = 11.0 Hz, 
3JHH = 3.0, CHPh), 4.78(1H, dd, 
2JHH = 11.0 Hz, 
3JHH = 3.0, CHPh), 
4.53 (4H, d, 2JHH = 13.0 Hz,OCH2-bpy), 4.45 (2H, d, 
2JHH = 13.0 Hz, OCH2-bpy), 4.29 
(1H, t, JHH = 11.0 Hz, CH2-CHPh), 4.14 (1H, t, JHH = 11.0 Hz, CH2-CHPh), 4.06 (1H, 
t, JHH = 11.0 Hz, CH2-CHPh), 3.59 (1H, dd, 
2JHH = 10.0 Hz, 
3JHH = 3.5, CH2-CHPh), 
3.52 (1H, dd, 2JHH = 11.0 Hz, 
3JHH = 3.0, CH2-CHPh), 3.45 (1H, dd, 
2JHH = 11.0 Hz, 
3JHH = 3.5, CH2-CHPh). 
13C {1H} NMR (125MHz, 298 K, CD3CN) δC 163.6/ 163.5 (q, F-Ph), 162.7/ 162.4/ 
161.7 (HC=N), 161.1 (q, F-Ph), 159.0/ 158.7/ 158.1 (q, py), 150.2/ 150.0/ 149.2 (bpy), 
149.1/ 148.9/ 148.6 (q, bpy), 148.1/ 147.7 (bpy), 147.6 (q, bpy), 142.9/ 142.6/ 142.5 
(bpy), 141.9/ 141.72 (q, TRZ), 141.70/, 141.4/ 141.1 (bpy), 139.8/ 139.7 (q, py), 138.4/ 
138.1/ 137.8 (py), 137.3/ 136.9/ 136.6 (q, PhCH2), 134.6/ 133.8/ 133.4 (q, Ph), 131.9/, 
131.8/ (py), 130.7/ 130.6/ 130.4/ 130.3/ 130.2/ 128.8/ 128.6/ 128.5/ 128.4/ 128.3 
(Ph/bpy), 127.3/ 127.2/ 126.9 (bpy), 126.6/ 126.1/ 126.0 (py), 125.6/ 124.9/ 124.8 
(TRZ), 124.7/ 124.5/ 124.4 (bpy), 123.7/ 123.4/ 123.2/ 122.6/ 122.5 (bpy), 155.8/ 
155.7/ 155.6/ 155.5 (F-Ph), 69.6/ 69.5 (CH2-bpy), 69.0/ 68.8 (CHPh), 68.5/ 68.4 (CH2-
CHPh), 66.9 (CHPh), 62.2/ 62.0 (TRZCH2O), 52.8/ 52.7/ 52.6 (F-Ph-CH2-TRZ). 
ESI-MS (+) m/z 600.4 [L+H]+, 622.3 [L+Na]+ 
Elemental Analysis found (Calculated for C105H90Cl4F3N21O6Zn2·28H2O) % C 49.02 
(48.96), H 3.53 (5.71), N 11.39 (11.42). 
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IR v cm-1 1602 (w), 1570 (w), 1315 (w), 1218 (m), 1076 (s), 841 (m), 788 (m), 751 




Yield 0.19 g, 74%. 
1H NMR (500 MHz, 298 K, CD3CN) δH 9.25 (1H, s, HC=N), 9.21 (1H, s, bpy), 9.14 
(1H, s, bpy), 9.10 (1H, s, HC=N), 8.73 (1H, s, HC=N), 8.52 (1H, d, 3JHH = 8.0 Hz, 
bpy), 8.48 (1H, d, 3JHH = 8.0 Hz, bpy), 8.36 (1H, s, bpy), 8.28 (1H, d,
3JHH = 9.0 Hz, 
py), 8.24-7.23 (54H, m, Ph/py/bpy/TRZ), 7.02 (2H, t, 3JHH = 7.0 Hz, Ph), 6.91 (2H, t, 
3JHH = 7.5 Hz, Ph), 6.85 (2H, d, 
3JHH = 8.0 Hz, Ph), 6.76 (2H, d, 
3JHH = 8.0 Hz, Ph), 
6.71 (2H, t, 3JHH = 8.0 Hz, Ph), 6.57 (2H, t, 
3JHH = 8.0 Hz, Ph), 6.06 (2H, d, 
3JHH = 8.0 
Hz, Ph), 5.96 (2H, d, 3JHH = 8.0 Hz, Ph),5.68 (2H, s, PhCH2TRZ), 5.65 (2H, s, 
PhCH2TRZ), 5.57 (2H, s, PhCH2TRZ), 5.41(1H, dd, 
2JHH = 11.0 Hz,
3JHH = 3.0, CHPh), 
5.36-5.08 (10H, m, TRZ-CH2O/OCH2-bpy), 4.94 (1H, dd, 
2JHH = 11.0 Hz,
3JHH = 3.0, 
CHPh), 4.80 (1H, dd, 2JHH = 11.0 Hz, 
3JHH = 3.0, CHPh), 4.53 (1H, d, 
2JHH = 13.0 Hz, 
OCH2-bpy), 4.52 (1H, d, 
2JHH = 13.0 Hz, OCH2-bpy), 4.45 (1H, d, 
2JHH = 13.0 Hz, 
OCH2-bpy), 4.28 (1H, t, JHH = 11.0 Hz, CH2-CHPh), 4.13 (1H, t, JHH = 11.0 Hz, CH2-
CHPh), 4.06 (1H, t, JHH = 11.0 Hz, CH2-CHPh), 3.60 (1H, dd, 
2JHH = 10.0 Hz, 
3JHH = 
3.5, CH2-CHPh), 3.52 (1H, dd, 
2JHH = 11.0 Hz, 
3JHH = 3.0, CH2-CHPh), 3.45 (1H, dd, 
2JHH = 11.0 Hz, 
3JHH = 3.5, CH2-CHPh). 
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13C {1H} NMR (125 MHz, CD3CN) δC 162.7/ 162.4/ 161.7 (HC=N), 159.0/ 158.8/ 
158.1 (q, py), 150.3/ 150.0/ 149.3 (bpy), 149.1/ 148.9/ 148.6 (q, bpy), 148.1/ 147.7 
(bpy), 147.6 (q, bpy), 142.9/ 142.6/ 142.5 (bpy), 142.1/ 141.9 (q, TRZ), 141.7/ 141.4/ 
141.2 (bpy), 140.9/ 140.8/ 140.7 (q, PhCN), 139.8/ 139.7 (q, py) 138.4/ 138.2/ 137.7 
(py), 137.3/ 137.0/ 136.7 (q, PhCH2), 134.6/ 133.9/ 133.5 (q, Ph), 132.9/ 132.8 (PhCN), 
131.9/ 131.8/ 130.7 (py), 129.1/ 128.8/ 128.7/ 128.6/ 128.5/ 128.4/ 128.3 (Ph/bpy), 
127.3/ 127.2/ 126.9 (bpy), 126.6/ 126.1/ 126.0 (py), 125.7/ 125.2/ 125.1/ 125.0/ 124.9/ 
124.5/ 123.7/ 123.5/ 123.2/ 122.6/ 122.5 (bpy), 118.3 (CN), 112.0 (q, PhCN), 69.7/ 
69.6 (CH2-bpy), 69.03 (CHPh), 69.00 (CH2-bpy), 68.9 (CH2-CHPh), 68.8 (CHPh), 
68.6/ 68.5 (CH2-CHPh), 67.0 (CHPh), 62.2/ 62.0/ 61.9 (TRZCH2O), 53.0/ 52.9/ 52.8 
(CNPh-CH2-TRZ). 
ESI-MS (+) m/z 607.3 [L+H]+ 
Elemental Analysis found (Calculated for C108H90Cl4N24O6Zn2·29H2O) % C 49.57 
(49.60), H 3.36 (5.70), N 12.84 (12.86). 
IR v cm-1 2229 (w), 1571 (m), 1475 (w), 1440 (w), 1317 (w), 1263 (w), 1218 (w), 




Yield 0.26 g, 90%. 
 
University of Warwick | Page 209 
 
1H NMR (500 MHz, 298 K, CD3CN) δH 9.22 (1H, s, HC=N), 9.17 (1H, s, bpy), 9.11 
(1H, s, bpy), 9.06 (1H, s, HC=N), 8.71 (1H, s, HC=N), 8.51 (1H, d,3JHH = 8.0 Hz, bpy), 
8.48 (1H, d,3JHH = 8.0 Hz, bpy), 8.34 (1H, s, bpy), 8.25 (1H, d, 
3JHH = 9.0Hz, py), 
8.23-8.15 (4H, m, py), 8.08-7.71 (20H, m, Ph/py/TRZ), 7.56 (1H, d, 4JHH = 2.5, py), 
7.52-7.45 (3H, m, Ph/py), 7.42-7.25 (10H, m, Ph/bpy/py), 7.20 (2H, d, 3JHH = 9.0 Hz, 
py), 7.06-6.83 (14H, m, Ph/py), 6.74 (2H, d, 3JHH = 8.0 Hz, Ph), 6.68 (2H, t, 
3JHH = 
8.0 Hz, Ph), 6.53 (2H, t, 3JHH = 8.0 Hz, Ph), 6.06 (2H, d, 
3JHH = 8.0 Hz, Ph), 5.93 (2H, 
d, 3JHH = 8.0 Hz, Ph), 5.49 (2H, s, PhCH2TRZ), 5.46 (2H, s, PhCH2TRZ), 5.43-5.37 
(3H, m, PhCH2TRZ/ CHPh), 5.26-5.06 (10H, m, TRZ-CH2O/OCH2-bpy), 4.91 (1H, 
dd, 2JHH = 11.0Hz, 
3JHH = 3.0, CHPh), 4.77 (1H, dd, 
2JHH = 11.0Hz, 
3JHH = 3.0, CHPh), 
4.52 (2H, d, 2JHH= 13.0 Hz, OCH2-bpy), 4.45 (2H, d, 
2JHH= 13.0 Hz, OCH2-bpy)), 4.26 
(1H, t, JHH = 11.0 Hz, CH2-CHPh), 4.11 (1H, t, JHH = 11.0 Hz, CH2-CHPh), 4.03 (1H, 
t, JHH = 11.0 Hz, CH2-CHPh), 3.78 (3H, s, OCH3), 3.76 (3H, s, OCH3),3.74 (3H, s, 
OCH3), 3.56 (1H, dd, 
2JHH= 10.0 Hz, 
3JHH= 3.5, CH2-CHPh), 3.49 (1H, dd, 
2JHH= 11.0 
Hz, 3JHH= 3.0, CH2-CHPh), 3.42 (1H, dd, 
2JHH= 11.0 Hz, 
3JHH= 3.5, CH2-CHPh). 
13C {1H} NMR (125 MHz, 298 K, CD3CN) δC 162.8/ 162.4/ 161.8 (HC=N), 159.9 (q, 
PhOCH3), 159.1/ 158.8/ 158.2 (q, py), 150.3/ 150.0/ 149.3 (bpy), 149.1/ 148.9/ 148.7 
(q, bpy), 148.1/ 147.8 (bpy), 147.6 (q, bpy), 143.0/ 142.6/ 142.5 (bpy), 141.9 (q, TRZ), 
141.8 (bpy), 141.7 (q, TRZ), 141.5/ 141.2 (bpy), 139.8/ 139.7 (q, py), 138.4/ 138.2/ 
137.7 (py), 137.3/ 137.0/ 136.7 (q, bpy), 134.7/ 133.9/ 133.5 (q, Ph), 131.9/ 131.8/ 
130.8 (py), 130.0/ 129.8/ 129.7 (PhOCH3) 128.8/ 128.7/ 128.6/ 128.5/ 128.4 (Ph), 
127.6/ 127.5 (PhOCH3), 127.3/ 127.2/ 126.9 (bpy), 126.7/ 126.1/ 126.0 (Ph), 125.8/ 
125.0/ 124.6 (py), 124.5/ 124.3 (TRZ), 123.8/ 123.5/ 123.3/ 123.2/ 122.6/ 122.5 (bpy), 
114.4/ 114.3/ 114.2 (PhOCH3), 69.7/ 69.6/ 69.1 (CH2-bpy), 69.0 (CHPh), 68.9 (CH2-
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CHPh), 68.8 (CHPh), 68.6/ 68.5 (CH2-CHPh), 67.0 (CHPh), 62.3/ 62.1 (TRZCH2O), 
55.1 (OCH3), 53.3/ 53.2/ 53.1 (CH3OPh-CH2-TRZ).  
ESI-MS (+) m/z 612.4 [L+H]+ 
Elemental Analysis found (Calculated for C108H99Cl4N21O9Zn2·28H2O) % C 49.44 
(49.66), H 3.74 (5.98), N 11.10 (11.26). 
IR v cm-1 1571 (m), 1514 (w), 1316 (w), 1248 (m), 1079 (s), 839 (w), 791 (m), 752 







3][ClO4]4 was synthesised using the procedure described for 
Sc,ɅZn,HHT-[Zn2L33][ClO4]4, substituting 5-(propargyloxy)picolinaldehyde (5) for 
(2R,3R,4S,5R,6S)-2-(acetoxymethyl)-6-((6-formylpyridin-3-yl)oxy)tetrahydro-2H-
pyran-3,4,5-triyl triacetate (21). 
Yield 0.38 g, 85% 
1H NMR (500 MHz, 298 K, CD3CN) δH ppm 9.30 (1H, s, HC=N), 9.21 (1H, s, HC=N), 
9.19 (1H, s, bpy), 9.13 (1H, s, bpy), 8.85 (1H, s, HC=N), 8.52 (1H, d, 3JHH = 8.2 Hz, 
bpy), 8.48 (1H, d, 3JHH = 8.2 Hz, bpy), 8.37-8.31 (2H, m, bpy overlapping with py), 
8.29-8.18 (3H, m, bpy overlapping with py), 8.12-7.92 (8H, m, bpy overlapping with 
py), 7.91 (1H, d, 3JHH = 8.2 Hz, bpy), 7.89-7.80 (3H, m, bpy overlapping with py), 
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7.78 (1H, d, 4JHH = 2.5 Hz, bpy), 7.76 (1H, d, 
3JHH = 8.0 Hz, Py), 7.60-7.48 (5H, m, 
bpy overlapping with py), 7.44 (1H, d, 4JHH = 2.5 Hz, py), 7.24 (1H, t, 
3JHH = 7.4 Hz, 
Ph), 7.17 (1H, d, 4JHH = 2.5 Hz, py), 7.09 (2H, t, 
3JHH = 7.7 Hz, Ph), 7.02 (1H, t, 
3JHH 
= 7.4 Hz, Ph), 6.96-6.89 (3H, m, Ph overlapping with py), 6.71 (2H, t, 3JHH = 7.7 Hz, 
Ph), 6.58 (2H, t, 3JHH = 7.7 Hz, Ph), 6.09 (2H, d, 
3JHH = 7.6 Hz, Ph), 5.97 (2H, d, 
3JHH 
= 7.6 Hz, Ph), 5.51-5.41 (4H, m, Hglu overlapping with CHPh), 5.38-5.04 (12H, m, 
Hglu overlapping with CH2-bpy), 4.95 (1H, d, 
3JHH = 9.1 Hz, CHPh), 4.79 (1H, d, 
2JHH 
= 9.1Hz, CHPh), 4.55 (2H, d, 2JHH = 13.0 Hz, CH2-bpy), 4.48 (1H, d, 
2JHH = 12.9 Hz, 
CH2-bpy), 4.34-3.94 (12H, m, Hglu overlapping with CH2-CHPh), 3.66 (1H, dd, 
2JHH 
= 10.3 Hz, 3JHH = 3.5 Hz, CH2-CHPh), 3.53 (1H, dd, 
2JHH = 11.0 Hz, 
3JHH = 2.8 Hz, 
CH2-CHPh), 3.45 (1H, dd, 
2JHH = 11.1 Hz, 
3JHH = 3.4 Hz, CH2-CHPh), 2.08-1.83 (36H, 
m, 12 × COCH3). 
13C {1H} NMR (126 MHz, 298 K, CD3CN) δC ppm 170.8, 170.8, 170.8, 170.5, 170.4, 
170.4, 170.1, 170.0, 170.0, 169.9, 169.8, 169.7 (12 × CO), 163.5, 163.1, 162.7 (HC=N), 
157.8, 157.3, 157.0 (q, py), 150.9, 150.7, 149.8 (bpy), 149.7, 149.5, 149.4, 149.0 (q, 
bpy), 149.0, 148.9, 148.8 (bpy), 148.6, 148.1 (q, bpy), 143.6, 143.3, 143.2, 142.5 (bpy), 
142.2, 142.1 (q, py), 142.0, 141.9, 140.4, 139.9, 139.9 (py), 137.9, 137.5, 137.4 (q, 
bpy), 135.2, 134.2, 133.8 (q, Ph), 132.7, 132.3, 131.7 (py), 129.4, 129.2, 129.2, 129.2, 
129.1 (Ph), 127.9, 127.8 (bpy), 127.5 (Ph), 127.3 (bpy), 126.9, 126.8 (py), 126.7, 126.5 
(Ph), 124.0, 123.8, 123.7, 123.7, 123.2, 123.1 (bpy), 98.5, 98.2 (C1Glu), 72.6, 72.6 
(C5Glu), 72.2, 72.2 (C3Glu), 71.1, 70.9, 70.7 (CHPh), 70.2, 70.2 (CH2-bpy), 69.6, 69.6 
(C2Glu), 69.5, 69.1, 69.0 (CH2-CHPh), 68.0, 67.7 (C4Glu), 61.7, 61.7, 61.6 (C6Glu), 20.7, 
20.5, 20.5, 20.5, 20.5, 20.4, 20.4, 20.4 (12 × CH3). 
Elemental Analysis found (Calculated for C117H120Cl4N12O49Zn2·4H2O) % C 49.47 
(49.78), H 4.23 (4.57), N 6.04 (5.95). 
 








3][ClO4]4 was synthesised using the procedure described for 
Sc,ɅZn,HHT-[Zn2L33][ClO4]4, substituting 5-(propargyloxy)picolinaldehyde (5) for 5-
(((2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-
yl)oxy)picolinaldehyde (22) 
Yield 0.30 g, 80% 
1H NMR (500 MHz, 298 K, CD3CN) δH ppm 9.29 (1H, s, HC=N), 9.21 (1H, s, bpy), 
9.18 (1H, s, HC=N), 9.15 (1H, s, bpy), 8.85 (1H, s, HC=N), 8.55 (1H, d, 3JHH = 8.2 
Hz, bpy), 8.50 (1H, d, 3JHH = 8.2 Hz, bpy), 8.38 (1H, s, bpy), 8.32 (1H, d, 
3JHH = 8.7 
Hz, Py), 8.23 (4H, m, Py/bpy), 8.12-7.89 (11H, m, bpy), 7.89-7.79 (5H, m, 3JHH = 8.2 
Hz, bpy), 7.76 (1H, d, 4JHH = 2.2 Hz, Py), 7.61-7.42 (9H, m, Py), 7.25 (1H, d, 
4JHH = 
2.3 Hz, Py), 7.19 (1H, t, 3JHH = 7.3 Hz, Ph), 7.11 (2H, t, 
3JHH = 7.6 Hz, Ph), 7.02 (1H, 
t, 3JHH = 7.5 Hz, Ph), 6.79 (2H, d, 
3JHH = 7.6 Hz, Ph), 6.91 (1H, t, 
3JHH = 7.4 Hz, Ph), 
6.71 (2H, t, 3JHH = 7.7 Hz, Ph),  6.57 (2H, t, 
3JHH = 7.7 Hz, Ph), 6.11 (2H, d, 
3JHH = 7.6 
Hz, Ph), 5.98 (2H, d, 3JHH = 7.6 Hz, Ph), 5.46 (1H, dd, 
2JHH = 11.5 Hz, 
3JHH  = 3.0 Hz, 
CHPh), 5.22 (1H, d, 2JHH=13 Hz, CH2-bpy) 5.20 (1H, d, 
2JHH=13 Hz, CH2-bpy), 5.17 
(1H, d, 2JHH=13 Hz, OCH2-bpy), 4.99-4.91 (3H, m, CHPh overlapping with Hglu), 
4.88-4.81 (2H, m, CHPh overlapping with Hglu), 4.55 (1H, d, 
2JHH=13 Hz, CH2-bpy), 
4.49 (1H, d, 2JHH=13 Hz, CH2-bpy), 4.31 (1H, t, JHH = 11.0 Hz, CH2-CHPh), 4.18 (1H, 
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t, JHH = 11.0 Hz, CH2-CHPh), 4.14-3.20 (38H, m, CH2-CHPh overlapping with Hglu), 
3.15 (1H, s, OH), 3.06 (1H, s, OH), 2.90 (1H, s, OH). 
13C {1H} NMR (125MHz, 298 K, CD3CN) δC 163.1/ 162.7/ 162.1 (HC=N), 158.0/ 
157.7/ 157.6 (q, py), 150.5/ 150.2/ 149.5 (bpy), 149.3/ 149.1/ 149.1 (q, bpy), 148.7 
(q)/ 148.4/ 148.3 (bpy), 148.26 (q, bpy) 147.9 (bpy), 147.8 (q, bpy), 143.2/ 142.9/ 
142.8 (bpy), 142.0/ 141.7/ 141.5 (bpy), 141.2/ 141.2/ 141.1 (q, py), 138.3/ 138.1 (py), 
137.6/ 137.2/ 137.0 (q, bpy), 134.9/ 133.9/ 133.6 (q, Ph), 132.2/ 132.1/ 131.1 (py), 
129.4/ 129.0/ 128.9/ 128.9/ 128.8/ 128.7 (Ph), 127.7/ 127.5/ 127.5 (bpy), 127.3/ 127.1/ 
127.0 (Ph), 126.7/ 126.3/ 126.2 (py), 124.0/ 123.7/ 123.5/ 123.4/ 122.8 (bpy), 100.5, 
100.1, 99.9 (C1Glu), 76.9, 76.9, 76.8 (C5Glu), 76.4, 76.3 (C3Glu), 73.3, 73.2 (C2Glu), 70.2, 
70.1 (C4Glu), 69.9 (CH2-bpy), 69.8 (C4Glu), 69.8 (CH2-bpy), 69.4/ 69.1 (CHPh), 69.1/ 
68.7/ 68.7 (CH2-CHPh), 67.4 (CHPh), 61.7/ 61.5/ 61.4 (C6Glu) 
MS (ESI) m/z 573.3 [L + H]+; 595.3 [L + Na]+ 
Elemental Analysis found (Calculated for C93H96Cl4N12O37Zn2·10H2O) % C 46.05 





Rc, ΔZn,HHT-[Zn2L7a3][ClO4]4 was synthesised using the procedure described for 
Sc,ɅZn,HHT-[Zn2L33][ClO4]4, substituting 5-(propargyloxy)picolinaldehyde (5) for 
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(2R,3R,4S,5R,6R)-2-(acetoxymethyl)-6-(4-formyl-1H-1,2,3-triazol-1-yl)tetrahydro-
2H-pyran-3,4,5-triyl triacetate (46) 
Yield 0.21 g, 83% 
1H NMR (500 MHz, 298 K, CD3CN) δH ppm 9.22 (1H, s, HC=N), 9.18 (1H, s, bpy), 
9.12 (2H, s, bpy overlapping with HC=N), 8.75 (1H, s, HC=N), 8.49 (1H, t, 3JHH = 9.0 
Hz, bpy), 8.35 (1H, s, bpy), 8.24 (1H, d, 3JHH = 8.7 Hz, py), 8.22-8.15 (5H, m, bpy 
overlapping with TRZ), 8.10 (1H, s, TRZ), 8.07-7.73 (19H, m, bpy overlapping with 
TRZ and py), 7.61-7.42 (7H, m, bpy overlapping with py), 7.40 (1H, d, 3JHH = 8.6 Hz, 
py), 7.30 (1H, d, 4JHH = 2.5 Hz, py), 7.06 (1H, t, 
3JHH = 7.4 Hz, Ph), 6.99 (2H, t, 
3JHH 
= 7.4 Hz, Ph), 6.93 (2H, t, 3JHH = 7.4 Hz, Ph), 6.88 (1H, t, 
3JHH = 7.4 Hz, Ph), 6.83 
(2H, d, 3JHH = 7.5 Hz, Ph), 6.68 (2H, t, 
3JHH = 7.7 Hz, Ph), 6.54 (2H, t, 
3JHH = 7.6 Hz, 
Ph), 6.06 (2H, d, 3JHH = 7.4 Hz, Ph), 6.09-5.92 (7H, m, Ph overlapping with Hglu), 5.75 
(1H, t, 3JHH = 9.5 Hz, Hglu), 5.65-5.08 (28H, m, Hglu overlapping with CHPh and CH2-
bpy), 4.92 (1H, d, 3JHH = 10.9 Hz, CHPh), 4.79 (1H, d, 
3JHH = 7.4 Hz, CHPh), 4.50 
(2H, d, 2JHH = 12.9 Hz, CH2-bpy), 4.44 (1H, d, 
2JHH = 12.9 Hz, CH2-bpy), 4.31-4.00 
(20H, m, Hglu overlapping with CH2-CHPh), 3.56 (1H, dd, 
2JHH = 11.0 Hz, 
3JHH = 3.0 
Hz, CH2-CHPh), 3.51 (1H, dd, 
2JHH = 11.0 Hz, 
3JHH = 3.0 Hz, CH2-CHPh), 3.43 (1H, 
dd, 2JHH = 11.0 Hz, 
3JHH = 3.0 Hz, CH2-CHPh), 2.05-1.65 (36H, m, 12 × COCH3). 
13C {1H} NMR (125 MHz, 298 K, CD3CN) δC ppm 170.6, 170.3, 170.2, 170.1, 169.3, 
169.3, 169.2 (12 × CO), 163.1, 162.2, 162.2 (HC=N), 159.2, 159.0, 158.3 (q, py), 
150.6, 150.4, 149.7 (bpy), 149.5, 149.3, 149.1 (q, bpy), 148.6 (bpy), 148.5 (q, bpy), 
148.2 (bpy), 148.0 (q, bpy), 143.4, 143.3, 142.9 (bpy), 142.8, 142.7, 142.5 (q, TRZ), 
142.2, 141.8, 141.6 (bpy), 140.4, 140.3, 140.2 (q, py), 138.9, 138.4, 138.3 (py), 137.7, 
137.4, 137.1 (q, bpy), 135.1, 134.3, 133.8 (q, Ph), 132.3, 132.3, 131.2 (py), 129.2, 
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129.1, 129.0, 128.8 (Ph), 127.7, 127.6, 127.3 (bpy), 127.2, 126.5, 126.4 (Ph), 126.0, 
125.3, 124.9 (py), 124.8, 124.3, 124. 3, 124.2, 123.9, 123.7 (bpy), 123.6, 123.0 (TRZ), 
85.3, 85.2 (C1Glu), 74.9, 74.8 (C5Glu), 72.8, 72.6 (C3Glu), 70.5, 70.4 (C2Glu), 70.1, 70.0 
(CH2-bpy), 69.4 (CHPh), 69.3 (CH2-CHPh), 69.2 (CHPh), 69.0, 68.9 (CH2-CHPh), 
68.1, 68.0, 68.0 (C4Glu), 67.4 (CHPh), 62.4, 62.2, 62.1 (TRZ-CH2), 61.9, 61.9 (C6Glu), 
20.1, 20.3, 20.2, 12.0, 19.9, 19.8 





Rc,ΔZn,HHT-[Zn2L8a3][ClO4]4 was synthesised using the procedure described for 
Sc,ɅZn,HHT-[Zn2L33][ClO4]4, substituting 5-(propargyloxy)picolinaldehyde (5) for 1-
benzyl-1H-1,2,3-triazole-4-carbaldehyde (37) 
Yield 0.29 g, 90% 
1H NMR (500 MHz, 298 K, CD3CN) δH ppm 9.21 (1H, s, HC=N), 9.17 (2H, s, 
HC=N/bpy), 9.14 (1H, s, bpy), 8.83 (1H, s, HC=N), 8.60 (1H, s, TRZ), 8.54 (1H, s, 
TRZ), 8.48 (1H, s, bpy), 8.45 (2H, d, 3JHH =8.2 Hz, bpy), 8.42 (2H, d, 
3JHH =8.3 Hz, 
bpy), 8.24-7.77 (15H, m, bpy/TRZ), 7.66-7.28 (17H, m, bpy/Ph), 7.22-6.94 (10H, m, 
bpy/Ph), 6.89 (2H, t, 3JHH =7.4 Hz, Ph), 6.74 (2H, t, 
3JHH =7.7 Hz, Ph), 6.56 (2H, t, 
3JHH =7.7 Hz, Ph), 6.11 (2H, d, 
3JHH =7.5 Hz, Ph), 5.98 (2H, d, 
3JHH =7.5 Hz, Ph), 5.61-
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5.46 (6H, m, PhCH2), 5.43 (1H, dd,
 3JHH = 11.4 Hz 
4JHH = 3.2, CHPh), 5.26-5.10 (3H, 
m, CH2-bpy), 4.88 (1H, d, 
3JHH =9.0 Hz, CHPh), 4.79 (1H, d, 
3JHH =8.2 Hz, CHPh), 
4.54-4.43 (3H, m, CH2-bpy), 4.18 (1H, t, JHH =11.2 Hz, CH2-CHPh), 4.09 (1H, t, JHH 
=10.8 Hz, CH2-CHPh), 4.03 (1H, t, JHH =10.9 Hz, CH2-CHPh), 3.66 (1H, dd,
 2JHH = 
10.4 Hz 3JHH = 3.5, CH2-CHPh), 3.53 (1H, dd,
 2JHH = 11.2 Hz 
3JHH = 3.1, CH2-CHPh), 
3.47 (1H, dd, 2JHH = 11.2 Hz 
3JHH = 3.4, CH2-CHPh). 
13C {1H} NMR (125 MHz, 298 K, CD3CN) δC ppm 157.1, 156.6, 156.1 (HC=N), 150.4, 
150.2, 149.9 (bpy), 149.4, 149.3, 149.0, 148.7, 148.5 (q, bpy), 148.1 (bpy), 147.6 (q, 
bpy), 147.5 (bpy), 143.6, 143.0, 142.9, 142.1, 142.1 (bpy), 141.9, 141.8 (q, TRZ), 
141.6 (bpy), 141.5 (q, TRZ), 138.0, 137.5, 137.4 (q, bpy), 135.0, 134.5, 134.4, 134.0, 
133.8, 133.7 (q, Ph), 130.1, 129.7, 129.7, 129.5, 129.5, 129.5, 129.3, 129.1, 129.0, 
128.8, 128.5, 128.4, 128.2 (Ph/TRZ), 127.8, 127.4, 127.3 (bpy), 127.2, 126.5, 126.4 
(Ph), 123.6, 123.2, 123.1, 123.1, 122.7 (bpy), 70.0, 69.9 (CH2-bpy), 69.7 (CHPh), 69.5 
(CHPh), 69.1 (CH2-bpy), 69.0, 68.9 (CH2-CHPh), 67.8 (CHPh), 55.5, 55.3, 55.1 
(PhCH2). 
Elemental Analysis found (Calculated for C87H78Cl4N18O19Zn2·4H2O) % C 51.61 
(51.62), H 4.04 (4.28), N 12.39 (12.45). 
ESI-MS (+) m/z 475.4 [L+H]+, 497.3 [L+Na]+ 










Rc,ΔZn,HHT-[Zn2L8b3][ClO4]4 was synthesised using the procedure described for 
Sc,ɅZn,HHT-[Zn2L
3
3][ClO4]4, substituting 5-(propargyloxy)picolinaldehyde (5) for 4-
((4-formyl-1H-1,2,3-triazol-1-yl)methyl)benzonitrile (39) 
Yield 0.28 g, 83% 
1H NMR (500 MHz, 298 K, CD3CN) δH ppm 9.24 (1H, s, HC=N), 9.21 (1H, s, HC=N), 
9.18 (1H, s, bpy), 9.14 (1H, s, bpy), 8.89 (1H, s, HC=N), 8.68 (1H, s, TRZ), 8.61 (1H, 
s, TRZ), 8.49 (1H, s, bpy), 8.44 (2H, d, 3JHH =8.5 Hz, bpy), 8.42 (2H, d, 
3JHH =8.5 Hz, 
bpy) 8.24-6.98 (37H, m, Ph/bpy/TRZ ), 6.89 (2H, t, 3JHH =7.4 Hz, Ph), 6.75 (2H, t, 
3JHH =7.7 Hz, Ph), 6.56 (2H, t, 
3JHH =7.7 Hz, Ph), 6.12 (2H, d, 
3JHH =7.6 Hz, Ph), 6.00 
(2H, d, 3JHH =7.6 Hz, Ph), 5.72-5.55 (6H, m, CNPhCH2), 5.44 (1H, dd,
 3JHH = 11.3 Hz 
4JHH = 3.2, CHPh), 5.27-5.11 (3H, m, CH2-bpy), 4.90 (1H, d, 
3JHH =9.2 Hz, CHPh), 
4.81 (1H, d, 3JHH =8.2 Hz, CHPh), 4.57-4.45 (3H, m, CH2-bpy), 4.20 (1H, t, JHH =11.2 
Hz, CH2-CHPh), 4.11 (1H, t, JHH =10.8 Hz, CH2-CHPh), 4.06 (1H, t, JHH =10.9 Hz, 
CH2-CHPh), 3.68 (1H, dd,
 2JHH = 10.4 Hz 
3JHH = 3.5, CH2-CHPh), 3.54 (1H, dd,
 2JHH 
= 11.2 Hz 3JHH = 3.0, CH2-CHPh), 3.49 (1H, dd,
 2JHH = 11.3 Hz 
3JHH = 3.4, CH2-CHPh). 
13C {1H} NMR (125 MHz, 298 K, CD3CN) δC ppm 157.2, 156.6, 156.2 (HC=N), 150.4, 
150.3, 149.9 (bpy), 149.3, 149.3, 149.0, 148.6, 148.5 (q, bpy), 148.1, 147.5 (bpy), 
147.5 (q, bpy), 143.6, 143.1, 143.0, 142.1, 142.1 (bpy), 142.0, 142.0 (q, TRZ), 141.6 
(bpy), 141.6 (q, TRZ), 139.6, 138.9, 138.1 (q, CNPh), 137.5, 137.5, 133.9 (q, bpy), 
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133.8, 133.5, 133.3, 133.2 (q, Ph), 129.9, 129.2, 129.0 (CNPh), 128.9, 128.9, 128.7 
(Ph, TRZ), 127.9, 127.7, 127.4 (bpy), 127.3, 126.5, 126.5 (Ph), 123.6, 123.2, 123.1, 
123.0, 122.6 (bpy), 118.6, 118.6, 118.5 (q, CNPh), 113.1, 112.8, 112.7 (CN), 70.0, 
70.0 (CH2-bpy), 69.8, 69.5 (CHPh), 69.0 (CH2-bpy), 69.0, 68.9 (CH2-CHPh), 67.8 
(CHPh), 54.7, 54.5, 54.3 (CNPh-CH2). 
Elemental Analysis found (Calculated for C90H75Cl4N18O19Zn2·8H2O) % C 49.36 
(49.78), H 3.81 (4.22), N 12.36 (13.55). 
ESI-MS (+) m/z 500.3 [L+H]+, 522.3 [L+Na]+ 






Rc,ΔZn,HHT-[Zn2L8c3][ClO4]4 was synthesised using the procedure described for 
Sc,ɅZn,HHT-[Zn2L
3
3][ClO4]4, substituting 5-(propargyloxy)picolinaldehyde (5) for 1-
(4-methoxybenzyl)-1H-1,2,3-triazole-4-carbaldehyde (40) 
Yield 0.30 g, 88% 
1H NMR (500 MHz, 298 K, CD3CN) δH ppm 9.20 (1H, s, HC=N), 9.17 (1H, s, HC=N), 
9.16 (1H, s, bpy), 9.13 (1H, s, HC=N), 8.81 (1H, s, bpy), 8.59-6.85 (55H, m, 
Ph/bpy/TRZ), 6.74 (2H, t, 3JHH =7.7 Hz, Ph), 6.56 (2H, t, 
3JHH =7.7 Hz, Ph), 6.10 (2H, 
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d, 3JHH =7.6 Hz, Ph), 5.97 (2H, d, 
3JHH =7.6 Hz, Ph), 5.58-5.38 (7H, m, PhCH2 
overlapping with CHPh), 5.23-5.02 (3H, m, CH2-bpy), 4.88 (1H, d,
 3JHH = 9.1 Hz 
CHPh), 4.78 (1H, d, 3JHH =7.9 Hz, CHPh), 4.56-4.41 (3H, m, CH2-bpy), 4.18 (1H, t, 
3JHH =11.2 Hz, CH2-CHPh), 4.08 (1H, t, 
3JHH =10.8 Hz, CH2-CHPh), 4.04 (1H, t, 
3JHH 
=10.9 Hz, CH2-CHPh), 3.87 (3H, s, OCH3), 3.85 (3H, s, OCH3), 3.79 (3H, s, OCH3), 
3.66 (1H, dd, 2JHH = 10.4 Hz 
3JHH = 3.5, CH2-CHPh), 3.52 (1H, dd,
 2JHH = 11.1 Hz 
3JHH 
= 3.0, CH2-CHPh), 3.46 (1H, dd,
 2JHH = 11.2 Hz 
3JHH = 3.4, CH2-CHPh). 
13C {1H} NMR (125 MHz, 298 K, CD3CN) δC ppm 160.9, 160.6, 160.5 (q, PhOCH3), 
157.1, 156.6, 156.0 (HC=N), 150.4, 150.2, 149.9 (bpy), 149.4, 149.2, 149.1, 148.7, 
148.5 (q, bpy), 148.1, 148.1 (bpy), 147.6 (q, bpy), 147.5 (bpy), 143.6, 143.0, 142.9, 
142.3, 142.1, 142.0 (bpy), 141.9, 141.7 (q, TRZ), 141.6 (bpy), 141.5 (q, TRZ), 137.9, 
137.5, 137.4 (q, bpy), 135.0, 134.0, 133.8 (q, Ph), 131.2, 130.3, 130.2, 130.1 
(PhOCH3), 129.8, 129.4, 129.2, 129.1, 129.0, 128.9, 128.8, 128.2 (Ph/TRZ), 127.8, 
127.4, 127.3 (bpy), 127.2, 126.5, 126.4 (Ph), 126.3, 126.2, 125.5 (q, PhOCH3), 123.6, 
123.3, 123.1, 123.1, 122.7 (bpy), 114.9, 114.8, 114.7 (PhOCH3), 70.0, 69.9 (CH2-bpy), 
69.7 (CHPh), 69.4 (CHPh), 69.1 (CH2-bpy), 69.0, 68.9, 68.9 (CH2-CHPh), 67.7 
(CHPh), 55.6, 55.5, 55.5 (OCH3), 55.0, 54.9, 54.7 (Anisole-CH2). 
Elemental Analysis found (Calculated for C90H84Cl4N18O22Zn2·8H2O) % C 49.09 
(49.44), H 3.82 (4.61), N 10.87 (11.53). 
ESI-MS (+) m/z 505.3 [L+H]+, 527.3 [L+Na]+ 
IR v cm-1 1604 (w), 1513 (w), 1440 (w), 1249 (w), 1070 (s), 791 (w), 750 (m), 700 
(m), 620 (s). 
  
 






Rc,ΔZn,HHT-[Zn2L8d3][ClO4]4 was synthesised using the procedure described for 
Sc,ɅZn,HHT-[Zn2L
3
3][ClO4]4, substituting 5-(propargyloxy)picolinaldehyde (5) for 1-
(4-fluorobenzyl)-1H-1,2,3-triazole-4-carbaldehyde (38) 
Yield 0.31 g, 92% 
1H NMR (500 MHz, 298 K, CD3CN) δH ppm 9.22 (1H, s, HC=N), 9.18 (1H, s, HC=N), 
9.17 (1H, s, bpy), 9.13 (1H, s, bpy), 8.85 (1H, s, HC=N), 8.68 (1H, s, TRZ), 8.61 (1H, 
s, TRZ), 8.54 (1H, s, bpy), 8.50-6.98 (36H, m, Ph/bpy/TRZ ), 6.89 (1H, t, 3JHH =7.4 
Hz, Ph), 6.74 (2H, t, 3JHH =7.7 Hz, Ph), 6.56 (2H, t, 
3JHH =7.7 Hz, Ph), 6.11 (2H, d, 
3JHH =7.6 Hz, Ph), 5.98 (2H, d, 
3JHH =7.6 Hz, Ph), 5.63-5.40 (7H, m, F-PhCH2 
overlapping with CHPh), 5.26-5.12 (3H, m, CH2-bpy), 4.88 (1H, d, 
3JHH =9.1 Hz, 
CHPh), 4.79 (1H, d, 3JHH =8.1 Hz, CHPh), 4.56-4.43 (3H, m, CH2-bpy), 4.19 (1H, t, 
3JHH =11.2 Hz, CH2-CHPh), 4.10 (1H, t, 
3JHH =10.8 Hz, CH2-CHPh), 4.04 (1H, t, 
3JHH 
=10.9 Hz, CH2-CHPh), 3.67 (1H, dd,
 2JHH = 10.4 Hz 
3JHH = 3.5, CH2-CHPh), 3.53 (1H, 
dd, 2JHH = 11.2 Hz 
3JHH = 3.1, CH2-CHPh), 3.47 (1H, dd,
 2JHH = 11.2 Hz 
3JHH = 3.4, 
CH2-CHPh). 
13C {1H} NMR (125 MHz, 298 K, CD3CN) δC ppm 164.5, 164.2, 164.1, 162.5, 162.3, 
162.2 (q, F-Ph), 157.2, 156.6, 156.1 (HC=N), 150.4, 150.2, 149.9 (bpy), 149.3, 149.3, 
149.0, 148.6, 148.5 (q, bpy), 148.1 (bpy), 147.6 (q, bpy), 147.5 (bpy), 143.6, 143.0, 
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142.9, 142.1, 142.1 (bpy), 141.9, 141.8 (q, TRZ), 141.6 (bpy), 141.5 (q, TRZ), 138.0, 
137.5, 137.4 (q, bpy), 135.0, 134.0, 133.8 (q, Ph), 131.8, 131.8, 130.8, 130.7, 130.7 
(F-Ph), 130.5, 130.5 (q, F-Ph), 130.1 (TRZ), 129.9 (q, F-Ph), 129.7 (TRZ), 129.3, 
129.1, 129.0, 128.9, 128.8 (Ph), 128.5 (TRZ), 127.8, 127.4, 127.3 (bpy), 127.2, 126.5, 
126.4 (Ph), 123.6, 123.2, 123.1, 123.1, 122.6 (bpy), 116.5, 116.3, 116.3, 116.3, 116.2, 
116.1 (F-Ph), 70.0, 70.0 (CH2-bpy), 69.7 (CHPh), 69. 5 (CHPh), 69.1 (CH2-bpy), 69.0, 
68.9 (CH2-CHPh), 67.8 (CHPh), 54.6, 54.5, 54.3 (PhF-CH2). 
Elemental Analysis found (Calculated for C87H75Cl4F3N18O19Zn2·6H2O) % C 49.52 
(49.42), H 3.61 (4.15), N 11.58 (11.92). 
ESI-MS (+) m/z 493.3 [L+H]+, 515.3 [L+Na]+ 
IR v cm-1 1603 (w), 1510 (w), 1475 (w), 1440 (w), 1224 (w), 1071 (s), 841 (m), 791 





Sc,ɅZn,HHT-[Zn2L9a3][ClO4]4 was synthesised using the procedure described for 
Sc,ɅZn,HHT-[Zn2L33][ClO4]4, substituting 5-(propargyloxy)picolinaldehyde (5) for 
(2R,3R,4S,5R,6R)-2-(acetoxymethyl)-6-(4-formyl-1H-1,2,3-triazol-1-yl)tetrahydro-
2H-pyran-3,4,5-triyl triacetate (46) 
Yield: 28 mg, 45%.  
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1H NMR (500 MHz, 298 K, MeCN) δH ppm 9.30 (1H, s, CHN), 9.25 (1H, s, CHN), 
9.19 (1H, s, bpy), 9.12 (1H, s, bpy), 8.85 (1H, s, CHN), 8.84 (1H, s, TRZ), 8.77 (1H, 
s, TRZ), 8.53 (3H, t, 3JHH =10.0 Hz, bpy), 8.45 (1H, s, bpy), 8.25 (3H, t, 
3JHH =7.9 Hz, 
bpy), 8.14-7.94 (9H, m, bpy/TRZ ), 7.87 (2H, d, 3JHH =8.1 Hz, bpy), 7.81 (2H, t, 
3JHH 
=10.0 Hz, bpy), 7.62 (1H, dd, 3JHH = 7.2 Hz, 
4JHH = 5.5, bpy), 7.54 (2H, dd, 
3JHH = 12.6 
Hz, 4JHH = 5.3, bpy), 7.31-7.21 (4H, m, bpy/Ph), 7.05 (1H, t, 
3JHH = 7.4 Hz, Ph), 6.97 
(2H, d, 3JHH = 7.4 Hz, Ph), 6.91 (1H, t, 
3JHH = 7.5 Hz, Ph), 6.74 (2H, t, 
3JHH = 7.7 Hz, 
Ph), 6.57 (2H, t, 3JHH = 7.7 Hz, Ph), 6.11 (2H, d, 
3JHH = 7.6 Hz, Ph), 6.02-5.95 (4H, m, 
Ph overlapping with Hglu), 5.89 (1H, d, 
3JHH = 8.7 Hz, Hglu), 5.58 (1H, t, 
3JHH = 9.6 Hz, 
Hglu), 5.50 (1H, t, 
3JHH = 9.6 Hz, Hglu), 5.45-5.11 (12H, m, Hglu overlapping with CHPh/ 
OCH2-bpy), 4.92 (1H, d, 
3JHH = 11.2 Hz, CHPh), 4.80 (1H, d, 
3JHH = 8.5 Hz, CHPh), 
4.57-4.44 (4H, m, Hglu overlapping with OCH2-bpy), 4.36-4.31 (2H, m, Hglu), 4.26-
4.17 (6H, m, CH2-CHPh overlapping with Hglu), 4.15-4.05 (5H, m, CH2-CHPh 
overlapping with Hglu), 3.73 (1H, dd,
 2JHH = 10.4 Hz 
3JHH = 3.4, CH2-CHPh), 3.53 (1H, 
dd, 2JHH = 11.2 Hz 
3JHH = 2.8, CH2-CHPh), 3.48 (1H, dd,
 2JHH = 11.2 Hz 
3JHH = 3.2, 
CH2-CHPh), 2.16-1.50 (36H, m, 12 × COCH3). 
13C {1H} NMR (126 MHz, 298 K, CD3CN) δC ppm 170.8, 170.6, 170.6, 170.2, 170.1, 
170.1, 167.0, 169.9, 169.5, 168.5 (12 × CO), 157.3, 156.6, 156.0 (CHN), 150.5, 150.4, 
149.9 (bpy), 149.4, 149.3, 149.0, 148.7, 148.6 (q, bpy), 148.0 (bpy), 147.8 (q, bpy), 
147.7, 146.6, 143.7, 143.2, 143.2, 142.2 (bpy), 142.0, 141.9 (q, TRZ), 141.7 (bpy), 
141.3 (q, TRZ), 138.0, 137.5 (q, bpy), 134.5, 133.7, 133.6 (q, Ph), 129.4, 129.3, 129.2, 
129.1, 128.9 (Ph/TRZ), 127.8, 127.5, 127.3 (bpy), 127.0, 126.5, 126.4 (Ph), 123.8, 
123.5, 123.5, 123.4, 123.2, 123.0 (bpy), 86.7, 86.4, 85.9 (C1Glu), 75.3, 75.3, 75.2 
(C5Glu), 72.3, 72.1, 71.8 (C3Glu), 71.6, 71.0, 70.1 (C2Glu), 70.0, 70.0 (CH2-bpy), 69.7, 
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69.7 (CHPh), 69.1, 68.9, 68.7 (CH2-CHPh), 68.2 (CHPh), 67.7, 67.6, 67.6 (C4Glu), 62.2, 
61.7, 61.6 (C6Glu), 20.5, 20.3, 20.3, 20.2, 20.2, 20.1, 19.7 (12 × CH3). 
MS (ESI) m/z 715.4 [L + H]+ 
IR v cm-1 1745 s, 1369 m, 1221 s, 1064 m, 925 w, 752 s 
Elemental Analysis found (Calculated for C108H114Cl4N18O46Zn2·6H2O) % C 46.60 





Sc,ɅZn,HHT-[Zn2L9b3][ClO4]4 was synthesised using the procedure described for 
Sc,ɅZn,HHT-[Zn2L33][ClO4]4, substituting 5-(propargyloxy)picolinaldehyde (5) for 
(2R,3S,4S,5R,6R)-2-(acetoxymethyl)-6-(4-formyl-1H-1,2,3-triazol-1-yl)tetrahydro-
2H-pyran-3,4,5-triyl triacetate (47) 
Yield: 45 mg, 54 %.  
1H NMR (500 MHz, 298 K, CD3CN) δH ppm 9.33 (1H, s, HC=N), 9.27 (1H, s, HC=N), 
9.23 (1H, s, bpy), 9.16 (1H, s, bpy), 8.91 (1H, s, TRZ), 8.87 (1H, s, TRZ), 8.83 (1H, 
s, HC=N), 8.56 (2H, m, bpy), 8.41 (1H, s, bpy), 8.27 (3H, m, bpy), 8.11 (2H, d, 3JHH 
= 8.5 Hz, bpy), 8.06 (2H, m, bpy), 7.99 (3H, m, bpy), 7.84 (3H, dd, 2JHH = 12.0, 
3JHH 
= 7.5 Hz, bpy), 7.63 (1H, m, bpy), 7.55 (2H, m, bpy), 7.36 (1H, t, 3JHH = 7.5 Hz, Ph), 
7.28 (2H, t, 3JHH = 7.5 Hz, Ph), 7.06 (1H, t, 
3JHH = 7.5 Hz, Ph), 7.01 (2H, d, 
3JHH = 7.5 
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Hz, Ph), 6.94 (1H, t, 3JHH = 7.5 Hz, Ph), 6.74 (2H, t, 
3JHH = 7.5, Ph), 6.59 (2H, t, 
3JHH 
= 7.5 Hz, Ph), 6.11 (2H, d, 3JHH = 7.5 Hz, Ph), 6.03 (1H, d, 
3JHH = 9.0 Hz, Hgal), 5.98 
(2H, d, 3JHH = 7.5 Hz, Ph), 5.91 (2H, m, Hgal), 5.61 (2H, m, Hgal), 5.52 (1H, d, 
3JHH = 
3.0 Hz, Hgal), 5.46 (3H, m, Hglu overlapping with CHPh), 5.36 (2H, m, Hgal), 5.22 (4H, 
m, Hglu overlapping with CH2-bpy), 4.92 (1H, d, 
3JHH = 9.5 Hz, CHPh), 4.77 (1H, d, 
3JHH = 8.5 Hz, CHPh), 4.63-4.29 (8H, m, Hglu overlapping with CH2-bpy), 4.25 (1H, 
t, 3JHH = 11.0 Hz, CH2-CHPh), 4.18-4.06 (6H, m, Hglu overlapping with CH2-CHPh), 
3.76 (1H, dd, 2JHH = 10.0 Hz, 
3JHH = 3.0 Hz, CH2-CHPh), 3.56 (1H, dd, 
2JHH = 11.0 
Hz, 3JHH = 3.0 Hz, CH2-CHPh), 3.49 (1H, dd, 
2JHH = 11.0 Hz, 
3JHH = 3.0 Hz, CH2-
CHPh), 2.19-1.78 (36H, s, 12 x CH3) 
13C NMR (125 MHz, 298 K, CD3CN) δc ppm 170.6, 170.5, 170.4, 170.0, 169.9, 169.8, 
169.5, 168.9 (12 x C=O), 157.3, 156.6, 156.2 (HC=N), 150.7, 150.3, 149.8 (bpy), 
149.4, 149.3, 148.9, 148.7, 145.5 (q, bpy), 148.2, 147.6 (bpy), 147.4 (q, bpy), 143.6, 
143.4, 142.3, 142.1, 141.9 (bpy), 140.8 (q, TRZ), 137.9, 137.5 (q, bpy), 134.6, 133.8, 
133.6 (q, Ph), 129.5, 129.4, 129.3, 129.1, 129.0 (Ph/TRZ), 127.9, 127.7, 127.5 (bpy), 
127.1, 126.5, 126.4 (Ph), 123.7, 123.6, 123.5, 123.3, 123.1, 122.9 (bpy), 86.8, 86.7, 
86.5 (C1Gal), 74.9, 74.7, 74.6 (C5Gal), 70.8, 70.6, 70.4 (C3Gal), 70.0 (CH2-bpy), 69.9, 
69.7 (CHPh), 69.2 (CH2-bpy), 69.1, 68.9, 68.8 (CH2-CHPh), 68.7, 68.53, 68.49 (C2Gal) 
68.1 (CHPh), 67.6, 67.3, 67.3, (C4Gal), 62.1, 61.7, 61.6 (C6Gal), 20.4, 20.3, 20.2, 20.1, 
20.0, 19.9 (12 x CH3) 
IR v cm-1 1742 s, 1440 w, 1367 m, 1214 s, 1041 s, 922 m, 621 s 
MS (ESI) m/z 715.4 [L + H]+ 
Elemental analysis found (Calculated for C108H114N18O46Cl4Zn2).4H2O % C 47.27 
(47.26) H 5.29 (4.48) N 9.19 (9.19) 
 








3][ClO4]4 was synthesised using the procedure described for 
Sc,ɅZn,HHT-[Zn2L33][ClO4]4, substituting 5-(propargyloxy)picolinaldehyde (5) for 
(2R,3S,4R,5R,6R)-5-acetamido-2-(acetoxymethyl)-6-(4-formyl-1H-1,2,3-triazol-1-
yl)tetrahydro-2H-pyran-3,4-diyl diacetate (48) 
Yield: 86 mg, 85%.  
1H NMR (500 MHz, 298 K, CD3CN) δH ppm 9.31 (1H, s, HC=N), 9.25 (1H, s, HC=N), 
9.22 (1H, s, bpy), 9.15 (1H, s, bpy), 8.83 (1H, s, TRZ), 8.80 (1H, s, HC=N), 8.78 (1H, 
s, TRZ), 8.53 (2H, dd, 3JHH = 8.0, 5.0 Hz, bpy), 8.40 (1H, s, bpy), 8.26 (2H, m, bpy), 
8.16-7.96 (6H, m, bpy/TRZ), 7.93 (1H, d , 3JHH = 8.0 Hz, bpy), 7.87-7.78 (3H ,m, bpy), 
7.63 (1H, m, bpy), 7.58-7.45 (2H, m, bpy), 7.32 (1H, t, 3JHH = 7.5 Hz, Ph), 7.25 (2H, 
t, 3JHH = 7.5 Hz, Ph), 7.04 (1H, t, 
3JHH = 7.5 Hz, Ph), 6.96 (2H, d, 
3JHH = 7.5 Hz, Ph), 
6.92 (1H, t, 3JHH = 7.5 Hz, Ph), 6.72 (2H, m, Ph/NH), 6.57 (1H, t, 
3JHH = 7.5 Hz, Ph), 
6.52 (1H, d, 3JHH = 9.0 Hz, NH), 6.44 (1H, d, 
3JHH = 9.0 Hz, NH), 6.13-6.04 (4H, m, 
Ph/HGlcNAc), 6.00-5.91 (3H, m, Ph/HGlcNAc), 5.49-5.12 (10H, m, HGlcNAc overlapping 
with CHPh/ CH2-bpy), 4.91 (1H, d, 
3JHH = 9.0 Hz, CHPh ), 4.77 (1H, d,
 3JHH = 9.0 Hz, 
CHPh), 4.68-4.36 (6H, m, HGlcNAc overlapping with CH2-bpy), 4.29-4.02 (13H, m, 
HGlcNAc overlapping with CH2-CHPh), 3.74 (1H, dd, 
2JHH = 11.0 Hz, 
3JHH = 3.0 Hz, 
CH2-CHPh), 3.55, (1H, dd, 
2JHH = 11.0 Hz, 
3JHH = 3.0 Hz, CH2-CHPh), 3.47 (1H, dd, 
2JHH = 11.0 Hz, 
3JHH = 3.0, Hz, CH2-CHPh), 2.20-1.78 (36H, s, 12x CH3) 
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13C NMR (125 MHz, 298 K, CD3CN) δc ppm 170.7, 170.6, 170.5, 170.4, 170.3, 170.0 
(12 x C=O), 157.3, 156.7, 156.1 (HC=N), 150.7, 150.3, 147.7 (bpy), 149.4, 149.3, 
148.9, 148.7, 148.4 (q, bpy), 148.2 (bpy), 147.4 (q, bpy), 143.6, 143.4, 142.3, 142.0, 
141.7 (bpy), 141.6, 141.4, 140.5 (q, TRZ), 137.9, 137.5 (q, bpy), 134.5, 133.9, 133.7 
(q, Ph), 129.5, 129.1, 128.9 (Ph/TRZ), 128.0, 127.7, 127.5 (bpy), 127.0, 126.5, 126.4 
(Ph), 123.6, 123.4, 123.3, 123.1, 123.0, 122.8 (bpy), 87.1, 86.9, 86.6 (C1GlcNAc), 75.4, 
75.2, 75.1 (C5GlcNAc), 72.4, 71.7, 71.4 (C4GlcNAc), 70.0 (CH2-bpy), 69.8, 69.6 (CHPh), 
69.1 (CH2-bpy), 69.0, 68.9, 68.8 (CH2-CHPh), 68.4, 68.2, 68.1 (C3GlcNAc), 62.2, 61.8 
(C6GlcNAc), 54.0, 53.2 (C2GlcNAc), 22.4, 22.3, 22.0, 20.4, 20.3, 20.2 (12 x CH3) 
IR v cm-1 1741 s, 1367 m, 1224 s, 1038 s, 925 w, 621 s 
MS (ESI) m/z 714.4 [L + H]+ 
Elemental analysis found (Calculated for C108H117N21O43Cl4Zn2·10H2O) % C 45.68 
(45.52) H 4.77 (4.85) N 10.04 (10.32) 
Rc,ΔFe,-[Fe2L13]Cl4· 
 
5- (Prop-2-yn-1-yloxy)picolinaldehyde (0.14 g, 0.85 mmol, 6.0 eq.) and (R,R)-bis(4-
{[2-amino-2-phenylethoxy]methyl}phenyl)ether (0.2 g, 0.43 mmol, 3.0 eq.) were 
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dissolved in methanol followed by addition of anhydrous FeCl2 (0.036 g, 0.29 mmol, 
2 eq.). The solution was heated at reflux for 48 h. The dark purple solid was isolated 
under reduced pressure. 
Yield = 0.3 g, 78%. 
1H NMR (500 MHz, 298 K, CD3OD) δH 9.24 (6H, s, HC=N), 7.54 (6H, d, 
3JHH =9.0 
Hz, py), 7.46 (12H, d, 3JHH =8.5 Hz, OPh), 7.37 (6H, d, 
3JHH = 8.0 Hz, py), 7.12 (6H, 
t, 3JHH = 7.0 Hz Ph), 7.04 (12H, t, 
3JHH = 7.5 Hz, Ph), 6.79 (12H, d, 
3JHH =7.0 Hz, Ph), 
6.71 (12H, d, 3JHH = 8.0 Hz, OPh), 6.48 (6H, s, py), 5.93 (6H, d, 
3JHH = 10.0 Hz, CHPh), 
5.02 (6H, d, 2JHH = 12.0 Hz, OCH2Ph), 4.73 (12H, d, 
4JHH = 3.5 Hz, CH2C≡C), 4.50 
(6H, t, 3JHH = 11.0 Hz, CH2-CHPh), 4.42 (6H, d, 
2JHH = 12.0 Hz, OCH2Ph), 3.26 (6H, 
d, 3JHH = 9.0 Hz, CH2-CHPh), 3.22 (6H, s, CH),  
13C{1H} NMR (125 MHz, 298K, CD3OD) δC ppm 169.9 (HC=N), 157.0 (q, OPh), 
155.8 (q, py), 152.5 (q, py), 141.2 (py), 135.4 (q, Ph), 132.82 (q, OPh), 129.8 (py), 
128.8 (Ph), 128.7(OPh), 128.2/ 125.7 (Ph), 123.8 (py), 118.5 (OPh), 78.1 (C≡CH),76.6 
(q, C≡CH), 72.7 (OCH2Ph), 72.3 (OCH2CH), 70.9 (OCH2CH), 55.9 (CH2C≡CH). 
Elemental analysis found (calculated for C144H126Cl4Fe2N12O15·9H2O) % C 64.74 
(64.53), H 4.81 (5.42), N 6.05 (6.27) 
  
 




(S)-1-phenyl-2-(prop-2-ynyloxy)ethanamine (8) (0.1 g, 0.57 mmol) and (E)-5,5'-(but-
2-ene-1,4-diylbis(oxy))dipicolinaldehyde (9) (85 mg, 0.29 mmol) were dissolved in 
methanol followed by the addition of FeCl2 (23.9 mg, 0.19 mmol). After reflux for 48 
h, the solution was filted through celite and the solvent was removed under reduced 
pressure to obtain the dark purple compound. 
Yield 0.17 g, 82% 
1H NMR (500 MHz, 298 K, CD3OD) δH ppm 9.03 (6H, s, CHN), 7.53-7.30 (14H, m), 
7.23-7.01 (18H, m), 6.87 (10H, d, 3JHH = 7.4 Hz), 6.50 (6H, s), 6.03 (6H, s), 5.87 (6H, 
d, 3JHH =9.2 Hz), 4.74-4.42 (30H, m), 3.72 (6H, d, 
3JHH =9.1 Hz), 3.17 (6H, s, CH).
  
13C {1H} NMR (125 MHz, 298 K, CD3OD) δC ppm 170.2 (CHN), 157.1, 151.6, 143.5, 
135.3, 130.0, 129.2, 128.9, 128.8, 128.5 (CHCH), 128.1. 127.0, 125.8, 120.0 (Ar), 
78.9, 76.1 (CCH), 71.0 (CHCH2), 69.7 (CHCH2), 68.7 (OCH2CHCH), 58.2 
(CH2CCH). 
HRMS Calculated for [Fe2L
2
3]
4+ m/z 487.1724, found m/z 487.1722 
Elemental Analysis found (Calculated for C114H108Cl4Fe2N12O12·14H2O) % C 58.32 
(58.42), H 4.69 (5.85), N 7.12 (7.17). 
Rc,ΔFe,-[Fe2L23]Cl4· 
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Yield 0.18 g, 85% 
HRMS Calculated for [Fe2L
2
3]
4+ m/z 487.1724, found m/z 487.1724 
Elemental Analysis found (Calculated for C114H108Cl4Fe2N12O12·13H2O) % C 58.94 




FeCl2 (0.10 g, 0.82 mmol) was added to a stirred solution of the 5-
(propargyloxy)picolinaldehyde (2) (0.20 g, 1.24 mmol) and (S)-2-(2,2'-bipyridin-5-
ylmethoxy)-1-phenylethanamine (14) (0.38 g, 1.24 mmol) in methanol (50 ml) at 
ambient temperature to give a purple solution that was then refluxed for 48 h. The 
reaction was cooled to room temperature, filtered through a Celite plug prior to the 
solvents being removed in vaccuo to yield the desired product as a purple solid. 
 
Yield 0.61 g, 90%. 
1 H NMR (500 MHz, 298 K, D2O) δH 9.57 (1H, s, HC=N), 9.48 (1H, s, HC=N), 9.16 
(1H, s, bpy),9.15 (1H, s, bpy), 9.06 (1H, s, HC=N), 8.44 (2H, d, 3JHH = 10.0 Hz, bpy), 
8.37 (1H, d, 3JHH = 10.0 Hz, py), 8.25 (1H, d, 
3JHH = 10.0 Hz, py), 8.04-7.98 (2H, m, 
bpy), 7.89 (1H, d, 3JHH = 5.0 Hz, bpy), 7.86-7.62 (9H, m, Ph/bpy/py), 7.54 (1H, s, bpy), 
7.50 (1H, d, 3JHH = 10.0 Hz, py), 7.35-6.84 (15H, m, Ph/py/bpy), 6.65 (2H, t, 
3JHH=7.5, 
Ph), 6.54 (2H, t,3JHH =7.5 Hz, Ph), 6.41(1H, d, 
4JHH=0.4 Hz, py), 5.77 (2H, s, Ph), 5.32 
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(1H, dd, 2JHH = 11.0Hz,
3JHH = 3.5, CHPh), 5.21 (1H, d, 
2JHH= 15.0 Hz, OCH2-bpy), 
5.19 (1H, d, 2JHH= 15.0 Hz, OCH2-bpy), 4.96 (2H, d, 
2JHH= 15.0 Hz, OCH2-bpy), 4.73-
4.60 (4H, m, CH2-CCH overlapping with D2O), 4.55-4.51 (4H, m, CH2-CCH/CHPh), 
4.45-4.38 (3H, m, OCH2-bpy/CH2-CHPh), 4.45-4.38 (2H, m, OCH2-bpy/ CH2-CHPh), 
4.21 (1H, t, 3JHH =10.0 Hz, CH2-CHPh), 3.54 (1H, dd, 
2JHH = 10.5 Hz, 
3JHH = 3.5 Hz, 
CH2-CHPh), 3.35 (1H, dd, 
2JHH = 10.5 Hz, 
3JHH = 3.5 Hz, CH2-CHPh), 3.25 (1H, dd, 
2JHH = 10.5 Hz, 
3JHH = 3.5 Hz, CH2-CHPh), 3.05 (1H, s, CH), 2.84 (1H, s, CH), 2.79 
(1H, s, CH). 
13C {1H} NMR (125 MHz, 298 K, D2O) δC 170.4/ 170.0/ 169.5 (HC=N), 159.7/ 158.9/ 
158.6/ 158.3/ 157.9/ 157.8 (q, bpy)/ 157.5/ 157.4 (bpy), 156.0/ 155.9/ 155.6 (q, py), 
154.5/ 153.8/ 153.4/ 153.3 (bpy), 152.3/ 152.0/ 151.8 (q, py), 142.6/ 141.8/ 141.7 (py), 
140.0/ 139.7/ 139.6/ 138.9/ 138.6/ 138.6 (bpy), 136.9/ 136.7/ 136.3 (q, bpy), 134.1/ 
132.5/ 132.2 (q, Ph), 131.1/ 130.7/ 130.2 (py), 129.1/ 129.0/ 128.9/ 128.8/ 128.7/ 128.6 
(Ph), 127.3/ 127.2/ 127.1 (bpy), 124.3 (py), 123. 9/ 123.8/ 123.7/ 123.6/ 123.5 (py/bpy), 
122.7/ 122.5/ 121.9 (bpy), 78.4/ 78.3/ 78.2 (C≡CH), 77.0/ 76.8/ 76.7 (q, C≡CH), 72.6/ 
72.5/ 70.4 (CHPh), 69.2/ 69.1/ 68.7 (CH2-bpy), 68.5/ 68.4/ 67.9 (CH2-CHPh), 56.5/ 
56.4 (CH2-C≡CH). 
HRMS Calculated for [Fe2L
3
3]
4+ m/z 364.1095, found m/z 364.1103  
IR v cm-1 3366 (br, m), 1606 (m), 1590 (m), 1557 (s), 1467 (m), 1403 (w), 1363 (m), 
1277 (m), 1227 (s), 1109 (m), 1074 (s), 1002 (s), 933 (m), 842 (m), 791 (m), 754 (m), 
697 (s).  
Elemental Analysis found (Calculated for C84H72Cl4Fe2N12O6·11H2O) % C 56.41 
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HRMS Calculated for [Fe2L
3
3]
4+ m/z 364.1095, found m/z 364.1098 
IR v cm-1 3370 (br, m), 1606 (m), 1591 (m), 1556 (s), 1493 (m), 1468 (m), 1404 (w), 
1364 (w), 1276 (m), 1227 (s), 1109 (w), 1074 (s), 1002 (s), 932 (m), 841 (m), 791 (m), 
755 (m), 697 (s). 
Elemental Analysis found (Calculated for C84H72Cl4Fe2N12O6·11H2O) % C 56.31 
(56.14), H 4.67 (5.27), N 9.28 (9.35). 
General synthesis of clicked HHT-[Fe2L
4a-e; 7a-i]Cl4  
The azide (4.5 eq.) and [Fe2L
3
3]Cl4 (1 eq.) was dissolved in methanol (20 ml), followed 
by the addition of copper (I) iodide (1 eq.). The solution was stirred under partial 
vacuum and heated at 65 ̊ C overnight. The solution was filtered to remove copper salt. 
The resulting purple solution yielded the desired product as a purple solid on the 




Yield 0.19 g, 82%. 
13C {1H} NMR (125 MHz, 298K, CD3OD) δC 171.2/ 171.1/ 170.3 (HC=N), 159.8/ 
159.2/ 158.9/ 158.8/ 158.3/ 158.2 (q, bpy), 157.54 (bpy), 157.51 (q, py), 157.4 (bpy), 
157.3/ 156.8 (q, py), 155.0 (bpy), 154.1/ 153.5/ 152.9 (py), 151.9/ 151.7/ 151.6 (q, py), 
143.2/ 142.6/ 142.2 (py), 134.0/ 139.9/ 139.7/ 138.8/ 138.5/ 138.2 (bpy), 137.3/ 137.0/ 
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136.9 (q, bpy), 135.3/ 135.2/ 135.1 (q, PhCH2), 134.4/ 132.9/ 132.6 (q, Ph), 131.7/ 
131.4/ 130.3 (py), 129.8/ 128.9/ 128.8/ 128.7/ 128.6/ 128.5/ 128.4/ 128.3/ 128.2/ 
128.1/ 128.0/ 127.8/ 127.7 (Ph), 127.5/ 127.4/ 127.3/ 127.1 (bpy), 125.5/ 125.0/ 124.7 
(TRZ), 124.3/ 124.1/ 123.6 (py), 123.4/ 123.1 122.8/ 122. 6/ 122.1 (bpy), 72.4/ 72.3/ 
70.3 (CHPh), 69.3/ 69.2/ 69.0 (CH2-bpy), 68.9/ 68.6/ 68.4 (CH2-CHPh), 61.8/ 61.5/ 
61.4 (TRZCH2O), 53.7/ 53.6/ 53.5 (Ph-CH2-TRZ). 
HRMS Calculated for [Fe2Ln]
4+ m/z 463.9076, found m/z 463.9073 
IR v cm-1 3381 (br, s), 3031 (br, s), 1603 (m), 1556 (s), 1495 (m), 1468 (s), 1403 (m), 
1361 (m), 1301 (m), 1220 (s), 1076 (s), 984 (m), 937 (m), 840 (w), 791 (w), 755 (w), 
723 (w), 696 (m), 536 (w), 451 (m). 
Elemental Analysis found (Calculated for C105H93Cl4Fe2N21O6·19H2O) % C 53.90 




Yield 0.18 g, 79%. 
HRMS Calculated for [Fe2Ln]
4+ m/z 463.9076, found m/z 463.9073 
IR v cm-1 3356 (br, s), 1604 (m), 1556 (s), 1468 (s), 1221 (s), 1111 (w), 1076 (s), 985 
(m), 936 (w), 840 (w), 791 (w), 754 (w), 726 (w), 697 (m).  
Elemental Analysis found (Calculated for C105H93Cl4Fe2N21O6·22H2O) % C 52.65 
(52.66), H 4.25 (5.77), N 12.18 (12.28). 
 





Yield 0.23 g, 75%. 
13C {1H} NMR (125 MHz, 298K, CD3OD) δC 171.4/ 171.3/ 170.5 (HC=N), 163.8/ 
163.7/ 161.8/ 161.8 (q, F-Ph), 159.8/ 159.2/ 158.9/ 158.8/ 158.3/ 158.2 (q, bpy), 157.6 
(bpy), 157.5 (q, py), 157.5 (bpy), 157.3/ 156.7 (q, py), 155.0 (bpy), 154.1/ 153.6/ 152.9 
(py), 151.9/ 151.7/ 151.6 (q, py), 143.3/ 142.7/ 142.3 (py), 140.0/ 139.9/ 139.8/ 138.9/ 
138.5/ 138.3 (bpy), 1374/ 137.1/ 136.9 (q, bpy), 134.4/ 132.9/ 132.6 (q, Ph), 131.8/ 
131.6 (py), 131.4/ 131.3/ 131.2 (q, F-Ph), 130.5/ 130.4/ 130.2/ 130.1/ 130.0 (F-Ph), 
128.9/ 128.7/ 128.6/ 128.5 (Ph), 128.2/ 127.5/ 127.1 (bpy), 125.5/ 125.0/ 124.8 (TRZ), 
124.3/ 124.0/ 123.6/ 123.5 (py/ bpy), 122.9/ 122.7/ 122.6/ 122.2 (bpy), 115.6, 115./ 
115.4/ 115.3 (F-Ph), 72.4/ 72.3/ 70.3 (CHPh), 69.6/ 69.5/ 69.0 (CH2-bpy), 68.9/ 68.7/ 
68.5 (CH2-CHPh), 61.8/ 61.6/ 61.5 (TRZCH2O), 52.9/ 52.8/ 52.8 (F-Ph-CH2-TRZ). 
 HRMS Calculated for [Fe2Ln]
4+ m/z 477.4004, found m/z 477.4004 
IR v cm-1 3348 (br, m), 1603 (w), 1556 (s), 1509 (m), 1468 (m), 1218 (s), 1075 (s), 
983 (m), 936 (m), 841 (m), 788 (m), 754 (m), 698 (s), 530 (s), 489 (s), 418 (s). 
Elemental Analysis found (Calculated for C105H90Cl4F3Fe2N21O6·19H2O) % C 52.75 
(52.66), H 3.96 (5.39), N 12.17 (12.28). 
 





Yield 0.25 g, 82%. 
HRMS Calculated for [Fe2Ln]
4+ m/z 477.4005, found m/z 477.4003 
IR v cm-1 3363 (br, m), 1603 (w), 1556 (s), 1510 (m), 1468 (m), 1218 (s), 1076 (s), 
984 (m), 936 (m), 839 (m), 788 (m), 754 (m), 697 (s), 533 (s), 421 (s). 
Elemental Analysis found (Calculated for C105H90Cl4F3Fe2N21O6·17H2O) % C 53.58 




Yield 0.26 g, 84%. 
13C {1H} NMR (125 MHz, 298K, CD3OD) δC 171.3/ 171.2/ 170.4 (HC=N), 159.8/ 
159.2/ 158.9/ 158.8/ 158.3/ 158.2 (q, bpy), 157.6 (bpy), 157.5 (q, py), 157.4 (bpy), 
157.3/ 156.7 (q, py), 155.0 (bpy), 154.1/ 153.6/ 152.9 (py), 152.0, 151.7/ 151.6 (q, py), 
143.3/ 142.6/ 142.3 (py), 140.7/ 140.6 (q, CN-Ph), 140.0/ 139.9/ 139.8/ 138.9/ 138.5/ 
138.3 (bpy), 137.4/ 137.1/ 136.9 (q, bpy), 134.4/ 132.9 (q, Ph), 132.6 (CN-Ph), 132.6 
(q, Ph), 132.5/ 132.5 (CN-Ph), 131.8/ 131.6/ 130.4 (py), 129.1/ 129.0/ 128.9/ 128.7/ 
128.7/ 128.6/ 128.5/ 128.4/ 128.3/ 128.2/ 128.1 (Ph), 127.5/ 127.1 (bpy), 125.5/ 125.2/ 
125.1 (TRZ), 124.3/ 124.1/ 123.6/ 123.5 (py/ bpy), 122.9/ 122.6/ 122.2 (bpy), 117.9/ 
117.86/ 117.84 (CN), 112.1/ 112.0 (q, CN-Ph), 72.4/ 72.36/ 70.32 (CHPh), 69.5/ 69.3/ 
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69.0 (CH2-bpy), 68.9/ 68.7/ 68.4 (CH2-CHPh), 61.7/ 61.6/ 61.4 (TRZCH2O), 53.0/ 
52.8/ 52.7 (CN-Ph-CH2-TRZ). 
HRMS Calculated for [Fe2Ln]
4+ m/z 482.6541, found m/z 482.6539 
Elemental Analysis found (Calculated for C108H90Cl4Fe2N24O6·17H2O) % C 54.85 
(54.51), H 4.15 (5.25), N 14.00 (14.13). 
IR v cm-1 3356 (br, s), 2226 (m), 1606 (m), 1556 (s), 1468 (s), 1221 (s), 1111 (w), 




Yield 0.25 g, 80%. 
HRMS Calculated for [Fe2Ln]
4+ m/z 482.6541, found m/z 482.6526  
IR v cm-1 3348 (br, s), 2227 (S), 1605 (S), 1557 (s), 1468 (s), 1220 (s), 1112 (w), 
1076 (s), 985 (m), 937 (w), 840 (w), 789 (m), 754 (m), 697 (m), 545 (M). 
Elemental Analysis found (Calculated for C108H90Cl4Fe2N24O6·20H2O) % C 53.36 





Yield 0.18 g, 88%. 
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13C {1H} NMR (125 MHz, 298K, CD3OD) δC 171.4/ 171.3/ 170.5 (HC=N), 160.0 (q, 
PhOCH3), 159.9/ 159.2/ 158.9/ 158.8/ 158.7/ 158.3/ 158.2 (q, bpy), 157.6 (bpy), 157.5 
(q, bpy), 157.4 (bpy), 157.3/ 157.2/ 156.7/ 156.6 (q, py), 155.0 (bpy), 154.1/ 153.6/ 
152.9 (py), 152.0/ 151.7/ 151.6 (q, py) 143.2/ 142.5/ 142.3 (py) 139.9/ 139.8/ 139.3/ 
138.9/ 138.5/ 138.3 (bpy), 137.4/ 137.1/ 136.9 (q, bpy), 134.4/ 132.9/ 132.6 (q, Ph), 
131.78/ 131.6/ 130.4 (py), 128.9/ 129.8/ 129.7/ 129.6/ 129.5/ 129.4 (PhOCH3), 129.1/ 
128.9/ 128.7/ 128.6/ 128.5/ 128.2/ 127.5 (Ph), 127.2/ 127.1/ 127.0 (q, PhOCH3), 125.5/ 
124.8/ 124.4 (TRZ), 124.3/ 124.2/ 123.6 (py), 123.5/ 123.4/ 123.0/ 122.7/ 122.6/ 122.2 
(bpy), 114.1/ 114.0/ 113. 9/ 113.8 (PhOCH3), 72.4/ 72.4/ 70.3 (CHPh), 69.5/ 69.4/ 
69.0 (CH2-bpy), 69.0/ 68.7/ 68.5 (CH2-CHPh), 61.9/ 61.6/ 61.5 (TRZCH2O), 54.5 
(OCH3), 53.3/ 53.2/ 53.1 (CH3OPh-CH2-TRZ). 
HRMS Calculated for [Fe2Ln]
4+ m/z 486.4155, found m/z 486.4154 
IR v cm-1 3361 (br, s), 1607 (m), 1556 (s), 1512 (s), 1467 (s), 1302 (m), 1241 (s), 1178 
(m), 1076 (s), 1025 (m), 937 (w), 839 (w), 788 (m), 755 (m), 698 (m). 
Elemental Analysis found (Calculated for C108H99Cl4Fe2N21O9·22H2O) % C 52.18 




Yield 0.17 g, 85%. 
HRMS Calculated for [Fe2Ln]
4+ m/z 486.4155, found m/z 486.4150 
IR v cm-1 3362 (br, s), 1607 (m), 1557 (s), 1513 (s), 1467 (s), 1302 (m), 1242 (s), 1177 
(m), 1076 (s), 1025 (m), 937 (w), 840 (w), 788 (m), 755 (m), 698 (m). 
Elemental Analysis found (Calculated for C108H99Cl4Fe2N21O9·21H2O) % C 52.83 
(52.58), H 4.46 (5.76), N 11.68 (11.92). 
 





Yield 0.26 g, 77%. 
13C {1H} NMR (125 MHz, 298K, CD3OD) δC 171.3/ 170.4 (HC=N), 159.8/ 159.2/ 
158.8/ 158.3/ 158.2 (q, bpy), 157.5 (bpy), 157.46 (q, py), 157.4 (bpy), 157.2/ 156.7 (q, 
py), 155.0 (bpy), 154.1/ 153.5/ 152.9 (py), 152.0/ 151.7/ 151.5 (q, py), 143.3/ 142.3/ 
142.1 (py), 140.1/ 140.0 (q, PhCOOH), 139.9/ 139.7/ 138.9/ 138.5/ 138.3 (bpy), 137.4/ 
137.0/ 136.9 (q, bpy), 134.3/ 132.9/ 132.6 (q, Ph), 131.7/ 130.3 (py), 128.9/ 128.7/ 
128.6 128.5/ 128.1/ 128.0/ 127.5/ 127.1 (Ph), 125.5/ 125.1 (TRZ), 124.6/ 124.3/ 123.6 
(py), 123.5/ 123.1/ 122.8/ 122.6/ 122.1 (bpy), 72.4/ 72.3/ 70.3 (CHPh), 69.3/ 69.0 
(CH2-bpy), 68.9/ 68.6/ 68.4 (CH2-CHPh), 61.8/ 61.6/ 61.4 (TRZCH2O), 53.2/ 53.1/ 
53.0 (COOHPh-CH2-TRZ) 
HRMS Calculated for [Fe2Ln]
4+ m/z 496.9000, found m/z 496.9020 
IR v cm-1 3360 (br, w), 1699 (m), 1606 (m), 1556 (s), 1467 (m), 1373 (m), 1220 (s), 
1178 (m), 1110 (m), 1076 (s), 1053 (m), 984 (m), 936 (m), 839 (m), 750 (s), 731 (s), 
697 (s). 
Elemental Analysis found (Calculated for C108H93Cl4Fe2N21O12·16H2O) % C 53.67 




Yield 0.25 g, 75%. 
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HRMS Calculated for [Fe2Ln]
4+ m/z 496.9000, found m/z 496.8998 
IR v cm-1 3339 (br, m), 1700 (m), 1605 (m), 1555 (s), 1468 (m), 1405 (m), 1372 (m), 
1220 (s), 1109 (m), 1075 (s), 985 (m), 936 (m), 840 (m), 752 (s), 731 (s), 697 (s). 
Elemental Analysis found (Calculated for C108H93Cl4Fe2N21O12·17H2O) % C 53.25 







3][ClO4]4 was synthesised using the procedure described for 
Sc,ɅFe,HHT-[Fe2L33]Cl4, substituting 5-(propargyloxy)picolinaldehyde (5) for 
(2R,3R,4S,5R,6S)-2-(acetoxymethyl)-6-((6-formylpyridin-3-yl)oxy)tetrahydro-2H-
pyran-3,4,5-triyl triacetate (21). 
Yield 89 mg, 89% 
1 H NMR (500 MHz, 298 K, CD3CN) δH 9.58 (1H, s, HC=N), 9.46 (1H, s, HC=N), 
9.15 (1H, s, bpy),9.13 (1H, s, bpy), 9.09 (1H, s, HC=N), 8.56-8.49 (3H, m, bpy/py), 
8.46 (1H, d, 3JHH = 9.0 Hz, py), 8.10-8.08 (2H, m, bpy), 7.99-7.60 (13H, m, Ph/bpy/py), 
7.47-6.90 (17H, m, Ph/bpy/py), 6.74-6.68 (3H, m, py/Ph), 6.61 (2H, t, 3JHH=7.5, Ph), 
6.24 (1H, d, 4JHH=2.0 Hz, py), 6.11-5.67 (3H, br, Ph), 5.42 (1H, t, 
3JHH=10.0, Hglu), 
5.38-4.96 (15H, m, Hglu overlapping with OCH2-bpy), 4.57-3.85 (17H, m, Hglu 
overlapping with OCH2-bpy, CH2-CHPh and CHPh ), 3.74 (1H, dd, 
2JHH = 
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11.0Hz,3JHH = 3.5, CHPh), 3.57 (1H, dd, 
2JHH = 10.5 Hz, 
3JHH = 4.0 Hz, CH2-CHPh), 
3.41 (1H, dd, 2JHH = 11.0 Hz, 
3JHH = 3.0 Hz, CH2-CHPh), 3.30 (1H, dd, 
2JHH = 11.0 
Hz, 3JHH = 3.0 Hz, CH2-CHPh), 2.09-1.88 (36H, m, 12 × COCH3). 
13C {1H} NMR (125 MHz, 298 K, CD3CN) δC 171.3/ 171.0/ 170.4 (HC=N), 170.4/ 
170.1/170.1/ 169.9/ 169.8/ 169.7/ 169.5/ 169.4/ 169.4/ 169.2/ 169.1/ 169.0 (q, CO), 
159.3/ 158.9/ 158.6/ 158.3/ 158.0/ 157.9 (q, bpy)/ 157.8/ 157.5/ 155.5 (bpy), 155.4/ 
155.4/ 155.0 (q, py), 154.3/ 154.0 (bpy), 153.7/ 153.5 (q, py), 153.2 (bpy), 144.1/ 
143.7/ 142.6 (py), 140.2/ 140.1/ 139.9/ 139.0/ 138.6/ 138.5 (bpy), 137.4/ 137.0/ 136.6 
(q, bpy), 134.2/ 132.5/ 132.3 (q, Ph), 132.0/ 131.8/ 130.7 (py), 128.9/ 128.8/ 128.8/ 
128.6/ 128.5 (Ph), 127.5/ 127.4/ 127.2 (bpy),125.3/ 125.1/ 124.7 (py), 124.1/ 123.9/ 
123.6/ 123.5/ 122.5/ 122.4 (bpy), 98.0/ 97.6 (C1Glu), 72.5/ 72.4 (C5Glu), 72.0/ 71.9/ 71.8 
(C3Glu), 71.5/ 71.4/ 70.6 (CHPh), 70.5/ 70.2/ 70.1 (C2Glu), 69.4/ 69.3/ 69.2 (OCH2-bpy), 
68.7/ 68.6/ 68.5 (CH2-CHPh), 67.4/ 67.4 (C4Glu), 61.4/ 61.2/ 61.1 (C6Glu), 12.0/ 12.0/ 
19.9/ 19.8/ 19.8/ 19.8 (12 × CH3). 
MS (ESI) m/z 763.4 [L + Na]+ 
Elemental Analysis found (Calculated for C117H120Cl4N12O49Fe2·6H2O) % C 49.30 










3][ClO4]4 was synthesised using the procedure described for 
Sc,ɅFe,HHT-[Fe2L33]Cl4, substituting 5-(propargyloxy)picolinaldehyde (5) for 5-
(((2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-
yl)oxy)picolinaldehyde (22) 
Yield 70 mg, 83% 
1 H NMR (500 MHz, 298 K, CD3CN) δH 9.53 (1H, s, HC=N), 9.38 (1H, s, HC=N), 
9.15 (1H, s, bpy),9.13 (1H, s, bpy), 9.00 (1H, s, HC=N), 8.54-8.48 (3H, m, bpy/py), 
8.37 (1H, d, 3JHH = 9.0 Hz, py), 8.17-8.08 (2H, m, bpy), 7.94-7.63 (13H, m, Ph/bpy/py), 
7.55 (1H, d, 3JHH = 9.0 Hz, py), 7.45-6.89 (19H, m, Ph/bpy/py), 6.80 (1H, d, 
4JHH=2.0 
Hz, py), 6.70 (2H, t, 3JHH=7.5, Ph), 6.58 (2H, t, 
3JHH=7.5, Ph), 6.29 (1H, d, 
4JHH=2.0 
Hz, py), 6.06-5.65 (2H, br, Ph), 5.31 (1H, dd, 2JHH = 11.0Hz,
3JHH = 3.5, CHPh), 5.22 
(2H, d, 2JHH = 12.5 Hz, CH2-bpy), 5.09 (1H, d, 
2JHH = 13.0 Hz, OCH2-bpy), 4.89 (1H, 
d,3JHH = 7.0 Hz, Hglu), 4.82 (1H, d,
3JHH = 7.0 Hz, Hglu), 4.64 (1H, d,
3JHH = 7.0 Hz, 
Hglu), 4.56-4.34 (6H, m, Hglu overlapping with CH2-bpy, CH2-CHPh and CHPh), 4.26 
(1H, t, 3JHH= 11.0, CH2-CHPh), 4.17 (1H, t,
 3JHH= 11.0, CH2-CHPh), 3.81-3.11 (32H, 
m, Hglu overlapping with CH2-bpy, CH2-CHPh and CHPh). 
13C {1H} NMR (125 MHz, 298 K, CD3CN) δC 171.7/ 171.4/ 170.7 (HC=N), 156.0/ 
159.4/ 159.2/ 156.0/ 158.6 (q, bpy)/ 158.3/ 158.0 (bpy), 156.7/ 156.6/ 156.3 (q, py), 
156.1/ 155.0/ 154.5/ 154.1 (bpy), 153.5/ 153.3/ 153.2 (q, py), 143.5/ 143.3/ 141.9 (py), 
140.8/ 140.5/ 140.4/ 139.5/ 139.1/ 139.0/ (bpy), 138.0/ 137.6/ 137.2 (q, bpy), 134.9/ 
133.3/ 133.0 (q, Ph), 132.5/ 132.3/ 131.1 (py), 129.5/ 129.5/ 129.3/ 129.2/ 129.1 (Ph), 
128.2/ 128.1/ 127.9/ 125.9/ 125.5/ 125.4 (bpy), 124.6/ 124.4/ 124.2 (py), 124.1/ 123.1/ 
122.9 (bpy), 100.7/ 100.2/ 99.9 (C1Glu), 77.1/ 77.0 (C5Glu), 76.6/ 76.6/ 76.5 (C3Glu), 
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73.6/ 73.5/ 73.4 (C2Glu), 73.0/ 72.9/ 71.1 (C4Glu), 70.3/ 70.2 (CHPh), 70.0 (CH2-bpy), 
69.8 (CHPh), 69.3/ 69.2 (CH2-CHPh), 61.8/ 61.5 (C6Glu). 
MS (ESI) m/z 573.4 [L + H]+; 595.3 [L + Na]+ 
Elemental Analysis found (Calculated for C93H96Cl4N12O37Fe2·10H2O) % C 46.40 





Yield 0.15 g, 87%. 
HRMS Calculated for [Fe2Ln]
4+ m/z 644.1943, found m/z 644.1914 
Elemental Analysis found (Calculated for C126H129Cl4Fe2N21O33·25H2O) % C 47.78 
(47.75), H 4.49 (5.69), N 9.52 (9.28). 
IR v cm-1 3381 (br, w), 1737 (s), 1559 (m), 1468 (m), 1366 (m), 1213 (s), 1077 (m), 




Yield 0.14 g, 82%. 
HRMS Calculated for [Fe2Ln]
4+ m/z 644.1943, found m/z 644.1939 
IR v cm-1 3386 (br, w), 1737 (s), 1562 (m), 1469 (m), 1366 (m), 1214 (s), 1076 (m), 
1036 (s), 921 (m), 791 (w), 755 (m), 698 (m). 
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Elemental Analysis found (Calculated for C126H129Cl4Fe2N21O33·26H2O) % C 47.30 





Yield 0.18 g, 79%. 
Elemental Analysis found (Calculated for C126H129Cl4Fe2N21O33·24H2O) % C 48.07 
(48.02), H 4.45 (5.66), N 9.64 (9.33). 
IR v cm-1 3369 (br, m), 1750 (s), 1677 (w), 1603 (w), 1555 (m), 1455 (m), 1367 (m), 
1217 (s), 1060 (s), 913 (m), 838 (w), 752 (w), 698 (w), 541 (w). 
HRMS Calculated for [Fe2Ln]




Yield 0.18 g, 81%. 
Elemental Analysis found (Calculated for C126H129Cl4Fe2N21O33·26H2O) % C 47.35 
(47.48), H 4.30 (5.72), N 9.57 (9.23). 
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HRMS Calculated for [Fe2Ln]
4+ m/z 643.9438, found m/z 643.9423 
IR v cm-1 3357 (br, m), 1740 (s), 1607 (w), 1558 (m), 1469 (w), 1367 (m), 1216 (s), 





Yield 0.22 g, 84%. 
Elemental Analysis found (Calculated for C126H129Cl4Fe2N21O33·19H2O) % C 49.42 
(49.44), H 4.47 (5.50), N 10.20 (9.61). 
IR v cm-1 3376 (br, S), 1750 (s), 1557 (m), 1468 (m), 1367 (m), 1217 (s), 1121 (m), 
1075 (s), 1043 (s), 936 (w), 840 (w), 788 (w), 755 (w), 698 (w). 
HRMS Calculated for [Fe2Ln]




Yield 0.23 g, 86%. 
Elemental Analysis found (Calculated for C126H129Cl4Fe2N21O33·19H2O) % C 49.50 
(49.44), H 4.52 (5.50), N 10.05 (9.61). 
IR v cm-1 3380 (br, S), 1739 (s), 1557 (m), 1469 (m), 1368 (m), 1217 (s), 1121 (m), 
1075 (s), 1043 (s), 937 (w), 839 (w), 789 (w), 755 (w), 698 (w). 
HRMS Calculated for [Fe2Ln]
4+ m/z 643.9438, found m/z 643.9431 
 






Yield 0.16 g, 92%. 
1H NMR (500 MHz, 298 K, D2O)δH 9.55 (1H, s, HC=N), 9.40 (1H, s, HC=N), 9.11 
(1H, s, bpy),9.09 (1H, s, bpy), 9.00 (1H, s, HC=N), 8.41-8.36 (3H, m, bpy), 8.30 (1H, 
s, triazole), 8.27 (1H, d, 3JHH =8.8 Hz, py), 8.06-8.01 (2H, m, triazole/Ph), 7.93 (1H, t,
 
3JHH = 7.5 Hz, bpy), 7.88-6.76 (24H, m, Ph/py/bpy), 6.63 (2H, t,
 3JHH = 7.0 Hz, Ph), 
6.50 (2H, t, 3JHH = 7.5 Hz, Ph), 6.27 (1H, s, py), 5.66 (1H, d, 
3JHH =9.2 Hz, HGal), 5.60 
(1H, d, 3JHH =9.3 Hz, HGal), 5.55 (1H, d, 
3JHH =9.2 Hz, HGal), 5.26-5.08 (8H, m), 4.92 
(1H, d, 2JHH =12.7 Hz, CH2-bpy), 4.48-4.36 (5H, m), 4.28-3.64 (24H, m), 3.50-3.20 
(3H, m). 
13C {1H} NMR (126 MHz, 298 K, D2O) δC ppm 170.3, 170.0, 169.4 (CHN), 159.6, 
158.7, 158.5, 158.2, 157.9, 157.6, 157.4 (bpy), 157.2 (bpy), 156.8, 156.7, 156.1, 154.5 
(bpy), 153.8, 153.3, 153.2, 152.0, 151.9, 151.6, 143.1, 142.8, 142.4 (C=CH (triazole)), 
142.2 (C=CH (triazole)), 142.0 (C=CH (triazole)), 141.7, 139.9, 139.7, 138.8, 138.6, 
136.9, 136.7, 136.3, 134.2, 132.5, 132.2, 131.2, 130.8, 130.2, 129.0, 128.9, 128.8, 
128.8, 128.6, 127.3, 127.2, 127.0, 124.5 (C=CH (triazole)), 123.8 (C=CH (triazole)), 
123.7, 123.5 (C=CH (triazole)), 123.4, 123.4, 123.3, 122.8, 122.5, 121.9 (Ar), 88.0, 
88.0 (C1Gal), 78.4, 78.3, 78.3 (C5Gal), 73.0, 72.8 (C3Gal), 72.5, 72.4, 70.3 (CHPh), 69.7, 
69.7, 69.6 (C2Gal), 69.3, 69.2, 68.7 (CH2-bpy), 68.5 (C4Gal), 68.4, 67.9 (CH2-CHPh), 
61.9, 61.7, 61.4 (TRZ-CH2), 60.9, 60.8 (C6Glu). 
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HRMS Calculated for [Fe2L3]
4+ m/z 518.1626, found m/z 518.1619 
IR v cm-1 3275 (br, s), 2874 (br, s), 2114 (w), 1605 (w), 1556 (s), 1468 (m), 1402 (w), 
1364 (m),  1303 (m), 1223 (s), 1073 (s), 1053 (s), 1010 (s), 983 (s), 936 (m), 883 
(m),840 (m), 791 (m), 745 (m), 698 (s), 534 (s). 
Elemental Analysis found (Calculated for C102H105Cl4Fe2N21O21·21H2O) % C 47.19 




Data as for S-enantiomer 
Yield 0.13 g, 77%. 
Elemental Analysis found (Calculated for C102H105Cl4Fe2N21O21·19H2O) % C 47.90 





Yield 0.21 g, 88%. 
1H NMR (500 MHz, 298 K, D2O) δH  9.56 (1H, s, HC=N), 9.41 (1H, s, HC=N), 9.12 
(1H, s, bpy),9.10 (1H, s, bpy), 9.01 (1H, s, HC=N), 8.41-8.37 (3H, m, bpy), 8.26 (2H, 
m, py/triazole), 8.09 (1H, s, triazole), 8.04-8.01 (2H, m, triazole/Ph), 7.96-6.63 (30H, 
m, Ph/py/bpy), 6.52 (2H, t, 3JHH = 7.3 Hz, Ph), 6.37 (1H, s, py), 6.08 (1H, s, HMan), 
5.98 (1H, s, HMan), 5.92 (1H, s, HMan), 5.26-5.08 (8H, m), 4.93 (1H, d, 
2JHH =12.3 Hz, 
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CH2-bpy), 4.65-4.24 (11H, m), 4.17 (1H, t, 
3JHH =10.7 Hz, CH2-CHPh), 4.10-3.95 (3H, 
m, HMan), 3.79-3.67 (9H, m, HMan), 3.51 (1H, d, 
3JHH =7.0 Hz, CH2-CHPh), 3.34-3.14 
(5H, m, HMan). 
13C {1H} NMR (126 MHz, 298 K, D2O) δC ppm 170.4, 170.0, 169.5 (CHN), 159.6, 
158.9, 158.6, 158.2, 157.9, 157.8, 157.5 (bpy), 157.3 (bpy), 156.8, 156.2, 154.5, 153.8 
(bpy), 153.2, 153.2, 152.0, 151.7, 151.5, 143.7, 143.1, 142.6, 142.3 (C=CH (triazole)), 
142.2 (C=CH (triazole)), 142.2 (C=CH (triazole)), 139.9, 139.7, 138.8, 138.6, 136.9, 
136.7, 136.3, 134.3, 132.5, 132.2, 131.2, 130.8, 130.3, 129.0, 128.8, 128.8, 128.6, 
127.3, 127.0, 125.3 (C=CH (triazole)), 124.9 (C=CH (triazole)), 124.8 (C=CH 
(triazole)), 123.7, 123.6, 123.5, 123.2, 122.8, 122.7, 122.5, 121.9 (Ar), 86.6, 86.6, 86.5 
(C1Man), 76.5, 76.4, 76.3 (C5Man), 72.5 (CHPh), 72.4 (CHPh), 70.6, 70.5, 70.4 (C3Man), 
69.3, 69.2, (CH2-bpy) 68.7, 68.4 (CH2-CHPh), 67.9 (CH2-bpy) 68.3, 68.2 (C2Man), 66.6, 
66.5 (C4Man), 61.7, 61.6, 61.3 (TRZ-CH2), 60.4, 60.3 (C6Man). 
HRMS Calculated for [Fe2L3]
4+ m/z 518.1626, found m/z 518.1612 
IR v cm-1 3277 (br, s), 1559 (s), 1468 (m), 1226 (s), 1110 (m), 1075 (s), 1010 (m), 936 
(w), 791 (w), 755 (w), 698 (w).  
Elemental Analysis found (Calculated for C102H105Cl4Fe2N21O21·15H2O) % C 49.41 




Data as for S-enantiomer 
Yield 0.20 g, 84%. 
Elemental Analysis found (Calculated for C102H105Cl4Fe2N21O21·14H2O) % C 49.69 
(49.66), H 4.68 (5.43), N 11.83 (11.92). 
 






Yield. 0.17g, 83%. 
HRMS Calculated for [Fe2L3]
4+ m/z 518.1626, found m/z 518.1633 
IR v cm-1 3239 (br, s), 1556 (s), 1468 (m), 1360 (m), 1303 (m), 1224 (s), 1074 (s), 936 
(m), 836 (m), 791 (m), 753 (s), 698 (s).  
Elemental Analysis found (Calculated for C102H105Cl4Fe2N21O21·14H2O) % C 49.85 




Data as for S-enantiomer 
Yield 0.19 g, 91%. 
Elemental Analysis found (Calculated for C102H105Cl4Fe2N21O21·14H2O) % C 49.48 
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Yield 0.21 g, 88%. 
1H NMR (500 MHz, 298 K, D2O) δH  9.55 (1H, s, HC=N), 9.40 (1H, s, HC=N), 9.11 
(1H, s, bpy),9.09 (1H, s, bpy), 8.95 (1H, s, HC=N), 8.41-8.35 (3H, m, bpy), 8.30 (1H, 
s, triazole), 8.26 (1H, d, 3JHH =8.8 Hz, Py), 8.01 (2H, m, triazole/Ph ), 7.92 (1H, t,
 3JHH 
= 7.8 Hz, bpy ), 7.88-6.62 (29H, m, Ph/py/bpy), 6.50 (2H, t, 3JHH = 7.5 Hz, Ph), 6.27 
(1H, s, py), 5.73 (1H, d, 3JHH =9.3 Hz, HGlu), 5.66 (1H, d, 
3JHH =9.3 Hz, HGlu), 5.60 
(1H, d, 3JHH =9.3 Hz, HGlu), 5.26-5.08 (8H, m), 4.92 (1H, d, 
2JHH =12.9 Hz, CH2-bpy), 
4.16 (1H, t, 3JHH =10.6 Hz, CH2-CHPh), 3.97 (1H, t, 
3JHH =9.2 Hz, CH2-CHPh), 3.87-
3.47 (21H, m), 3.33-3.19 (2H, m) 
13C {1H} NMR (126 MHz, 298 K, D2O) δC ppm 170.4, 170.0, 169.4 (CHN), 159.6, 
158.7, 158.5, 158.2, 157.9, 157.6, 157.4 (bpy), 157.2 (bpy), 156.8, 156.7, 156.0, 154.5 
(bpy), 153.8, 153.3, 153.2, 152.0, 151.9, 151.7, 143.0, 142.8, 142.3 (C=CH (triazole)), 
142.2 (C=CH (triazole)), 142.0 (C=CH (triazole)), 141.6, 139.9, 139.7, 138.8, 138.6, 
136.9, 136.7, 136.3, 134.2, 132.5, 132.2, 131.2, 130.8, 130.2, 129.0, 128.8, 128.8, 
128.8, 128.6, 127.2, 127.2, 126.9, 124.9 (C=CH (triazole)), 124.0 (C=CH (triazole)), 
123.9 (C=CH (triazole)), 123.7, 123.6, 123.5, 123.4, 123.3, 122.8, 122.5, 121.8 (Ar), 
87.5, 87.4, 87.4 (C1Glu), 78.4, 78.9 (C5Glu), 76.0, 75.8, 75.8 (C3Glu), 72.5, 72.4 (CHPh), 
72.2 (C2Glu), 70.3 (CHPh), 69.2 (CH2-bpy), 69.1 (CH2-bpy), 69.0, 68.9 (C4Glu), 68.7 
(CH2-bpy), 68.5, 68.4, 67.9 (CH2-CHPh), 61.9, 61.7, 61.3 (TRZ-CH2), 60.4, 60.4, 60.3 
(C6Glu)  
HRMS Calculated for [Fe2L3]
4+ m/z 518.1626, found m/z 518.1625 
IR v cm-1 3307 (br, s), 1557 (m), 1468 (m), 1363 (w), 1227 (s), 1075 (s), 1010 (s), 937 
(m), 989 (m), 838 (m), 791 (m), 754 (s), 698 (s).  
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Elemental Analysis found (Calculated for C102H105Cl4Fe2N21O21·17H2O) % C 48.81 




Data as for S-enantiomer 
Yield 0.21 g, 89%. 
Elemental Analysis found (Calculated for C102H105Cl4Fe2N21O21·19H2O) % C 47.91 





Yield 0.16 g, 79%. 
1H NMR (500 MHz, 298 K, D2O) δH  9.54 (1H, s, HC=N), 9.40 (1H, s, HC=N), 9.10 
(1H, s, bpy),9.07 (1H, s, bpy), 9.00 (1H, s, HC=N), 8.41-8.33 (4H, m, bpy/triazole), 
8.24 (1H, d, 3JHH = 9.0 Hz, py), 8.09 (1H, s, triazole), 8.02-8.00 (2H, m, triazole/Ph), 
7.94 (1H, t, 3JHH =7.5 Hz, Ph), 7.87-7.34 (13H, m, Ph/py/bpy), 7.30 (1H, t,
 3JHH = 7.55 
Hz, Ph), 7.22-6.62 (15H, m, Ph/py/bpy), 6.51 (2H, t, 3JHH = 7.5 Hz, Ph ), 6.32 (1H, s, 
py), 5.85 (1H, d, 3JHH =10.0 Hz), 5.70 (2H, t, 
3JHH =9.6 Hz), 5.25-5.05 (8H, m), 4.92 
(1H, d, 2JHH =13.1 Hz, CH2-bpy), 4.47-4.14 (11H, m), 4.03 (2H, t, 
3JHH =10.0 Hz), 
3.85-3.55 (19H, m), 3.98 (1H, d, 3JHH =10.0 Hz, CH2-CHPh), 3.31 (1H, d,
 3JHH =10.0 
Hz, CH2-CHPh), 3.19 (1H, d, 
3JHH =10.0 Hz, CH2-CHPh), 1.68 (1H, s, COCH3), 1.60 
(1H, s, COCH3), 1.57 (1H, s, COCH3). 
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13C {1H} NMR (126 MHz, 298 K, D2O) δC ppm 174.1, 173.7, 173.7 (COCH3), 170.4, 
170.0, 169.4 (CHN), 159.6, 158.8, 158.5, 158.2, 157.9, 157.7, 157.4 (bpy), 157.2 (bpy), 
156.7, 156.6, 156.0, 154.5 (bpy), 153.7, 153.2, 153.1, 151.9, 151.7, 151.5, 143.5, 
142.9, 142.4 (C=CH (triazole)), 142.2, 142.0 (C=CH (triazole)), 141.9 (C=CH 
(triazole)), 139.9, 139.7, 138.8, 138.5, 136.8, 136.7, 136.3, 134.2, 132.5, 132.2, 131.2, 
130.8, 130.3, 129.4, 129.0, 128.8, 128.8, 128.6, 127.3, 127.2, 127.0, 127.0, 124.2, 
123.7 (C=CH (triazole)), 123.6, 123.6 (C=CH (triazole)), 123.5 (C=CH (triazole)), 
123.2, 123.2, 123.1, 122.8, 122.5, 121.9 (Ar), 86.5, 86.5 (C1GlcNac), 79.0, 78.9 (C5GlcNac), 
73.5, 73.3, 73.3 (C3GlcNac), 72.5, 72.4, 70.2 (CHPh), 69.3, 69.2 (C4GlcNac), 68.7, 68.4, 
67.8 (CH2-bpy), 61.7, 61.6, 61.2 (CH2-CHPh/TRZ-CH2), 60.5, 60.4 (C6GlcNac), 55.4, 
55.4, 55.3 (C2GlcNac), 21.7, 21.5, 21.5 (COCH3). 
HRMS Calculated for [Fe2L3]
4+ m/z 548.9324, found m/z 548.9324 
IR v cm-1 3257 (br, m), 3055 (br, m), 1654 (m), 1556 (s), 1468 (s), 1371 (m), 1304 (m), 
1225 (s), 1107 (s), 1075 (s), 1002 (s), 937 (m), 900 (w), 837 (w), 793 (m), 754 (m), 
698 (s).  
Elemental Analysis found (Calculated for C108H114Cl4Fe2N24O21·17H2O) % C 49.02 




Data as for S-enantiomer 
Yield 0.18 g, 91%. 
Elemental Analysis found (Calculated for C108H114Cl4Fe2N24O21·18H2O) % C 48.55 
(48.73), H 4.90 (5.68), N 12.57 (12.63). 
 






Yield 0.17 g, 85%. 
1H NMR (500 MHz, 298 K, D2O)δH  9.54 (1H, s, HC=N), 9.47 (1H, s, HC=N), 9.13 
(1H, s, bpy),9.10 (1H, s, bpy), 9.01 (1H, s, HC=N), 8.42-8.35 (3H, m, bpy), 8.28-8.24 
(2H, m, py/ triazole), 8.17 (1H, s, triazole), 8.06 (1H, s, triazole), 8.03-6.79 (28H, m, 
Ph/py/byp), 6.63 (2H, t, 3JHH = 7.4 Hz, Ph), 6.50 (2H, t, 
3JHH = 7.8 Hz, Ph), 6.29 (1H, 
d, 4JHH =2.4 Hz, py), 5.76-5.62 (3H, m, HGalNAc), 5.27-5.03 (9H, m), 4.92 (1H, d, 
2JHH 
=13.0 Hz, CH2-bpy), 4.47-4.36 (6H, m), 4.29-4.15 (5H, m), 4.05-4.01 (3H, m), 3.69-
3.87 (6H, m), 3.76-3.71 (6H, m), 3.48 (1H, d, 3JHH = 9.0 Hz, CH2-CHPh), 3.31 (1H, d,
 
3JHH =9.0 Hz, CH2-CHPh), 3.20 (1H, d,
 3JHH = 9.0 Hz, CH2-CHPh), 1.71 (3H, s, OCH3), 
1.55 (3H, s, OCH3), 1.51 (3H, s, OCH3). 
13C {1H} NMR (126 MHz, 298 K, D2O) δC ppm 174.2, 173.9, 173.8 (COCH3), 170.3, 
170.0, 169.4 (CHN), 159.6, 158.8, 158.6, 158.2, 157.9, 157.6, 157.4 (bpy), 157.2 (bpy), 
156.7, 156.6, 156.2, 154.5 (bpy), 153.8, 153.3, 153.2, 151.8, 151.7, 151.4, 143.6, 
143.5, 142.4 (C=CH (triazole)), 142.2, 142.1 (C=CH (triazole)), 142.0 (C=CH 
(triazole)), 139.9, 139.7, 138.8, 138.5, 136.8, 136.7, 136.3, 134.2, 132.5, 132.2, 131.2, 
130.7, 130.2, 129.0, 128.9, 128.8, 128.8, 128.6, 127.3, 127.2, 127.0, 124.2 (C=CH 
(triazole)), 123.7, 123.5, 123.4 (C=CH (triazole)), 123.3 (C=CH (triazole)), 122.9, 
122.8, 122.5, 121.9 (Ar), 87.0 (C1GalNAc), 78.5, 78.4, 78.4 (C5 GalNAc), 72.5 (CHPh), 
72.4 (CHPh), 70.6, 70.5, 70.4 (C3GalNAc), 70.3 (CHPh), 69.2, 69.1, 68.7 (CH2-bpy), 
 
University of Warwick | Page 252 
 
68.5, 68.4, 67.9 (CH2-CHPh), 67.6 (C4GalNAc), 61.6, 61.5, 61.3 (TRZ-CH2), 61.0, 60.9 
(C6GalNAc), 52.0, 52.0, 51.9 (C2GalNAc), 21.7, 21.5 (COCH3). 
HRMS Calculated for [Fe2L3]
4+ m/z 548.9325, found m/z 548.9335 
IR v cm-1 3242 (br, s), 2987 (br, s), 1654 (m), 1556 (s), 1467 (m), 1370 (m), 1304 (m), 
1225 (s), 1076 (s), 1056 (s), 936 (w), 886 (w), 754 (w), 698 (m).  
Elemental Analysis found (Calculated for C108H114Cl4Fe2N24O21·19H2O) % C 48.64 




Data as for S-enantiomer 
Yield 0.18 g, 90%. 
Elemental Analysis found (Calculated for C108H114Cl4Fe2N24O21·17H2O) % C 49.04 







3]Cl4 was synthesised using the procedure described for 
Sc,ɅFe,HHT-[Fe2L33]Cl4, substituting 5-(propargyloxy)picolinaldehyde (5) for 1-
benzyl-1H-1,2,3-triazole-4-carbaldehyde (37) 
Yield 0.58 g, 81% 
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1H NMR (500 MHz, 298 K, MeOD) δH ppm 9.65 (1H, s, HC=N), 9.47 (1H, s, HC=N), 
9.39 (1H, s, bpy), 9.30 (1H, s, bpy), 9.20 (1H, s, HC=N), 9.19 (1H, s, TRZ), 9.01 (1H, 
s, TRZ), 8.75-8.56 (5H, m, bpy), 8.35 (1H, s, TRZ), 8.26-7.89 (13H, m, bpy ), 7.78-
7.74 (2H, m, bpy), 7.50-6.93 (42H, m, Ph/bpy), 6.78 (2H, t, 3JHH =7.6 Hz, Ph), 6.60 
(2H, t, 3JHH =7.7 Hz, Ph), 5.90 (1H, s, Ph), 5.68 (2H, s, PhCH2), 5.64-5.50 (4H, m, 
PhCH2), 5.34 (1H, dt, 
3JHH=15.1, 7.4 Hz, CHPh), 5.25 (2H, d, 
2JHH=13.0 Hz, CH2-
bpy), 5.14 (1H, d, 2JHH=18.1 Hz, CH2-bpy), 4.78 (1H, d, 
3JHH=11.3 Hz, CHPh), 4.60-
4.48 (6H, m, CHPh / CH2-bpy), 4.28 (1H, t, 
3JHH=11.0 Hz), 3.54-3.51 (3H, m, CH2-
CHPh), 3.43-3.41 (1H, m, CH2-CHPh), 3.37 (1H, CH2-CHPh overlap with MeOD). 
13C {1H} NMR (125 MHz, 298 K, CD3OD) δC ppm 163.4, 163.1, 162.6 (HC=N), 160.1, 
159.9, 159.3, 159.2, 158.5, 158.4 (q, bpy), 157.9, 157.2, 155.8, 154.3, 154.0, 153.3 
(bpy), 149.5, 149.5, 149.4 (q, TRZ), 139.9, 139.8, 139.5, 138.7, 138.5, 138.3, 137.7 
(bpy), 137.4, 136.8, 136.8 (q, bpy), 134.4, 134.2, 134.1, 134.0, 133.4, 132.9, 132.5 (q, 
Ph), 130.2 (TRZ), 129.3, 129.2, 129.0 (Ph), 129.0 (TRZ), 128.9, 128.9, 128.8, 128.7, 
128.6 (Ph), 128.3 (TRZ), 127.9, 127.5, 127.3, 127.2, 127.2, 127.2 (Ph), 126.9, 126.3, 
125.8, 125. 6, 123. 5, 123.0, 122.7, 122.5, 122.4, 121.6 (bpy), 72.9, 72.6 (CHPh), 71.3 
(CH2-bpy), 70.8 (CHPh), 69.1, 69.1 (CH2-bpy), 68.7, 68.5, 68.5 (CH2-CHPh), 55.6, 
55.5, 55.2 (PhCH2). 
HRMS Calculated for [Fe2Ln]
4+ m/z 383.6292, found m/z 383.6297 
Elemental Analysis found (Calculated for C87H78Cl4Fe2N18O3·13H2O·EtOAc) % C 
54.44 (54.66), H 5.12 (5.65), N 12.31 (12.61). 
IR v cm-1 3371 (br, s), 3028 (br, s), 1603 (m), 1468 (m), 1359 (w), 1076 (s), 1010 (w), 
933 (w), 697 (s). 
 





Yield 0.57 g, 79% 
HRMS Calculated for [Fe2Ln]
4+ m/z 383.6297, found m/z 383.6297 
Elemental Analysis found (Calculated for C87H78Cl4Fe2N18O3·13H2O·EtOAc) % C 







3]Cl4 was synthesised using the procedure described for 
Sc,ɅFe,HHT-[Fe2L33]Cl4, substituting 5-(propargyloxy)picolinaldehyde (5) for 4-((4-
formyl-1H-1,2,3-triazol-1-yl)methyl)benzonitrile (39) 
Yield 0.65 g, 88% 
1H NMR (500 MHz, 298 K, MeOD) δH 9.69 (1H, s, HC=N), 9.54 (1H, s, HC=N), 9.40 
(1H, s, bpy), 9.31 (1H, s, bpy), 9.30 (1H, s, HC=N), 9.29 (1H, s, TRZ), 9.12 (1H, s, 
TRZ), 8.76-6.93 (42H, m, Ph/TRZ/bpy), 6.79 (2H, t, 3JHH =7.6 Hz, Ph), 6.61 (2H, t, 
3JHH =7.6 Hz, Ph), 5.93 (1H, brs, Ph), 5.82-5.65 (6H, m, CNPhCH2), 5.42-5.32 (1H, 
m, CHPh), 5.28 (2H, d, 2JHH=12.7 Hz, CH2-bpy), 5.18 (1H, d, 
2JHH=12.9 Hz, CH2-
bpy), 4.79 (1H, d, 3JHH=12.9 Hz, CHPh), 4.68-4.35 (8H, m, CHPh/CH2-bpy), 3.86-
3.61 (3H, m, CH2-CHPh), 3.57-3.54 (1H, m, CH2-CHPh), 3.43 (1H, d,
 3JHH=8.6 Hz, 
CH2-CHPh), 3.37 (1H, CH2-CHPh overlap with MeOD). 
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13C {1H} NMR (125 MHz, 298 K, CD3OD) δC ppm 163.5, 163.3, 162.8 (HC=N), 160.1, 
159.8, 159.2, 159.1 (q, bpy), 158.4, 158.4, 158.3, 157.9, 157.3, 155.8, 154.4, 154.1, 
153.9, 153.7, 153.3 (bpy), 149.8, 149.6, 149.5 (q, TRZ), 140.0, 139.9, 139.6 (bpy), 
139.4, 139.2 (q, bpy), 138.7, 138.7, 138.5 (bpy), 138.4 (q, bpy), 137.8 (bpy), 137.5, 
137.0, 136.8 (q, bpy), 134.5, 134.2 (q, Ph), 132.8, 132.8, 132.6, 132.5, 132.4 (CNPh), 
130.7 (TRZ), 129.4, 129.3 (Ph), 129.0 (TRZ), 128.9, 128.7, 128.6, 128.4 (Ph), 128.4 
(TRZ), 128.3, 127.3, 127.2, 127.2, 127.2, 126.9 (Ph), 126.4, 125.9, 125.6, 123.9, 123.7, 
123.6, 123.5, 123.0, 122.7, 122.5, 122.4, 121.5 (bpy), 117.8, 117.7, 117.6 (q, CNPh), 
112.8, 112.6, 112.3 (CN), 73.0 (CHPh), 72.6 (CHPh), 71.4 (CH2-bpy), 70.9 (CHPh), 
69.2, 69.0 (CH2-bpy), 68.7, 68.6, 68.5 (CH2-CHPh), 54.8, 54.6, 54.4 (Benzonitrile-
CH2). 
HRMS Calculated for [Fe2Ln]
4+ m/z 402.3761, found m/z 402.3748 
Elemental Analysis found (Calculated for C90H75Cl4Fe2N21O3·12H2O·3EtOAc) % C 
54.81 (54.87), H 4.79 (5.55), N 13.26 (13.17). 
IR v cm-1 3394 (br, s), 3028 (br, s), 1603 (m), 1467 (m), 1078 (s), 934 (w), 790 (s), 




Yield 0.59 g, 80% 
HRMS Calculated for [Fe2Ln]
4+ m/z 402.3761, found m/z 402.3758 
Elemental Analysis found (Calculated for C90H75Cl4Fe2N21O3·11H2O·3EtOAc) % C 
55.44 (55.32), H 4.73 (5.51), N 13.36 (13.28). 
 








3]Cl4 was synthesised using the procedure described for 
Sc,ɅFe,HHT-[Fe2L33]Cl4, substituting 5-(propargyloxy)picolinaldehyde (5) for 1-(4-
methoxybenzyl)-1H-1,2,3-triazole-4-carbaldehyde (40) 
Yield 0.42 g, 83% 
1H NMR (500 MHz, 298 K, MeOD) δH ppm 9.65 (1H, s, HC=N), 9.47 (1H, s, HC=N), 
9.39 (1H, s, bpy), 9.30 (1H, s, bpy), 9.19 (1H, s, HC=N), 9.12 (1H, s, TRZ), 8.96 (1H, 
s, TRZ), 8.85-8.51 (7H, m, bpy), 8.26 (1H, s, TRZ), 8.25-7.73 (18H, m, TRZ/bpy ), 
7.57-6.82 (50H, m, Ph/bpy), 6.78 (2H, t, 3JHH =7.7 Hz, Ph), 6.60 (2H, t, 
3JHH =7.7 Hz, 
Ph), 5.90 (1H, brs, Ph), 5.68-5.42 (6H, m, CH2PhOCH3), 5.34 (1H, dd, 
3JHH=11.3, 
4JHH=3.7 Hz, CHPh), 5.25 (2H, d, 
2JHH=11.9 Hz, CH2-bpy), 5.16 (1H, d, 
2JHH=13.0 Hz, 
CH2-bpy), 4.77 (1H, d, 
3JHH=8.6 Hz, CHPh), 4.68-4.42 (6H, m, CHPh / CH2-bpy), 
4.29 (1H, t, 3JHH=10.9 Hz CH2-CHPh), 3.90-3.61 (9H, m, OCH3/ CH2-CHPh), 3.56-
3.49 (1H, m, CH2-CHPh), 3.44-3.39 (1H, m, CH2-CHPh), 3.37 (1H, CH2-CHPh 
overlap with MeOD). 
13C {1H} NMR (125 MHz, 298 K, CD3OD) δC ppm 163.4, 163.1, 162.5 (HC=N), 160.7, 
160.4, 160.3 (q, PhOCH3), 160.1, 159.9, 159.3, 159.2, 158.5, 158.4 (q, bpy), 157.9, 
157.3, 155.7, 154.3, 154.0, 153.3 (bpy), 149.4, 149.4, 149.3 (q, TRZ), 139.9, 139.8, 
139.5, 138.7, 138.5, 138.3, 137.7 (bpy), 137.4, 136.8 (q, bpy), 134.4, 132.9, 132.5 (q, 
Ph), 130.6, 129.6, 129.3, 129.0, 129.0, 128.7, 128.6, 128.3, 128.3, 127.3, 127.2, 127.2, 
 
University of Warwick | Page 257 
 
127.2 (TRZ/ PhOCH3/ Ph), 126.3 (bpy), 126.0 (q, PhOCH3), 125.8 (bpy), 125.7 (q, 
PhOCH3), 125.6 (bpy), 125.2 (q, PhOCH3), 123.9, 123.7, 123.5, 123.0, 122.7, 122.5, 
122.4, 121.5 (bpy), 114.2, 114.1, 114.0 (PhOCH3), 72.9 (CHPh), 72.6 (CHPh), 71.5 
(CH2-bpy), 70.8 (CHPh), 69.1, 68.9 (CH2-bpy), 68.8, 68.5, (CH2-CHPh), 55.3, 55.1, 
54.9 (Anisole-CH2), 54.6, 54.5, 54.4 (OCH3). 
HRMS Calculated for [Fe2Ln]
4+ m/z 406.1376, found m/z 406.1380 
Elemental Analysis found (Calculated for C90H84Cl4Fe2N18O6·14H2O·EtOAc) % C 
53.31 (53.57), H 5.01 (5.74), N 11.75 (11.96). 
IR v cm-1 3375 (br, s), 3026 (br, s), 1604 (m), 1512 (m), 1466 (m), 1246 (m), 1076 (s), 




Yield 0.44 g, 87% 
HRMS Calculated for [Fe2Ln]
4+ m/z 406.1376, found m/z 406.1380 
Elemental Analysis found (Calculated for C90H84Cl4Fe2N18O6·14H2O·EtOAc) % C 










3]Cl4 was synthesised using the procedure described for 
Sc,ɅFe,HHT-[Fe2L33]Cl4, substituting 5-(propargyloxy)picolinaldehyde (5) for 1-(4-
fluorobenzyl)-1H-1,2,3-triazole-4-carbaldehyde (38) 
Yield 0.38 g, 78% 
1H NMR (500 MHz, 298 K, MeOD) δH ppm 9.67 (1H, s, HC=N), 9.50 (1H, s, HC=N), 
9.38 (1H, s, bpy), 9.30 (1H, s, bpy), 9.23 (1H, s, HC=N), 9.20 (1H, s, TRZ), 9.03 (1H, 
s, TRZ), 8.79-8.52 (7H, m, bpy), 8.34 (1H, s, TRZ), 8.29-7.72 (18H, m, bpy), 7.55-
6.85 (50H, m, Ph/F-Ph/bpy), 6.78 (2H, t, 3JHH =7.6 Hz, Ph), 6.60 (2H, t, 
3JHH =7.6 Hz, 
Ph), 6.19-5.82 (4H, m, Ph), 5.73-5.46 (6H, m, F-PhCH2), 5.35 (1H, dd, 
3JHH=11.4, 
4JHH=3.5 Hz, CHPh), 5.25 (2H, d, 
2JHH=13.1 Hz, CH2-bpy), 5.16 (1H, d, 
3JHH=13.0 Hz, 
CH2-bpy), 4.77 (1H, d, 
3JHH=8.8 Hz, CHPh), 4.67-4.43 (6H, m, CHPh/ CH2-bpy), 4.30 
(1H, t, 3JHH=11.0 Hz CH2-CHPh), 3.88-3.63 (3H, m, CH2-CHPh)3.54 (1H, dd,
 
3JHH=10.4, 3.6 Hz CH2-CHPh), 3.42 (1H, d,
 3JHH=8.4 Hz CH2-CHPh), 3.37 (1H, CH2-
CHPh overlap with MeOD). 
13C {1H} NMR (125 MHz, 298 K, CD3OD) δC ppm 164.3, 164.0, 163.9 (q, F-Ph), 
163.4, 163.2, 162.6 (HC=N), 162.3, 162.1, 161.9 (q, F-Ph), 160.1, 159.8, 159.3, 159.1, 
158.5, 158.4 (q, bpy), 157.9, 157.3, 155.7, 154.3, 154.0, 153.3 (bpy), 149.6, 149.5, 
149.4 (q, TRZ), 139.9, 139.8, 139.5, 138.7, 138.5, 138.3, 137.7 (bpy), 137.4, 136.9, 
136.8 (q, bpy), 134.4, 132.9, 132.5 (q, Ph), 131.2, 131.1, 130.4, 130.3, 130.0, 129.9 
(F-Ph), 129.3, 129.0, 129.0, 128.9, 128.8, 128.7, 128.6, 128.6, 128.3, 127.3, 127.2, 
127.2, 127.2, 126.9 (TRZ/ Ph), 126.3, 125.8, 125.6, 123.5, 123.0, 122.7, 122.5, 122.4, 
121.5 (bpy), 115.8, 115.7, 115.6, 115.5, 115.5, 115.3 (F-Ph), 72.9 (CHPh), 72.6 
(CHPh), 71.3 (CH2-bpy), 70.8 (CHPh), 69.1, 69.0 (CH2-bpy), 68.7, 68.5, 68.5 (CH2-
CHPh), 54.8, 54.6, 54.4 (PhF-CH2). 
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HRMS Calculated for [Fe2Ln]
4+ m/z 397.1226, found m/z 397.1221 
Elemental Analysis found (Calculated for C87H75Cl4F3Fe2N18O3·13H2O·EtOAc) % C 
53.23 (53.23), H 4.91 (5.35), N 11.98 (12.28). 
IR v cm-1 3374 (br, s), 3026 (br, s), 1602 (m), 1509 (m), 1468 (m), 1220 (m), 1077 (s), 




Yield 0.36 g, 75% 
HRMS Calculated for [Fe2Ln]
4+ m/z 397.1226, found m/z 397.1224 
Elemental Analysis found (Calculated for C87H75Cl4F3Fe2N18O3·13H2O·EtOAc) % C 







3]Cl4 was synthesised using the procedure described for 
Sc,ɅFe,HHT-[Fe2L33]Cl4, substituting 5-(propargyloxy)picolinaldehyde (5) for 4-((4-
formyl-1H-1,2,3-triazol-1-yl)methyl)benzoic acid (39) 
Yield 0.44 g, 86% 
13C {1H} NMR (125 MHz, 298 K, CD3OD) δC ppm 163.4, 163.2, 162.6 (HC=N), 160.1, 
159.8, 159.3, 159.2, 159.0, 158.5, 158.4, 158.3, 158.2, 157.9 (bpy), 157.3 (bpy), 155.8 
(bpy), 154.4, 153.9, 153.7, 153.3, 153.1, 152.5, 151.9, 149.6 (q, TRZ), 149.6 (q, TRZ), 
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149.5 (q, TRZ), 139.9, 139.8, 139.6, 138.7, 138.5, 138.3, 138.3, 138.0, 137.8, 137.5, 
136.9, 136.8, 134.4, 134.0, 134.0, 133.9, 132.8, 132.5, 130.0 (TRZ), 129.3, 129.3, 
129.3, 129.0 (TRZ), 129.0, 128.7, 128.6, 128.3 (TRZ), 127.7, 127.6, 127.4, 127.2, 
127.2, 127.2, 126.4, 125.9, 125.6, 123.9, 123.7, 123.6, 123.5, 123.0, 122.7, 122.5, 
121.5 (Ar), 73.0 (CHPh), 72.6 (CHPh), 71.3 (CH2-bpy), 70.8 (CHPh), 69.2, 69.1 
(CH2-bpy), 69.0, 68.7, 68.5 (CH2-CHPh), 55.0, 55.0, 54.7 (Ph-CH2). 
HRMS Calculated for [Fe2Ln]
4+ m/z 416.6221, found m/z 416.6219 
Elemental Analysis found (Calculated for C90H78Cl4Fe2N18O9·15H2O·EtOAc) % C 
52.05 (52.09), H 4.76 (5.39), N 11.13 (11.63). 
IR v cm-1 3371 (br, s), 2851 (br, s), 1694 (m), 1591 (m), 1525 (m), 1467 (m), 1401 (s), 




Yield 0.42 g, 82% 
HRMS Calculated for [Fe2Ln]
4+ m/z 416.6221, found m/z 416.6227 
Elemental Analysis found (Calculated for C90H78Cl4Fe2N18O9·16H2O·EtOAc) % C 










3]Cl4 was synthesised using the procedure described for 
Sc,ɅFe,HHT-[Fe2L33]Cl4, substituting 5-(propargyloxy)picolinaldehyde (5) for 1-
((2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)-
1H-1,2,3-triazole-4-carbaldehyde (49) 
Yeild: 99 mg, 58 %. 
1H NMR (500 MHz, 298 K, MeOD) δH ppm 9.75 (s, 1H), 9.53 (s, 1H), 9.51 (s, 1H), 
9.44 (s, 1H), 9.36 (s, 1H), 9.26 (s, 1H), 9.17 (s, 1H), 8.67 (m, 4H), 8.20 (m, 12H), 8.05 
(m, 2H), 7.99 (s, 1H), 7.92 (s, 2H), 7.74 (s, 2H), 7.40 (m, 10H), 7.07 (m, 2H), 6.94 (s, 
1H), 6.88 (s, 1H), 6.78 (s, 2H), 6.60 (s, 2H), 5.88 (s, 1H), 5.66 (d, 3JHH = 8.0 Hz, 1H), 
5.61 (d, 3JHH = 8.0 Hz, 2H), 5.55 (d, 
3JHH = 9.0 Hz, 1H), 5.42 (t, 
3JHH = 11.5 Hz, 2H), 
5.29 (t, 3JHH = 19.5 Hz, 2H), 5.19 (d, 
3JHH = 12.5 Hz, 2H), 4.52 (m, 6H), 4.01 (t, 
3JHH 
= 18.5 Hz, 2H), 3.66 (m, 13H). 
13C NMR (125 MHz, 298 K, MeOH) δc ppm 164.9, 164.8, 164.1 (HC=N), 161.4, 161.3, 
160.6, 160.5, 159.8, 159.7 (q, bpy), 159.2, 158.7, 157.0, 155.6, 154.6 (bpy), 151.2, 
151.1, 150.7 (q, TRZ), 141.6, 141.3, 140.2, 139.9, 139.2 (bpy), 138.7, 138.3, 138.2 (q, 
bpy), 135.3, 134.2, 133.8 (q, Ph), 130.9, 130.7, 130.1, 129.7, 128.6 (Ph/TRZ), 127.8, 
127.3, 126.9, 125.3, 124.9, 124.6, 124.2, 124.1, 124.0, 123.2 (bpy), 89.3, 89.1, 89.1 
(C1Glu), 80.3, 80.2, 80.0 (C5Glu), 77.4, 76.8, 76.7 (C3Glu), 74.5, 74.3 (CHPh), 74.1, 74.0 
(C2Glu), 73.9 (CHPh), 72.6 (OCH2-bpy), 72.5, 70.9 (C4Glu), 70.3, 69.9 (CH2-CHPh), 
62.4, 62.2, 62.0 (C6Glu). 
IR v cm-1 3242 (br, s), 2864 w, 1604 m, 1360 m, 1219 m, 1016 s 
MS (ESI) m/z 547.3 [L + H]+  
HRMS Calculated for [Fe2Ln]Cl2
2+ m/z 910.2376, found m/z 910.2362 
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Elemental analysis found (Calculated for C84H90N18O18Cl4Fe2·15H2O) % C 46.37 




Yeild: 88 mg, 70 %. 
IR v cm-1 3242 (br, s), 2859 w, 1604 w, 1441 w, 1357 w, 1225 w, 1073 s, 699 m 
MS (ESI) m/z 547.4 [L + H]+ 
Elemental analysis found (Calculated for C84H90N18O18Cl4Fe2·10H2O) % C 48.74 
(48.66) H 5.03 (5.35) N 11.48 (12.16) 
6.5 Circular dichroism 
Samples were dissolved in methanol to 0.1 mg/mL and the spectra were measured on 
a Jasco J-815 spectrometer. Measurements were collected using a 0.1 cm path-length 
quartz cuvette. The parameters used were; bandwidth 1 nm, response time 1 sec, 
wavelength scan range 200-800 nm, data pitch 0.2 nm, scanning speed 100 nm/min 
and accumulation 10. 
6.6 Absorbance spectroscopy and stability 
UV-vis absorbance spectra for stability studies were recorded using a Carey IE 
spectrometer. Measuerments were collected in a 1 cm path-length polystyrene cuvette 
and the standard parameters used were bandwidth 1 nm, response time 1 sec, 
wavelength scan rang 200-800 nm, data pitch 1 nm, scanning speed 200 nm/min and 
accumulation 1. A concentration of each compound (0.01 mg/mL) was measured in 
pH 7 aqueous solution. 
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6.7 Chemosensitivity (MTT assay) 
HCT116 p53++ (human colon carcinoma) cells or ARPE19 (human retinal pigment 
epithelial) cells were incubated in 96-well plates at a cell concentration of 0.5 × 104 
cells/ml. The cells were used when between 50 and 80% confluent in the stock flasks. 
Complete cell media containing DMEM, supplemented with 10% foetal calf serum 
and L-glutamine (2 mM), was used to prepare the desired cell concentration and 
reference wells. Plates containing cells were incubated for 24 h at 37°C in an 
atmosphere of 5% CO2, prior to drug exposure. Cell media (200 µl) was added to the 
reference cells and differing concentrations of drug solution (200 µl) were added to 
the remaining wells. The plates were incubated for a further 96 h at 37°C in an 
atmosphere of 5% CO2. 3- (4,5-Dimethylthiazol-1-yl)-2,5-diphenyltetrazolium 
bromide (MTT) solution (0.5 mg/ml, 20µl per well) was added to each well and 
incubated for a further 4 h at 37°C in an atmosphere of 5% CO2. Upon completion all 
solutions were removed from the wells and dimethyl sulfoxide (150 µl) was added to 
each well to dissolve the purple formazan crystals. A Thermo Scientific Multiskan EX 
microplate photometer was used to measure the absorbance at 540 nm. Lanes 
containing 100% cell media and untreated cells were used as a blank and 100% cell 
survival respectively. Cell survival was determined as the absorbance of treated cells 
minus the blank cell media, divided by the absorbance of the untreated control; this 
value was expressed as a percentage. The IC50 values were determined from a plot of 
percentage cell survival against drug concentration (µM). All assays were conducted 
in triplicate and the mean IC50 ± standard deviation was determined. 
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